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Abstract 
 
Optical control of cellular function with high temporal and spatial precision has been 
a goal for many years. Neuroscience was especially lacking tools that would allow 
for detailed noninvasive studies of neuronal communications within networks. At the 
beginning of this century, the dawn of a field called optogenetics, including 
optochemical genetics, appeared.[1,2,3] Here genetics, optics and to a certain extent 
chemistry are combined to generate strategies for the reversible control of ion 
channels, receptors and neuronal activity with light. This methodology has been 
received with great attention and already helped to gain numerous insights into 
scientific and medical questions.[4,5,6,7]  
 
One optogenetic approach takes advantage of the known pharmacology of neuronal 
transmembrane receptors and ion channels. Here the strategy targets specific 
receptors with photoswitches that contain an azobenzene, a pharmacophore and a 
variable group.[2,8] If freely diffusible, these photoswitches are called photochromic 
ligands (PCLs).[9,10,11,12] Photoswitches possess a cis and trans state, which can be 
converted into each other by different wavelengths of light. Both states of a PCL 
show different efficacies towards its receptor, which allows for a reversible light 
dependent activation or inactivation of the receptor.[2,8]  
 
The doctoral thesis presented here, discusses a selection of PCLs for voltage-gated 
sodium (Nav), calcium (Cav) and potassium (Kv) channels.  
 
QAQ, a membrane impermeable photoswitch contains twice the core structure of 
QX-314, a permanently charged version of the local anesthetic lidocaine.[13] 
Electrophysiological characterization revealed that the photoswitch blocks the 
conductance of Nav, Cav and Kv channels from the cytosolic site, in a light 
dependent manner.[13] 
Furthermore, this doubly charged PCL allows for the reversible silencing of neuronal 
activity, once delivered into neurons. An alternative, noninvasive strategy to load 
cells with QAQ requires the expression of TRPV1 or P2X7 ion channels. Both 
	   v	  
channels enter a dilated pore state after prolonged agonist application, which allows 
bulky compounds to access the inner cell.[14,15,16,17] Thus, extended agonist and QAQ 
incubation of HEK293 cells, expressing TRPV1 or P2X7 channels, offers the 
opportunity to load cells and photoregulate the conductance of voltage-gated ion 
channels.  
Endogenous expression of TRPV1 is mainly limited to specific neurons called 
nociceptors, which are responsible for the detection of pain.[18] This anatomical 
condition allows for a selective, non-genetic strategy to load QAQ into nociceptors 
and to control their activity with light. Thus, QAQ acts as a photoswitchable local 
anesthetic.[13]  
The presence of the TRPV1 dilated pore state under normal physiological conditions 
in tissues has not been confirmed. Whether pore dilation of TRPV1 takes place in 
relation to inflammation phenotypes, like in chronic pain, also remains elusive. 
Quantification of QAQ loading under different conditions into intact DRG could 
provide empirical information about these questions. Therefore a method was 
established to record photoswitching with a multi-electrode array of intact dorsal 
root ganglia, resulting in a proof of principle that the technology could be applied to 
answer the raised questions.[13] 
 
To extend the applications of QAQ and related PCLs of voltage-gated potassium 
channels, investigations have been performed to red-shift the action spectrum. QAQ 
was derivatized, with e.g. dimethoxy-, dimethyl-, dimorpholino and other 
substituents in its 2,2´ and 6,6´ positions, ortho to the diazen unit. Out of six QAQ-
derivatives, three allow for light control of Nav and Kv channel conductance, once 
applied to the internal side of the channels. One active derivative, 2,2’-dimethoxy-
QAQ, shows a red-shifted action spectrum. The trans and the cis state of the 
photoswitch can be converted into each other by using blue light or darkness, 
respectively. The trans state of all QAQ-derivatives blocks the channel conductance. 
Furthermore, neuronal activity of cortical pyramidal neurons can be reversibly 
silenced by internal 2,2’-dimethoxy-QAQ application. 
  
Studies on PCLs for Kv channels demonstrated how to red-shift the action spectra 
by substituting the 4 position of azobenzene photoswitches.[11] Diethyl or other 
	   vi	  
amino functions attached generate push-pull systems that shift the absorption 
maxima to approximately 470 nm light. Thus, blue light can be used to convert the 
photoswitch into its cis state. In the dark the PCL relaxes rapidly back into the trans 
state. One detailed investigated compound is DENAQ, which acts as trans blocker 
on specific Kv channel subtypes. Compared to QAQ, these PCLs are applied on the 
external side of cells and reliably allow for the reversible light control of Kv channel 
conductance.[11]  
 
Another chapter of this thesis describes the efforts to generate photoswitchable L-
type calcium channel agonists and antagonists. Based on the agonist FPL-64176 [19] 
and the 1,4-dihydropyridine antagonist Felodipin,[20] six derivatives were synthesized 
containing one azobenzene each. Compared to Felodipin, electrophysiological 
recordings of 1,4-dihydropyridine derivatives revealed no clear antagonistic effect 
on L-type calcium channels expressed in HEK293T cells. Furthermore, the latter 
compounds and the FPL-derivative did not allow for light control of L-type calcium 
channel conductance. The data presented here provide a fundament to launch 
further investigations to create PCLs for L-type calcium channels. 
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“The trick then is not to use the clumsy and inefficient
techniques of classical organic chemistry by themselves but to
make use of Nature’s tools.”
Sir Francis Crick, 1999[1]
1. Introduction
Natures molecular devices are unsurpassed in their
beauty, efficiency, and ability to integrate into complex
systems. This is not entirely surprising, given that they have
evolved over billions of years. Organic chemistry, by contrast,
is about two hundred years old. The synthesis of complex
molecules is barely a third of that age, and far from being a
mature and efficient technique. Nevertheless, synthetic
chemistry has made remarkable progress over the last few
decades and many molecules have been created that have no
structural or functional counterpart in nature.
Still, what we can make today comes nowhere near to
what nature can achieve. The drugs we synthesize are
comparatively simple molecules and the switches, motors,
and machines we forge are conceptually beautiful, but pale in
comparison with natures devices.[2] These have been studied
in great detail by using various biophysical methods, and our
understanding of how they work has dramatically increased in
recent years. Some famous examples of molecular machines
that have now been elucidated in atomic detail include ATP
synthase,[3] the ribosome,[4] RNA polymerase,[5] various
molecular motors,[6] and ion channels that control nervous
activity.[7] Although they operate on a scale where the
peculiarities of quantum mechanics apply, they can often be
described in terms of relatively simple and intuitive mechan-
ical models.
This much-improved understanding of natures molecular
machines opens the door for their functional manipulation
using synthetic chemistry. Just as macroscopic engines can be
taken apart, “souped up”, and fitted with an ignition key,
nanomachines can be manipulated and endowed with addi-
tional features and control elements. This can be done to a
certain extent at a genetic level, that is, through classical
protein engineering, but also by adding and attaching
synthetic molecules. The trick is then not to use the traditional
techniques of synthetic organic chemistry by themselves, but
to make use of them in combination with natures tools. This
approach creates hybrid devices that can be controlled with
unnatural input signals and can be easily integrated into
highly complex biological systems. As such, they not only
function in vitro or in single cells, but also in complex cellular
networks—even in neural tissues and in living animals.
[*] T. Fehrentz, M. Schçnberger, D. Trauner
Department of Chemistry, Ludwig-Maximilians-Universitt and
Center for Integrated Protein Science
81377 Munich (Germany)
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Transmembrane receptors allow a cell to communicate with its
environment in response to a variety of input signals. These can be
changes in the concentration of ligands (e.g. hormones or neuro-
transmitters), temperature, pressure (e.g. acoustic waves or touch),
transmembrane potential, or light intensity. Many important
receptors have now been characterized in atomic detail and our
understanding of their functional properties has markedly increased
in recent years. As a consequence, these sophisticated molecular
machines can be reprogrammed to respond to unnatural input
signals. In this Review, we show how voltage-gated and ligand-gated
ion channels can be endowed with synthetic photoswitches, and how
the resulting artificial photoreceptors can be used to optically
control neurons with exceptional temporal and spatial precision.
They work well in animals and might find applications in the
restoration of vision and the optical control of other sensations. The
combination of synthetic photoswitches and receptor proteins
contributes to the field of optogenetics and adds a new functional
dimension to chemical genetics. As such, we propose to call it
“optochemical genetics”.
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In this Review, we will show how the paradigm—that
natures molecular machines can be harnessed with synthetic
chemistry—can be applied to a set of transmembrane proteins
that play key roles in neurophysiology. To this end, we will
first review some of the elementary machinery that is
involved in sensory perception, synaptic transmission, and
the generation of action potentials. We will then discuss in
general terms how it can be reprogrammed to become
sensitive to a very useful stimulus—light—and how the
resulting artificial photoreceptors can be used to control
and study neural networks. This is also the goal of “opto-
genetics”, a new field of neuroscience that is currently
undergoing rapid expansion.[8] We will show how the addition
of a chemical component complements and extends optoge-
netics and how “optochemical genetics” contributes to the
dissection and functional enhancement of nervous systems in
new and exciting ways.[9]
2. Transmembrane Receptors and Their Role in
Neurobiology
Transmembrane receptors underlie cellular communica-
tion, including the electrical and chemical communication
within and in-between neurons. For the purposes of this
Review, we define these receptors as transmembrane proteins
that respond to changes in an input signal, be it light intensity,
pressure, voltage, temperature, or the concentration of a small
ligand. These include ion channels (ionotropic receptors), G-
protein-coupled receptors (metabotropic receptors), and
receptor-linked enzymes. For many years, these proteins
were considered to be very difficult to study by structural
methods, particularly by X-ray crystallography. This percep-
tion changed in 1998, when MacKinnon and co-workers
disclosed the X-ray structure of KcsA, a potassium-selective
ion channel sensitive to changes in pH value.[10] Since this
groundbreaking study, representatives of several fundamental
receptor classes have been characterized in atomic detail,
including G-protein-coupled receptors (GPCRs),[11] iono-
tropic glutamate receptors (iGluRs),[12] trimeric ATP recep-
tors (P2X),[13] voltage-gated ion channels,[14] and pentameric
ligand-gated ion channels (pLGICs).[15] For convenience,
these receptors are grouped in Figure 1 according to their
symmetry. Note that these receptors can exist as homomul-
timers, but often assemble as heteromultimers composed of
several similar, but not identical, subunits.
With the exception of rhodopsin,[11b] none of the receptors
shown in Figure 1 are inherently light-sensitive. Three of
them, GluA2,[12] P2X4,
[13] and the nicotinic acetylcholine
receptor,[15a] are ligand-gated ion channels that respond to
changes in the concentration of neurotransmitters or extra-
cellular metabolites. Voltage-gated ion channels, such as
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Kv1.2,
[16] are opened and closed by changes in transmembrane
potential. However, they can also be influenced by ligands,
such as channel blockers. As a consequence, all of the
receptors shown in Figure 1 can be regulated in one form or
another by a small molecule. Provided this small molecule can
be persuaded to change its activity in response to light, the
whole receptor–ligand assembly could be transformed into a
photoreceptor.
Before we address this topic, however, it may be worth-
while to briefly review how some of these receptors are
involved in neurotransmission and the all-important gener-
ation of action potentials (APs).[17] These can be studied by
electrophysiology, a very powerful technique that allows for
microsecond to millisecond resolution. The generalized shape
of an AP and a schematic view of a typical neuron are shown
in Figure 2. Ligand-gated cationic ion channels, such as
ionotropic glutamate receptors (in the human central nervous
system) or nicotinic acetylcholine receptors (mostly in the
periphery) are responsible for the initial depolarization of the
postsynaptic membrane. Binding of the neurotransmitter to
its respective channel leads to pore opening, thereby allowing
sodium and potassium ions to pass. Given the resting
potential of the neuron and the tightly controlled relative
concentrations of sodium and potassium on either side of the
membrane, this will lead to a net influx of positive charge,
which changes the membrane potential (Figure 2). Once a
certain value has been reached (typically around 40 mV),
voltage-gated sodium channels begin to open. As sodium
rushes in, the membrane is further depolarized and the
transmembrane potential inverts its sign (up to + 50 mV). The
neuron is quickly repolarized, however, as the voltage-gated
sodium channels deactivate, and voltage-sensitive potassium
channels begin to open after a brief delay. Once those are
deactivated, the cell regains its resting potentials through the
action of transporters and pumps, such as Na/K-ATPase.
Ion channels can have both excitatory and inhibitory
effects on neurons, depending on whether they make the
transmembrane potential less or more negative when opened.
This is not only dependent on the charge of the ions they
conduct but also on the relative concentration of ions on
either side of the membrane. Consequently, at physiological
conditions, nonselective cation channels and sodium channels
will depolarize, whereas potassium channels hyper- or repo-
larize cells when opened. Chloride channels, such as GABAA
or glycine receptors are generally inhibitory on AP firing.[17a]
Figure 1. Selected transmembrane receptors of different symmetry characterized by X-ray crystallography and electron microscopy. Each receptor
is shown in side and top views (from the extracellular side) and fitted to the same scale. Left to right: Rhodopsin, a G-protein-coupled receptor
responsible for vision (pdb 1U19); GluA2, a glutamate-gated ion channel involved in excitatory neurotransmission (pdb 2KG2); P2X4, an ATP-
gated cation channel that mediates pain sensation (pdb 3H9V); Kv1.2, a voltage-gated potassium channel involved in controlling cellular
excitability (pdb 2A79); nAChR, a nicotinic acetylcholine receptor that mediates the communication between nerves and muscles (pdb 2BG9). The
dotted lines in this and other figures describe the boundaries between the cell interior, the membrane, and the space outside the cell.
Optochemical Genetics
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In addition to these primary ion channels, there are
receptors that perform a more modulatory role and influence
the shape, duration, and frequency of the action potentials.
These receptors can also be ion channels (such as KCNQ
channels)[18] or, more often, G-protein-coupled receptors
(GPCRs).[17a, 19] In comparison to ion channels, GPCRs are
“slow acting”, since their effect is mediated by heterotrimeric
G proteins, enzymes, second messengers, and transcription
factors. Notably, the same neurotransmitter, for example,
glutamate, acetylcholine, or GABA, can act on both the
ionotropic receptors and the metabotropic receptors. Even
neuromodulators that primarily target metabotropic recep-
tors, such as serotonin, have an occasional ion channel
target.[20]
3. Lighting up the Brain
Amongst different input signals that can actuate a
receptor, light stands out for a variety of reasons: light can
be modulated in its intensity within
femtoseconds, can be focused onto
very small areas (on the order of its
wavelength), and can carry enough
energy to trigger larger molecular
motions (such as isomerizations). As
such, it is unsurpassed in its temporal
and spatial precision, as well as in its
ability to remote-control molecular
devices and systems, including neural
systems.
Light has been used for eons to
glean information from the environ-
ment. Visual systems have emerged at
almost all levels in evolution and have
been greatly enhanced by human tech-
nology, such as microscopy. This is still a
highly active area of research, with new
imaging technologies continuing to be
developed. Recent examples include
superresolution microscopy[21] and two-
photon imaging.[22] As a consequence of
these technical advances, neurons can
now be described in incredible detail,
action potentials can be visualized with
fluorescent calcium sensors, and the
activity of many neurons in a network
can be monitored simultaneously in live
animals.[23]
Light, however, can also be used to
put information into systems—provided
suitable photoreceptors are present. As
in imaging, this can be done with
exquisite temporal and spatial preci-
sion, and the optical setups needed are
largely the same. If the light intensities
are not too high and the wavelengths
are not too short, it can be done with
little damage to the tissues, especially
when compared with the invasiveness of multiple electrodes.
The usefulness of light as an input signal for neuroscience was
realized by none other than Sir Francis Crick, who stated in
1999: “The ideal signal [to study and control a brain] would be
light, probably at an infrared wavelength to allow the light to
penetrate far enough. This seems rather far-fetched but it is
conceivable that molecular biologists could engineer a partic-
ular cell type to be sensitive to light in this way.”[1]
It did not take long for molecular biologists to take up this
challenge, which gave rise to a new field called “optogenetics”
(Figure 3).[8a,b] In essence, optogenetics is an effort to control
neurons, or other cells of interest, with genetically targeted
photoreceptors. As a result of this genetic component, the
sensitivity to a stimulus and not the stimulus itself can be
precisely located. Therefore, the light beam itself does not
need to be spatially controlled with very high resolution, and
light scattering is less of an issue than it is in imaging.
The targeting of innately “blind” neurons with genetically
encoded photoreceptors has been achieved in several ways.
Historically, the first system used was “ChARGe”, which
Figure 2. An overview of neurotransmission. a) The action potential: 1) the transmembrane potential of a
neuron at rest; 2) a neurotransmitter binds to a ligand-gated ion channel, for example, a glutamate
receptor (iGluR), and evokes an excitatory postsynaptic potential; 3) voltage-gated sodium channels (NaV)
respond and further depolarize the membrane, but quickly deactivate; 4) voltage-gated potassium
channels (KV) follow suit and repolarize the membrane, even beyond its resting potential (5); 6) the
undershoot is removed through the concerted action of channels that are open at the resting potential
and by ATP-driven ion pumps. b) A representative neuron from the visual cortex. The dendrites, the soma,
and the axon are clearly visible. The soma resides in layer 2/3 (L2/3) and is much less extended than the
axon, which spans several layers of the cortex. c) The most important neurotransmitters and neuro-
modulators.
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essentially consists of the primary components of the
Drosophila visual cascade (rhodopsin, the associated hetero-
trimeric G protein, and arrestin).[24] This multicomponent
system was shown to trigger APs when heterologously
expressed in dissociated hippocampal neurons. This was
quickly followed by early optochemical systems, which will
be discussed in much more detail below. In 2004, a natural
photoreceptor called channelrhodopsin-2 (ChR2) was intro-
duced, which has since established itself as the most practical
and popular tool.[25] ChR2 is an excitatory cation channel
isolated from the alga Chlamydomonas reinhardtii.[25a] It can
be activated with blue light and is rapidly deactivated once
the light is gone, which allows for the control of AP firing with
high precision.[25b] Similar to the rhodopsins, it uses retinal as a
photoswitch, but unlike the mammalian visual pigments, the
retinal is not excised after photoswitching. Therefore, ChR2
can be repeatedly used to trigger action potentials. As an
added advantage, retinal is endogenously produced in many
tissues and does not need to be added externally.[26]
Shortly after the excitatory photoreceptor channel ChR2
was identified, an inhibitory counterpart, namely a light-
driven chloride pump called Natromonas pharaonis halorho-
dopsin (NpHR) was introduced.[27] NpHR can be activated
with bright yellow light and is capable of silencing neurons,
also with millisecond resolution. Importantly, as a conse-
quence of little spectral overlap, ChR2 and NpHR can be
expressed and used in the same neuron simultaneously.[8b,27]
Variants of ChR2 and NpHR with modified spectral and
kinetic features continue to be developed,[28] and other
systems, such as light-driven proton pumps, have recently
been discovered that can control neuronal activity with
light.[29]
Since its inception at the beginning of the new millen-
nium, optogenetics has found many applications in dissecting
neuronal circuitries and has helped to answer fundamental
questions in neuroscience. As a testament to its enthusiastic
reception by the scientific community, it was deemed
“Method of the Year” in 2010.[8a,c] In addition to its important
role in basic neuroscience, optogenetics has, within the last
few years, also found its first applications in clinical research.
For example, ChR2 and NpHR have been used to investigate
the mechanism of deep-brain stimulation, which ameliorates
the symptoms of Parkinson disease.[30] A second study was
aimed at Retinitis pigmentosa, a condition which involves the
loss of photoreceptor cells. Here, the light sensitivity of the
retina could be restored by expressing NpHR, which resulted
in visually guided behavior in previously blind mice.[31] In
another application of ChR2 and NpHR, cardiac pacemaker
cells of zebrafish could be optically stimulated or inhibited,
thus enabling the control of heart beat patterns.[32]
4. Optochemical Genetics
Given that the molecular tools used in optogenetics are
mostly derived from bacteria and protozoa, they work
amazingly well in the neurons of worms, flies, and furry
animals. These neurons, however, express numerous recep-
tors on their own that are easily accessible on their
extracellular side but are not inherently photosensitive. The
challenge then is to persuade endogenous receptors to
become sensitive toward light.
Three general strategies have emerged to do just that by
using small synthetic molecules (Figure 4). The simplest and
oldest approach employs caged ligands (CLs).[33] Here, a
ligand is endowed with a protecting group that renders it
pharmacologically ineffective. This protecting group is rarely
a true molecular cage (in the sense a chemist would use this
term), but typically a photolabile moiety that masks a
functional group crucial to the ligand–receptor interaction.
Photochemical cleavage of the protecting group then sets the
active ligand free and triggers the desired biological effect.
Caged ligands have indeed been applied to great effect in
neuroscience. Caged glutamate, for example, has been very
useful for unraveling neural systems, and two-photon cages
have enabled the stimulation of single synapses through the
spatial precision that can be achieved with two-photon
techniques.[34] The photosensitization of P2X2 receptors and
TRPV1 channels with caged ATP and capsaicin, respectively,
was the first approach shown to work in living animals (in this
case decapitated fruit flies, to ensure that the visual system
was inactivated).[35]
There are, however, certain functional disadvantages
associated with caged ligands. Uncaging is an irreversible
process and it is difficult, if not impossible, to “stuff the beast
Figure 3. Optogenetics. a) Schematic representation of ChR2, a light-
gated ion channel. The chromophore 13-trans-retinal (shown here
conjugated as a Schiff base) undergoes isomerization with blue light
and thermal relaxation, thereby gating the channel. b) Shining blue
light on ChR2 triggers depolarization. c) Control of mouse behavior
with blue light. Note the glass fiber cable that delivers light deep into
the brain.[8b]
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back into the cage”. Unless one is interested in tonic effects,
such as a sustained receptor activation or inhibition, one can
only hope that the ligand leaves the active zone as quickly as
possible or is cleared by either a reuptake pump or a
deactivating enzyme. The former exists for glutamate itself
but not for more-selective synthetic agonists and antagonists.
In addition, uncaging produces by-products, that is, the
remnants of the protecting group, which can be toxic. The
background release of the neurotransmitter, for example,
through thermal hydrolysis, can also be a problem, as can be
the fact that some caged compounds have off-target effects,
for example as antagonists to other receptors.
Some of these shortcomings can be overcome with a
second approach called the photochromic ligand (PCL)
approach. Here, the ligand carries a photoswitchable side
chain that can be switched between two configurations. As the
photoswitch toggles between these states, the efficacy of the
ligand changes, thereby triggering the desired biological effect
in a reversible fashion. The ligand can change its efficacy upon
photoswitching and could even be an agonist in one form and
an antagonist in the other.
Figure 4. Three strategies used in optochemical genetics. a) A ligand binds to a generic receptor (not necessarily the clamshell-like receptor
domain shown here), triggering a biological response. b) A caged ligand (CL) is broken apart with light, thus releasing its active form. c) Caged
capsaicin, used to stimulate TRPV1 channels. d) A photochromic ligand (PCL) reversibly acts on a receptor. e) 4-GluAzo, a PCL that functions as
“reversibly caged glutamate”. f) A covalently attached photoswitchable tethered ligand (PTL) can optically regulate a receptor. g) MAG-1, a typical
PTL in its unconjugated form.
D. Trauner et al.Reviews
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PCLs have all the advantages of small-molecule drugs,
including their ease of application and fast distribution in
tissues. As with drugs, selectivity between receptor subtypes
can be a challenge, but this can often be overcome through
systematic variation of the molecule. In addition, one could be
concerned that their photoisomers show relatively small
differences in efficacy. However, in our experience PCLs
work remarkably well in complex systems that have nonlinear
responses, particularly in neural networks. Here, it is often the
case that small changes in the activity of a modulator have
dramatic effects on the output. Since the AP is an “all or
nothing” response that is triggered only when a certain
threshold is reached after a complex cellular integration,
compounds that subtly influence this integration can have
pronounced effects.
Of course, there are situations where receptor-subtype
selectivity and cellular targeting is highly desirable. In this
case, a third approach, which we call the photoswitched
tethered ligand approach (PTL approach), can be employed.
Here, the ligand is covalently attached to its receptor through
a tether that contains a photoswitch. As the photoswitch
toggles between long and short forms, the local concentration
and/or efficacy of the ligand changes, thereby triggering a
biological response in a reversible fashion. Importantly, PTLs
can be genetically encoded, since the point of attachment is an
engineered cysteine residue or any other encodable chemical
motif that allows for specific bioconjugation. Since the PTL is
covalently tethered, its local concentration at the site of
attachment is very high in the active form of the photoswitch,
which means that the affinity of the ligand is not a major
concern. In fact, low-affinity ligands are usually preferred to
ensure that photoswitching removes the ligand from the
binding site.
The PTL approach is essentially a variant of optogenetics,
since it combines a genetically encodable receptor with light
to precisely control neural activity. In contrast to “classical”
optogenetics, a synthetic component, that is, a reactive
chemical, is needed, which is not endogenously produced,
but needs to be synthesized and supplied by a chemist. The
PCL and the CL strategies, on the other hand, are more akin
to “chemical genetics”.[36] Chemical genetics aims to address
every protein target with a selective small-molecule ligand.
Although such pharmacological control has a rapid onset, it is
still not fast enough for many applications in neuroscience,
where millisecond precision is required. This limitation can be
overcome by optically controlling the small molecules that
function as ligands.
Taken together, the CL, PCL, and PTL approaches
provide the basis for what we call “optochemical genetics”.
It is an effort to control neural activity (or any network
activity) with light and light-responsive synthetic molecules,
with or without a genetically determined component. It shares
with chemical genetics a certain desire to overcome the
limitations of conventional genetic manipulation, but it also
acknowledges that the targeted expression of proteins can be
very powerful.
Which variant is used depends on the exact application.
For therapeutic applications, where a certain lack of selectiv-
ity can be tolerated or is even desirable,[37] the PCL approach
may be more suitable. On the other hand, in the analysis of
functional pathways, for example, in neural circuitry mapping,
the genetically targeted transfection of a specific cell is clearly
advantageous. In addition, PTLs could be extremely useful in
the functional dissection of closely related receptor subtypes,
since selectivity can be achieved through covalent attachment
to genetically engineered isoforms (Figure 5). Following
conjugation, tonic activation or inhibition of the receptor
can be prevented through action of the photoswitch. Overall,
this PTL approach to selective pharmacology bears a certain
resemblance to the “bump-hole” technique, which has been
used so successfully in dissecting the human kinome, that is,
the total of all human kinases.[38] In both cases, engineered
proteins and unnatural ligands are needed. The PTL
approach, however, not only provides a precise answer to
the question “who”, but also to “when” and “where”.
Caged ligands have been mostly developed by other
research groups and have been extensively reviewed else-
where,[33] which is why our discussion here will focus on
Figure 5. The PTL approach to selective pharmacology. a) Chemical
genetics and pharmacology generally aim at individually targeting
receptors and receptor isoforms. This requires ligands that bind with
high affinity and selectivity. b) In optochemical genetics, selectivity can
be achieved through genetic engineering of a bioconjugation site. In
addition, the photoactivatable ligand can have low affinity to the
receptor subtype.
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synthetic photoswitches, that is, on PTLs and PCLs. Of the
different photoswitch architectures investigated, azobenzenes
have so far proven to be the most versatile and reliable
ones.[39] This is due to several distinguishing functional
features (Figure 6). For example, their geometries in their
cis and trans states are well defined and the conformational
space that can be mapped by both isomers has relatively little
overlap. Substituents in the 4- and 4’-positions are substan-
tially closer in their cis form than in their trans form, an effect
that can be amplified further by appropriate substitution.
Although azobenzenes are helically chiral in their cis form,
which is not planar, they are typically not optically active
because of facile racemization, and they do not generate
stereocenters upon switching between a long and short form.
Azobenzenes often display high extinction coefficients
and quantum yields, which mean that light of relatively low
intensity can be used for photoisomerization. In addition,
azobenzenes undergo photoswitching at very fast rates, which
prevents intersystem crossing and the formation of triplet
diradicals. These would react with triplet oxygen to generate
singlet oxygen, a highly reactive and cytotoxic species, which
is also damaging to the chromophore itself. Consequently,
azobenzenes are relatively photostable and can be switched
over many cycles. Their spectral tuning through substitution is
straightforward and follows well-established rules. While
most azobenzenes used to date are isomerized to their cis
form with UV-A or deeply violet light (315–380 nm), red-
shifted versions that are less harmful upon prolonged
application to tissue are also known (see Section 6). Finally,
azobenzenes are relatively easy to synthesize and modify, as
several synthetic strategies are available, including diazonium
coupling, Mills reactions, and transition-metal-catalyzed
cross-coupling strategies.[40] One potential disadvantage is
their comparatively low solubility, but this can usually be
overcome with appropriate functional groups, in particular
with charged substituents.
Notably, azobenzene photoswitches are marked by photo-
stationary states that are a function of the wavelength. While
they can exist 100% in the thermodynamically more stable
trans form (also the dark-adapted form) and their photosta-
tionary cis/trans ratios can exceed 9:1 at short wavelengths
(Figure 6),[41] it is practically impossible to push them fully
into the cis state through irradiation. Therefore, the back-
ground activity of the remaining trans isomer is a concern, but
for the reasons stated above this is often not a problem in
neural networks. In fact, the dependence of the photosta-
tionary ratio on the wavelength also offers an opportunity to
tune the response by gradually tuning the color. The thermal
bistability of photoswitches can be further influenced through
appropriate substitution. PTLs wherein one end of the cis-
azobenzene interacts with the protein covalently and the
other noncovalently show slow thermal relaxation, at least on
a neurobiological time scale. On the other hand, certain red-
shifted azobenzene PCLs can revert to their dark-adapted
state within milliseconds.[42]
Once a photoswitch has been chosen, the design of PTLs
and PCLs is straightforward, provided both the structural
coordinates for the receptor and extensive structure–activity
relationship data for the ligands are available. The latter is
often the case, since neuropharmacology is a well-developed
field. Today, one cannot complain about a lack of the former
either, since relevant structures appear in the literature
almost every week.
The design of PCLs and PTLs is closely intertwined. It
typically starts out with a structure of a ligand, gleaned from
the crystal structure or from the pharmacology literature.
From this, it is often immediately clear where and how to
attach the photoswitch to the ligand and which stereochem-
istry to choose at the point of attachment. In an intermediate
stage, a so-called “tether model” is sometimes synthesized,
which retains one phenyl ring of an azobenzene. This is then
extended to a full-blown PCL that contains the entire
chromophore and, finally, after addition of an electrophilic
functional group, to the corresponding PTL. In general,
extensive structure–activity data are sufficient to design a
PCL with a reasonable chance of success, whereas X-ray
structures are normally needed for a PTL. The latter requires
cysteine sites for covalent attachment, and choosing those can
be difficult without structural coordinates. Increasingly,
sophisticated computational tools are used for that purpose.
Since most PTLs that have been used to date are cysteine-
reactive compounds, unspecific labeling of the cell-surface
might be a concern. However, one has to bear in mind that
reduced, accessible cysteine residues are rare on the surface
Figure 6. The logic of azobenzene photoswitches. a) Azobenzenes
change their configuration and length upon irradiation with light of
different wavelengths. They revert thermally or photochemically to their
thermodynamically more stable state, which is usually the trans state.
b) The mercaptoethanol conjugate of MAG-1, a model for the tethered
PTL. c) The photostationary cis/trans ratio of the MAG-1 conjugate as a
function of wavelength.
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of cells and the bioconjugation typically proceeds through
affinity labeling. This means that the noncovalent interaction
of the PTL with its ligand-binding site precedes formation of
the covalent bond, thereby enhancing the rate and selectivity
of the labeling, which will also depend on the state of the
photoswitch. In addition, cells seem to be remarkably tolerant
toward molecules attached to their surface, as long as they do
not interfere with vital cell–cell interactions.[43]
The design of suitable PTLs and PCLs also goes hand in
hand with their syntheses. These can present considerable
challenges since the chemistry of photoswitches needs to
interface with the chemistry of polar and charged ligands,
which requires intricate protecting-group operations. In the
case of PTLs, this is acerbated by the presence of an
electrophile, which should be introduced into the molecule
as late as possible. The syntheses have to be practical and
efficient enough to support a sustained biology program that
includes in vivo investigations and, eventually, behavioral
studies in animals.
In the following sections we will show how optochemical
genetics can be applied to some of the most basic molecular
machines involved in synaptic transmission: voltage-gated
potassium channels and ionotropic glutamate receptors. To
this end, we will first discuss their innate functions and
systemic roles in some detail
and then show how they can
be converted into hybrid
photoreceptors through
covalent or noncovalent
attachment of azobenzene
photoswitches. Afterwards,
we will address other targets,
such as the nicotinic acetyl-
choline receptor (nAChR)
or the P2X4 receptor, where
this has been previously
studied to a limited extent.
Finally, we will address a few
receptors that have not yet
been converted into photo-
receptors, but which are “sit-
ting ducks” for the opto-
chemical approach.
5. Voltage-Gated
Potassium Channels
Together with voltage-
gated sodium channels
(Nav), voltage-gated potas-
sium channels (Kv) modulate
cellular excitability and play
a key role in the generation
of action potentials.[17c] Kv
channels are transmembrane
proteins that assemble as
tetramers from four single
polypeptide chains that are
known as a subunits.[4] In humans, 40 genes encode 12 a-
subunit families (Kv1–Kv12).
[44] Within each subfamily, differ-
ent genes exist, as indicated by an additional number, for
example, Kv1.2. This diversity is further increased by hetero-
tetrameric assembly of the a subunits, which results in a very
large number of potential combinations. Kv1 channels addi-
tionally interact with intracellular tetrameric b subunits that
alter the gating behavior.[45]
To date, several potassium channels have been elucidated
in atomic detail by X-ray crystallography. The first structure
to be reported was that of KcsA, a simple bacterial channel
from Streptomyces lividans. Its disclosure in 1998 stands as a
milestone in biophysics.[10] Subsequently, the structures of a
calcium-gated potassium channel (MthK),[46] several inward-
rectifier potassium channels (e.g. Kir3.1),
[47] a sodium- and
potassium-conducting channel (NaK),[48] and several prokary-
otic and eukaryotic voltage-gated potassium channels have
been reported.[14b, 16] The structure of Kv1.2, a mammalian
voltage-gated ion channel that modulates the electric excit-
ability of neurons, in its open form is shown in Figure 7.[14b] In
this representative structure, the voltage sensors, the pore,
and both the inner cavity and outer vestibule of the channel
are clearly visible (the b subunit is removed here, but present
in Figure 1). Each single subunit contains an intracellular
Figure 7. Structure and function of voltage-gated potassium channels. a) A highly schematic representation
of Kv channels illustrating their functional cycle and channel blocking. b) A single Kv1.2 subunit showing the
extracellular S1-S2 linker, the voltage-sensing domain, the pore domain embedded in the membrane, and
the intracellular T1 domain (pdb 3LUT). The b subunit has been removed and the ball peptide is not
resolved in this structure. c) Two of the four subunits, indicating the architecture of the selectivity filter and
the inner vestibule. d) Expanded view of the TEA binding sites in the inner and outer vestibules (pdb 2BOB
and 2BOC). e) Chemical structures of extracellular and intracellular potassium channel blockers.
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tetramerization domain, a voltage sensor domain (with
helices S1–S4), and a pore domain (containing helix S5, a
short pore helix, a pore loop, and the C-terminal helix S6).[44]
Both the N and the C termini are located in the cytosol, but
the N-terminal domain is not resolved in the structure.
Like most ion channels, Kv channels have three elemen-
tary functions that are physically represented by their protein
domains and their movements: 1) an “activation gate” that
interacts with the input signal (i.e. voltage) and opens the
channel, 2) a “selectivity filter”, which determines which ions
can pass through the channel, and 3) an “inactivation gate”,
which is responsible for their desensitization. Activation is
initiated by the voltage sensor once the membrane potential
reaches40 mV. The S4 helix of the voltage sensor domain in
each subunit contains several positively charged residues,
usually arginines, that move across the membrane as the cell
depolarizes. This movement is mechanically coupled with a
hinged motion of the inner helix bundle (S6) of the pore
domain, which opens a gate through which the ions can
pass.[7, 44, 45] Driven by the electrochemical gradient, the ions
then permeate the selectivity filter, thereby generating a
current that is specific for Kv channels. The selectivity filter is
essentially a stack of backbone carbonyl groups that com-
pensate for the hydration sphere of the cation as it passes
through. This compensation is energetically more favorable
for potassium ions than sodium ions.[7]
There are two native mechanisms of inactivation of Kv
channels: N-type and C-type inactivation. N-type inactivation
is mediated by the positively charged intracellular N termi-
nus, which functions like a “ball” (or plug) on a chain. Once
the voltage gate is opened, the N terminus follows the
outward K+ current. This pushes the “ball” into the inner
vestibule of the channel and blocks further ion conduction.[49]
In comparison, slow or C-type inactivation depends on
permeant ions and blockers, and is believed to occur through
a conformational change near the extracellular pore
region.[48a, 49] In a physiological context, fast inactivation of
the sodium channels and currents through the Kv channel
repolarize the neurons after an AP and determine the
duration and frequency of the APs.[51]
Kv channels can be blocked by Cs
+ ions, small organic
cations, and venom peptides. Venom peptides, such as
agitoxin-2, are produced by some of the most dangerous
animals known, for example, the death-stalker scorpion,
certain sea anemones, and the green mamba.[45, 52] These
peptides bind to the outer vestibule of the channel and
literally plug its pore from the extracellular side, usually with
a protonated lysine side chain. Typical small organic Kv
channel blockers are quaternary ammonium ions, such as
tetraethylammonium (TEA) and 4-aminopyridine (4-AP;
Figure 7).[17c,53]
Interestingly, Kv channels feature both an internal and
external binding site for quaternary ammonium ions.[54]
External TEA mimics the protonated lysine side chain that
functions as the plug in agitoxin-2, whereas internally applied
TEA acts similar to the positively charged ball peptide
involved in N-type inactivation. This blockade requires
opening of the activation gate. Therefore, charged blockers
that act from the internal side are called “open-channel
blockers” or “use-dependent blockers.”[17c] The KcsA struc-
ture was also solved in the presence of analogues of TEA,
which helped to exactly locate its intracellular and extracel-
lular binding sites.[54]
6. Photosensitizing Voltage-Gated Potassium
Channels
With their structures elucidated and their functions
reasonably well understood, voltage-gated potassium chan-
nels have become prime targets for optochemical genetics.
The first system to emerge was the “synthetic photoisomer-
izable azobenzene-regulated K+ channel” (SPARK), which is
an example of the PTL approach (Figure 8).[55] As a conse-
quence of its hyperpolarizing effect, it was later renamed H-
SPARK. H-SPARK consists of the channel blocker MAQ
(maleimide/azobenzene/quaternary/ammonium) covalently
attached to a genetically introduced cysteine residue on an
extracellular loop of a Kv1-type channel. The location of this
cysteine residue (E422C) could be determined on the basis of
existing X-ray structures and previous experiments with
“molecular tape measures.”[56] Once attached, MAQ essen-
tially functions as TEA on a leash that can be lengthened or
shortened with light. MAQ was designed to block the channel
in its elongated trans state, that is, at 500 nm or in the dark,
whereas the blockage would be lifted in the cis state of the
photoswitch, that is, at 380 nm. Slow and fast inactivation of
the channel had to be prevented by using genetic engineering
to make H-SPARK an effective modulator of membrane
potential. The activation voltage was shifted from 35 to
70 mV through another point mutation (L366A), which led
to a constantly open channel before conjugation of trans
MAQ. As a result, the potassium channel is blocked in the
dark or under 500 nm light. Illumination with light of
wavelength 380 nm unblocks the pore and the resulting
outward current leads to re- or hyperpolarization of the
membrane. To our amazement, SPARK not only worked in
excised patches from Xenopus oocytes but also in excitable
cells, such as dissociated hippocampal neurons.[55] Indeed,
when SPARK was introduced in 2004, it was the first system
that allowed for optical silencing of neuronal activity.
As a complement to the silencing H-SPARK, a depola-
rizing version, termed d-SPARK, was engineered.[57] A single
additional mutation (V443Q) was sufficient to convert the
potassium selective H-SPARK into a nonselective cation
channel. With this mutation in the selectivity filter, the
permeability ratio of the K+/Na+ ions changes to 0.7:1, and
Na+ influx into the cell dominates the net effect on the
membrane potential. After covalent attachment of MAQ, the
channel depolarizes the membrane upon UV illumination
instead of hyperpolarizing it, thus allowing for AP firing
rather than silencing. This is a nice case of “sign inversion,”
which is often encountered in neuroscience.
The diversity of K+ channels, the lack of selective
pharmacology, and the success of H/d-SPARK provided the
motivation to extend the PTL strategy to other members of
the family.[58] Kv1.3, which is involved in membrane repola-
rization after AP firing of neurons and has immunosuppres-
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sive effects when blocked, became the next channel to be
rendered light-sensitive by attachment of MAQ. Its very low
affinity for TEA could be overcome by introducing a point
mutation (H401Y). Both Kv3.1 and Kv7.1 could be converted
into photoreceptors in a similar fashion. As a consequence of
their fast deactivation, Kv3.1 channels play an important role
in generating high-frequency APs, which occur in neurons of
the auditory brainstem and the cerebellum. Finally, the PTL
concept could be applied to the small conductance Ca2+-
activated K+ channel 2 (SK2), a channel that is naturally
sensitive to voltage and an intracellular ligand.[58] Taken
together, these studies provide a first example for the PTL-
driven selective pharmacology discussed in Figure 5.
As an alternative to PTLs, PCLs offer a way to control
native Kv channels and neuronal activity with light. For this
purpose, the cysteine-reactive maleimide group of MAQ was
replaced with various moieties. This yielded a series of
photochromic blockers, termed XAQs, which display differ-
ent pharmacological and photophysical properties.[59] These
compounds include the benzoate BzAQ, the propyl derivative
PrAQ, and the acrylamide AAQ (Figure 9). Detailed inves-
tigations showed that the XAQs act as use-dependent,
photochromic open-channel blockers.[59a] This also applies to
AAQ, which does not react with the extracellular surface of
native channels, as initially
hypothesized. To reach the
inner vestibule, the amphi-
philic XAQs have to cross the
membrane or they can be
added to the cytosol through
a patch pipette. External ap-
plication of AAQ and BzAQ
to cells or tissues blocks Kv
channels in the trans state of
the photoswitch, that is, in
the dark or under 500 nm
irradiation, while 380 nm
light relieves the block. Inter-
estingly, PrAQ preferentially
blocks in its cis state (i.e. at
380 nm), which is another
example of sign inversion.[59a]
Structurally, as well as
functionally, XAQs resemble
the well-known analgesic
lidocaine or its permanently
charged derivative QX-314,
with the important difference
that their efficacy is light-
dependent. Similar to lido-
caine, XAQs can be simply
added to nervous tissues,
which make them very attrac-
tive for therapeutic applica-
tions. After a brief waiting
period, they reliably control
action potential firing
(Figure 9). When added to
cerebellar slices, AAQ con-
trols the activity of Purkinje neurons, mostly through its effect
on inhibitory interneurons known as basket neurons.[59b] AAQ
also has effects on the heartbeat of the medicinal leech
Hirudo medicinalis.[59b] In this animal, central pattern gen-
erator interneurons (co-called HN cells) control the fre-
quency of heart contractions. Earlier studies indicated that K+
channels play a crucial role in burst firing of these HN cell.
After application of AAQ, the activity of HN neurons could
be modulated with light. Interestingly, burst periods
decreased under 380 nm light illumination, whereas 500 nm
light extended the period.
A major goal of our research program is to shift the
absorption and action spectra of PTLs and PCLs toward the
red, which would allow for deeper tissue penetration and
would diminish the phototoxicity. This can easily be done
through chemical derivatization of the azobenzene chromo-
phore. For example, the introduction of an electron-donating
substituent yielded XAQs that can be isomerized to their cis
isomers with blue light. As an added advantage, these
compounds revert to their trans form in the dark within
milliseconds, effectively turning themselves off (Figure 10).
Therefore, it is not necessary to toggle between two different
wavelengths. An example of this type of compound is
DENAQ, whose action spectrum reaches a maximum at
Figure 8. SPARK, the light-sensitive potassium channel. a) A highly schematic representation of H-SPARK,
the hyperpolarizing channel. b) A schematic representation of D-SPARK, the depolarizing variant. c) The
chemical structure of MAQ, the PTL used for SPARK. d) Reversible light control of potassium currents by
H-SPARK. Irradiation in the UV range unblocks channels, while 500 nm light induces blocking. By
convention, outward currents are plotted upwards. e) Light-dependent induction of AP firing by H-SPARK
expressed in neurons. This is the original recording of the first experiment where neuronal activity was
controlled reversibly by a PTL.
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480 nm. Interestingly, its analogue PhENAQ does not act as
a blocker in the trans state but rather in the cis state (another
case of sign inversion). It can also be switched to the
blocking state with blue light and reverts to the inactive state
automatically. Therefore, neuronal firing could be triggered
with irradiation and quickly silenced by turning the light
off.[42]
7. Ionotropic Glutamate Receptors
Ionotropic glutamate receptors (iGluRs) play a central
role in synaptic transmission.[17a,50, 60] Located primarily in
postsynaptic membranes, these ligand-gated ion channels
respond to the neurotransmitter glutamate released from
vesicles on the presynaptic side. Upon glutamate binding,
iGluRs generate a depolarizing current, which results in an
excitatory postsynaptic potential (EPSP). With their funda-
mental involvement in neuronal communication, iGluRs are
Figure 10. Red-shifted photochromic blockers. a) The chemical struc-
tures of DENAQ and PhENAQ, two red-shifted XAQs. b) Action
spectrum of DENAQ. c) Controlling neuronal firing with PhENAQ.
Figure 9. PCLs for voltage-gated ion channels. a) A schematic depiction
of a XAQ that functions as a photochromic open-channel blocker of Kv
channels. b) The chemical structures of BzAQ, AAQ, and PrAQ, three
typical XAQ PCLs for potassium channels. c) AAQ reversibly blocks
potassium currents of a Kv1 family channel. d) AP firing of hippocampal
neurons controlled by AAQ. e) Controlling the heart beat of a leech with
AAQ.
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associated with a wide variety of neurological diseases,
including Alzheimers disease, epilepsy, and neuronal
damage from stroke, and have therefore been very important
neuropharmacological targets.[61]
All ionotropic glutamate receptors in higher animals
assemble as tetramers and allow the permeation of mono-
valent cations with little selectivity (Figure 11). Some are also
permeable to calcium. On the basis of functional differences
and their response to synthetic ligands, they can be classified
into N-methyl-d-aspartate (NMDA) receptors and non-
NMDA receptors. The latter can be divided into three
subgroups, namely so-called AMPA, kainite, and d recep-
tors.[51,62]
AMPA receptors, named after a selective agonist, form
homo- and heteromeric channels composed of GluA1–GluA4
subunits.[51, 62] They mediate postsynaptic depolarization after
release of glutamate from the presynaptic side and exhibit fast
activation and deactivation kinetics (within a few millisec-
onds). This feature makes them the principle molecular
component of fast excitatory synaptic transmission.[51,62]
By contrast, kainate receptors play a role in the modu-
lation of neuronal excitability rather than in fast excitatory
transmission.[62, 63] Their mode of action, however, is not as
well understood as in the case of AMPA receptors. Homo-
and heteromeric channels assemble from so-called GluK1–
GluK5 subunits. d Receptors assemble as homomeric recep-
tors of GluD1 or GluD2 subunits. The function of these
receptors, however, remains largely unknown.[62]
NMDA receptors assemble as obligate heterotetramers
from a pool of seven subunits. Activation requires not only
the simultaneous binding of glutamate and glycine (or d-
serine), but also an elevated membrane potential of greater
than 30 mV. This renders NMDA receptors coincidence
detectors, since they are sensitive to both the release of
ligands by the presynaptic neuron (and from glial cells)[51,62]
and changes in voltage on the postsynaptic side. In addition,
NMDA receptors are not only permeable for Na+ and K+, but
also for Ca2+ ions. These activate various intracellular targets,
such as the Ca2+/calmoduline-dependent protein kinase II
(CamKII). As such, NMDA receptors are involved in the
Figure 11. Ionotropic glutamate receptors. a) A highly schematic illustration of glutamate receptor gating. b) X-ray structure of a single GluA2
subunit, indicating the TMD (including M1–4), the extracellular LBD, and TMD. c) The fully functional tetrameric GluA2 channel cocrystallized
with an antagonist (yellow; pdb 3KG2). d) Expanded view of a GluA2 LBD cocrystallized with glutamate, emphasizing the clamshell (pdb 1FTJ).
e) The chemical structures of various agonists and antagonists for iGluRs.
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strengthening of synapses, which is believed to underlie
learning and memory.[51, 64]
A single iGluR subunit contains an extracellular amino-
terminal domain (NTD), a ligand-binding domain (LBD), a
transmembrane domain (TMD), and an intracellular carboxy-
terminal domain (CTD). The NTD is involved in subtype-
specific assembly and modulation of the receptor, while the
LBD provides a binding site for agonists (and antagonists).
Two subdomains called D1 and D2 form the LBD in a
clamshell-like arrangement. The TMD is composed of three
transmembrane helices (M1, M3, M4) and a pore helix (M2).
The CTD plays a role in channel localization, stabilization,
and targeting for degradation.[51,62]
X-ray crystallographic studies on GluRs began with
soluble versions of LBD clamshells carved out of the full-
length receptors through clever protein engineering.[63] These
structures were obtained in conjunction with various ligands
and proved to be remarkably insightful, since they could
explain the activity of agonists, antagonists, and modifiers that
affect desensitization.[63] For example, they showed that the
binding mode of glutamate to the LBD clamshell is highly
conserved in glutamate receptors and that the degree of
closure of the clamshell is roughly correlated with the activity
of a partial or full agonist.[62,65] In line with this logic,
antagonists, such as DNQX, bind to the clamshell but do
not allow it to close tight enough to trigger the biological
effect.[61] This “foot-in-the-door” mechanism of antagonism
also explains why relatively small changes in the molecular
structure can turn an agonist into an antagonist.
In a recent breakthrough in structural biology, the first
crystal structure of a full-length homomeric GluA2 receptor
was determined at 3.6  resolution (Figure 11b).[12] This
AMPA receptor was cocrystallized with a strong competitive
antagonist, thus resulting in a closed, nonconducting state of
the receptor. The structure confirmed that the subunits
arrange as a dimer of dimers with an overall C2 symmetry.
The TMD architecture resembles an “inverted” K+ channel,
which is linked to a ligand sensor (the LBD) instead of a
voltage sensor.
The activation cycle of glutamate receptors can be divided
into an inactive resting state, an active nondesensitized state,
and an inactive desensitized state. The LBDs of the four
subunits are arranged in such a way that two clamshells on
either side of the C2 axis are sitting back to back. The binding
of glutamate to the LBD of the inactive receptor initiates
closure of the clamshell cleft. The movement of the lower lobe
of the clamshell (D2) during this event rearranges the
connector between the LBD and the TMD, which exerts a
mechanical force that opens the channel. However, this active
non-desensitized state creates tension at the LBD interface.
This tension can be lifted by dissociation of the agonist or by
rearrangement at the LBD dimer interface to give a closed,
desensitized state.[62]
8. Photosensitizing Ionotropic Glutamate Receptors
Just as the outer vestibule of Kv channels had provided a
suitable platform for the attachment of MAQ, the structurally
well-characterized extracellular clamshell of glutamate recep-
tors presented an opportunity to explore tethered ligands (i.e.
PTLs). In this case, we opted for an agonist, instead of a
blocker or antagonist. This approach yielded LiGluR, the
“light-gated ionotropic glutamate receptor,” which combines
a genetically engineered kainate receptor (GluK2) with a
PTL called MAG-1 (Figure 12).[66] MAG-1 consists of a
maleimide for covalent attachment, an azobenzene photo-
switch, and a substituted glutamate as the ligand. Once MAG-
1 is attached to a cysteine residue at the LBD of GluK2
(L439C), light-induced cis and trans isomerization of the
azobenzene moiety results in reversible binding of the
tethered agonist, which translates into opening and closing
of the channel.
The design of LiGluR was based on the crystal structure
of a closed GluK2-LBD containing the agonist (2S,4R)-4-
methylglutamate (pdb 1SD3).[63] This structure suggested the
existence of a small “exit tunnel” from the bound ligand to the
surface of the closed clamshell. It was, therefore, hypothe-
sized that a tethered glutamate with this stereochemistry
could bind to the LBD and still activate the receptor as an
agonist or at least a partial agonist. A so-called tether model
(T-Mod) was synthesized to support this hypothesis. It could
be shown by calcium imaging in HEK293 cells that the tether
model, and later MAG-1, indeed act as agonists.[66] Other
crystal structures, such as the one of the partial agonist
domoic acid bound to GluK2 (pdb 1YAE) also facilitated the
design of suitable PTLs.[67]
Once the tether model was found to work, the molecule
was extended to MAG-1 by installing the azobenzene photo-
switch and adding a maleimide as an electrophile for cysteine
conjugation. Several cysteine mutants of GluK2 were gen-
erated by site-directed mutagenesis to find a suitable attach-
ment site for this maleimide. After screening about a dozen
mutants, L439C turned out to be the best position for MAG-1
attachment and light-dependent activation of the channel.[66]
Since it was not clear whether and how the attachment of
the PTL to the protein would affect the photophysics of its
azobenzene moiety, the optimal wavelength for activation
and inactivation was determined experimentally
(Figure 12).[66] It was found that 380 nm light gave the
maximum current, whereas 500 nm led to the fastest channel
closure. Interestingly, this observation corresponds very well
to the photostationary states of MAG-1 in solution
(Figure 12). In addition, the thermal relaxation of cis-MAG-
1 bound to the channel was found to be much slower than in
solution, probably because of the noncovalent interaction of
the glutamate ligand with the clamshell, which stabilizes the
cis configuration.[41]
When expressed in neurons, which contain the full
machinery to generate APs, LiGluR allows for the optical
control of neuronal firing with millisecond resolution.[68] Brief
light pulses (1–5 ms) alternating between 380 nm and 500 nm
are sufficient to generate reproducible patterns of APs. APs
can be induced in dissociated hippocampal neurons with a
frequency of up to 50 Hz without missing a beat
(Figure 12).[68] The cis stability of MAG means that it is
possible to induce constant AP firing for seconds following a
single flash of 380 nm light that lasts only a few milliseconds.
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Thus, long illumination periods leading to toxic side effects
can be avoided.[68,69]
LiGluR shows some fundamental functional differences
compared with SPARK. Both irradiation and depolarization
are needed to open the SPARK channel (corresponding to a
logic AND gate). By contrast, in LiGluR, either soluble
glutamate or light is sufficient to allow ions to flow along their
electrochemical gradient (corresponding to a logic OR gate).
LiGluR is a light-powered molecular machine, since the
energy of the photoisomerization translates into the free
energy released upon ligand binding, triggering clamshell-
closure and channel opening. It can be reset through slow
thermal isomerization or active photoswitching with a longer
wavelength. SPARK, on the other hand, is a more passive
system, since the tethered blocker functions as an extracel-
lular gatekeeper but does not trigger large molecular motions
itself. These need to be generated by membrane depolariza-
tion, which moves the voltage sensor and opens the voltage
gate.
One of the hallmarks of our systems in general, and
LiGluR in particular, is their remarkable flexibility and
tunability. This is evident at the level of the photoswitches and
Figure 12. The light-gated glutamate receptor LiGluR. a) A highly schematic illustration of LiGluR. b) The chemical structure of 4-methylglutamate
and the “tether model” (T-Mod), two important milestones on the way to LiGuR. c) The chemical structure of MAG-0, MAG-1, and MAG-2. d) The
action spectrum of LiGluR. By convention, inward currents are plotted downwards. The phototunability of the system is apparent. e) LiGluR
controls AP firing with millisecond precision. A very brief UV flash induces a train of APs, thus demonstrating the cis stability of the system.
f) LiGluR enables AP firing of up to 50 Hz. g) Controlling the escape reflex in zebrafish.
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also at the level of the protein. In addition to MAG-1, further
derivatives called MAG-0 and MAG-2 with different lengths
and stiffnesses were synthesized, and additional attachment
sites were generated by site-directed mutagenesis. This “mix
and match” approach led to some interesting results. For
example, MAG-0 anchored at L439C provided the biggest
change in the effective concentration in competition with the
antagonist DNQX. In comparison, MAG-1, our original PTL,
and MAG-2 are less effective.[69]
In another case of “sign inversion,” we found that the
point of attachment can determine whether a PTL activates
the channel in the cis or in the trans form of the photoswitch
(Figure 13).[69] MAG-0 bound to L439C, our original attach-
ment site, acts as a cis agonist but becomes a trans agonist
when attached to L486C. This is somewhat surprising given
that these two sites are only a few ngstroms apart in the X-
ray structures of GluK2. As a consequence of this inverted
wavelength sensitivity, the transfection of neurons with
L486C followed by MAG-0 attachment triggers AP firing at
500 nm and not at 380 nm, as previously observed.
Just as H-SPARK could be converted into d-SPARK,
LiGluR, a light-gated depolarizing ion channel, could be
converted into a hyperpolarizing ion channel, called
HyLighter.[70] As before, this could be achieved by changing
the ion selectivity of the transmembrane domain through
genetic manipulation. However, in the case of HyLighter, not
a single point mutation, but the exchange of a whole protein
domain was necessary. HyLighter combines the GluK2-
derived photosensitive LBD of LiGluR with the potassium-
selective TMD of the prokaryotic glutamate receptor
SGluR0, which contains the signature GYG motif of K+
channels.[71] Expression of HyLighter in hippocampal neurons
showed that inhibition of neuronal firing can be reversibly
turned on and off by irradiation with 380 nm and 500 nm light,
respectively (Figure 13). The main advantage of HyLighter in
comparison to fully genetically encoded hyperpolarizing
systems is the thermal stability of cis-MAG-1 bound to the
LBD. Therefore, in analogy to LiGluR, a single flash of
380 nm light of a few milliseconds is sufficient to prevent
neurons from firing for seconds to minutes.
One of the big surprises in the development of opto-
chemical systems was how quickly they could be transferred
to animals and could be used to dissect behavior.[68, 70] The first
in vivo experiments with LiGluR were performed in zebrafish
larvae.[68] Zebrafish at this stage of development are fully
transparent, which is a necessary requirement for reaching
neuronal circuits with light. To implement LiGluR, iGluK2-
L439C was genetically encoded in small subsets of neurons
which are involved in touch sensation and located at the head
and trunk of the animals. For the delivery of the photoswitch
to the tissue of interest, it was enough to bath the larvae in a
solution containing MAG-1. Following this treatment, an
escape reflex initiated by touching the trunk with a pipette tip
could be controlled by optical activation of LiGluR. This
reflex could be suppressed by brief illumination with 365 nm
light and restored with 488 nm light.[68] HyLighter could be
applied to zebrafish larvae in a similar way.[70]
In more sophisticated subsequent studies, LiGluR was
genetically targeted to a single type of cell and used to
elucidate the functional role of so-called Kolmer–Agduhr
neurons—a mystery unsolved for 75 years. They turned out to
be the central pattern generators of locomotion in the early
development of vertebrates.[72]
In addition to PTLs, PCLs also turned out to be applicable
to glutamate receptors (Figure 14). Their design was based on
Figure 13. Sign inversion through variation of LiGluR. a) MAG-0 at-
tached to mutant 439C activates at 380 nm, whereas MAG-0 attached
to mutant 486C induces neuronal firing at 500 nm. b) Schematic
representation of HyLighter, a hyperpolarizing light-gated glutamate
receptor. c) HyLighter can be used to silence neurons. Evoked AP
firing can be stopped and re-induced by light pulses at 380 nm and
500 nm, respectively, thus demonstrating the bistability of the system.
Figure 14. The PCL logic applied to ionotropic glutamate receptors.
a) Schematic view of a PCL operating on LiGluR. b) The structures of
LY-339434 and its derivative 4-GluAzo, a PCL that targets kainate
receptors. c) Controlling the AP firing of hippocampal neurons with
4-GluAzo.
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the extensive pharmacology of iGluR agonists, antagonists,
and blockers, but was also supported by the LBD X-ray
structures. Replacement of the naphthyl moiety of LY339434,
a know agonist of GluK1 and GluK2, with an azobenzene
moiety gave 4-GluAzo. This compound turned out to be a
highly effective photochromic agonist of certain kainate
receptors.[73] Its application to GluK1 and GluK2 channels
expressed in HEK293 cells demonstrated the reversible
control of inward currents in a light-dependent manner. In
this case, the trans state of the azobenzene preferentially
activates the receptors, and 4-GluAzo showed a slightly
higher selectivity for GluK1 than for GluK2. When applied to
dissociated rat hippocampal neurons, 4-GluAzo functioned as
“reversibly caged” glutamate.[73] Action potential firing could
be triggered by changing from 380 to 500 nm light and
stopped by switching back to the lower wavelength. In
subsequent studies, the burst firing of cerebellar Purkinje
neurons could be effectively controlled with 4-GluAzo.[74]
Detailed biophysical studies will be needed to understand
how 4-GluAzo and other PCLs work. In particular, it would
be interesting to know whether the photoisomerization can
take place while they are attached to their binding sites or
whether have to dissociate before switching can occur. X-ray
crystallographic studies could also provide important insights
into the binding modes of PCLs (and PTLs) and guide their
further development.
9. Pentameric Ligand-Gated Ion Channels
Pentameric ligand-gated ion channels (pLGICs) also play
important roles in synaptic transmission.[51] In contrast to
mammalian glutamate receptors, they can have both excita-
tory and inhibitory effects on the postsynaptic cell, which can
be a neuron or a muscle cell. The superfamily of pLGICs
includes nicotinic acetylcholine receptors (nAChR), g-amino-
butyric acid receptors (GABAA and GABAC), 5-hydroxy-
tryptamine receptors (5-HT3), and glycine receptors
(GlyRs).[75] They are sometimes also called Cys-loop recep-
tors because of the fact that all pLGICs subunits feature an
extracellular disulfide bond in a conserved region. GABAA
and GABAC are chloride-selective ion channels that mediate
fast inhibition of neuronal activity in the brain and the
retina.[76] The serotonin receptor 5-HT3 is an excitatory cation
channel that modulates neurotransmitter release. Similar to
GABAA receptors, GlyRs have an inhibitory effect on
neuronal communication. They are ligand-gated chloride
channels that are mostly expressed in the spinal cord and the
brain stem (Figure 15).[77]
Nicotinic acetylcholine receptors are excitatory cation
channels that are expressed throughout the mammalian
nervous system and at the neuromuscular junction.[78] Five
classes of subunits exist for the muscle-type receptor nAChR:
a1, b1, g, e, and d.
[51, 78b] Together, they form a cation-selective
pentameric ion channel with (a1)2b1gd stoichiometry. In
contrast, the neuronal types are composed of a2–a10 and b2–
b4 subunits and can form both heteromeric (e.g. (a4)2(b2)3)
and homomeric (e.g (a7)5) pentamers. Notably, only a7, a8,
and a9 form homomers when expressed heterologously.
[78b,79]
Each subunit of the nAChR is divided into an extracel-
lular, N-terminal ligand-binding domain, a transmembrane
region with four transmembrane spanning helices, and an
intracellular region (Figure 15). Both the N and C terminus
are located in the extracellular space. The transmembrane
helices of five single subunits line up to form the pore of the
ion channel. The (a1)2b1gd receptor at the neuromuscular end
plate has two ligand-binding sites located between the a–g
and a–d subunits, which have distinct affinities for the
neurotransmitter acetylcholine (Ach). Both binding sites
must be occupied to open the channel pore.[51, 78b]
The structural biology of nAChR has a long history, since
it was accessible from the electric organ of the ray Torpedo
californica well before the advent of molecular cloning and
heterologous expression.[17c,51] By using electron microscopy,
a structural model of the Torpedo nAChR could be gradually
built and ultimately refined to 4  resolution.[15a, 80] More
recently, X-ray structures of the two bacterial homologues
ELIC and GLIC were solved in their closed and open states,
respectively, which provided a detailed view of the pentame-
ric assembly and shed some light on channel gating.[15b,c]
Unfortunately, none of the abovementioned receptors were
crystallized and elucidated in conjunction with agonists or
antagonists.
The X-ray structure of two acetylcholine-binding proteins,
isolated from the sea snails Limnia stagnalis (l-AChBP) and
Aplysia californica (A-AChBP) provided more insight into
the interaction of pLGICs with their ligands.[81] These soluble
proteins are homologous to the extracellular ligand-binding
domain of pLGICs, but lack their transmembrane domain.
Sequence alignment of l-AChBP with various pLGICs gave a
20–24% match with the nAChR subunits and a 15–18%
match to the 5-HT3, GABAA, GABAC, and glycine receptor
subunits.[81b] The X-ray structures of l-AChBP cocrystallized
with the agonists nicotine and carbachol showed that the
cationic ligands bind at the interface between two subunits in
an “aromatic box” made up mostly of tyrosine and tryptophan
side chains. This confirmed the importance of cation–p
interactions that had been previously proposed on the basis
of intricate biophysical studies with labeled amino acids.[81c]
One side of the binding site is covered by the so-called C loop,
which closes like a flap upon binding of the agonist. This
flexible C loop also carries a cysteine disulfide at its tip but is
not to be confused with the Cys loop, which is located closer
to the membrane.
Subsequently, other ligands for pLGICs, such as epibati-
dine (an agonist for nAChR),[81d] lobeline (a mixed agonist/
antagonist for nAChR),[81d] methyllycaconitine (an antagonist
for nAChR),[81d] as well as strychnine (an antagonist for
GlyR),[82] were cocrystallized with A-AChBP. These struc-
tures showed that the C loop indeed acts as an induced-fit
sensor for ligands, and that the degree of C-loop closure
correlates with the agonist versus antagonist activity. How this
movement is mechanically linked with the opening of the
channel is still a matter of debate.
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10. Photosensitizing Pentameric Ligand-Gated Ion
Channels
The nicotinic acetylcholine receptor has been studied for
many decades, since it was the first ligand-gated ion channel
to be isolated and characterized as a protein.[17c] It occurs in
high concentrations in the electric organs of certain fish, such
as the ray Torpedo electroplax and the eel Electrophorus
electricus, which is why it could be investigated with biophys-
ical methods that were not applicable to other types of
receptors at the time. This may be the reason why the nAChR
was also the first receptor to be photosensitized, both with a
PCL and a PTL.[83] Amazingly, this was done in the early
1970s, well before the advent of molecular cloning, heterol-
ogous expression, modern structural biology, and patch-clamp
electrophysiology. It took more than three decades to repeat
this achievement with other types of receptors!
The PCL used in this case was an azobenzene unit called
Bis-Q, which bears a quaternary ammonium ion (Q) on both
sides of the chromophore. This simple, symmetric molecule
functions as a photoswitchable version of the natural agonist
acetylcholine.[83] Whereas trans-Bis-Q activated nAChRs in
Electrophorus electricus, the corresponding cis isomer was
found to be less active. The activity of the two isomers was
assayed by measuring the transmembrane potential of
Electrophorus electroplaques, which are specialized cells
from its electric organ. The system was later used to
determine the opening and closing rates of nAChRs.[84]
The corresponding PTL system was based on careful
reasoning and a bit of luck, since the native receptor could be
used without genetic manipulation. It turns out that nAChRs
Figure 15. Pentameric ligand-gated ion channels (pLGICs). a) A highly schematic view of nAChR gating. b) Crystal structure of the acetylcholine-
binding protein (AChBP) cocrystallized with nicotine (pdb 1UW6). c) A single subunit of a pLGIC, showing the transmembrane domain, the
extracellular ligand-binding domain, and the Cys loop (pdb 3P4W). d) Endogenous ligands that gate pLGICs. e) Other well-known ligands of
pentameric ligand-gated ion channels that have been cocrystallized with the AChBP.
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possess a disulfide bond on the tip of their C loops in the
a subunits, in proximity to the ligand-binding site (Figure 16).
This disulfide could be reduced without greatly affecting the
function of the receptor, thereby providing a reactive thiol for
the covalent attachment of a PTL.[83] The PTL was a benzylic
bromide, called QBr, which also carried the requisite
quaternary ammonium ion for activation of the receptor.
Conveniently, QBr could be obtained through a slight
modification of the synthetic protocol used to make Bis-Q.
Once attached to nAChRs, QBr could be used to reversibly
stimulate Electrophorus electroplaques, frog muscles, and rat
myoballs with light.[85]
Of course, in the 1970s and 1980s the light-activated
nAChR could not be heterologously expressed and genet-
ically targeted, and it was, therefore, never used to control AP
firing. Similarly, Bis-Q was mostly seen as a tool to study the
innate function of nAChRs and not as a practical way to
optically control nervous systems or animal behavior. How-
ever, with detailed structures and the modern tools of
molecular biology now available, it is highly likely that
light-gated nAChRs will soon resurface and be used in
optochemical genetics. In addition, PCLs and PTLs for other
pLGICs are bound to be developed.
11. An Abundance of Targets
From the preceding paragraphs it is clear that a variety of
receptors from different structural classes can be rendered
photosensitive by using synthetic PTLs and PCLs. However,
the vast majority of potential candidates with sufficient
structural and pharmacological data have not yet been
investigated, and opportunities abound to explore the opto-
chemical genetics of these targets. For example, given the
many structural and functional similarities between voltage-
gated potassium (Kv), sodium (Nav), and calcium channels
(Cav), the photochromic open-channel blockers discussed
above could be applied to the latter as well. In addition, Nav
and Cav channels have extensive pharmacology of their own,
which could be exploited to design more selective PCLs. The
long-awaited X-ray structure of a Nav channel has just been
reported and should greatly facilitate the design of the
corresponding PTLs.[86]
Even if one were confined to clamshell-bearing receptors,
there would be a large number of interesting targets to work
on. Clamshell-like ligand-binding domains appeared early in
evolution and are a prime example of how a successful
structural motif has been used again and again in different
functional contexts.[87]
Originally evolved as bacterial periplasmic binding pro-
teins (such as the well-known maltose-binding protein or
amino acid binding proteins), clamshells have subsequently
been integrated as functional and structural domains into
prokaryotic and eukaryotic transmembrane proteins. Appa-
rently, they were first captured by bacterial ABC transporters
that initially interacted with soluble periplasmic binding
proteins in a noncovalent fashion. At some point, they
made their way into ion channels, such as ionotropic
glutamate receptors. These include several prokaryotic glu-
tamate-gated channels,[71] a plant receptor,[88] and one that
was recently found in a comparatively simple eukaryotic
rotifer.[89] As discussed in Section 7, glutamate-gated ion
channels have assumed a major role in the fast synaptic
transmission of higher animals. However, glutamate-binding
clamshells can also be found in metabotropic glutamate
receptors (mGluRs), which are family C GPCRs.[90] This large
and important class also includes GABAB receptors
[91] and
T1R taste receptors,[92] and is found in many places in
neurophysiology. The clamshell of several of these mGluRs
has been characterized by X-ray crystallography in atomic
detail and their pharmacology is very well developed
(Figure 17).[93] Therefore, they are logical next targets for
manipulation with PTLs or PCLs. Finally, clamshell-like
ligand binding domains have been found in certain receptor-
linked enzymes, which represent the third major class of
receptors involved in signal transduction, in addition to ion
channels and GPCRs. An example is the ANP receptor, the
clamshell-dimer of which has been crystallized bound to the
atrial natriuretic peptide (Figure 17).[94] Clamshell-containing
receptor tyrosine kinases have also been recently de-
scribed.[95]
The X-ray structure of a full-length GPCR of family C
that includes the transmembrane domain has not yet been
reported. In contrast, several GPCRs belonging to family A
have been recently elucidated by X-ray crystallography
(Figure 18). These receptors comprise the largest class of
GPCRs and have a ligand-binding site that is embedded
more- or less-deeply within the membrane. They include such
Figure 16. Photosensitizing the nicotinic acetylcholine receptor. A
highly schematic depiction of a) a PTL reversibly acting on a nAChR,
and b) a PCL controlling the nAChRs. c) The structure of QBr, a PTL,
and d) BisQ, a PCL.
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important pharmacological targets as adrenergic receptors
(e.g. b2A),[96] adenosine receptors (e.g. A2A, which is a target
of the antagonist caffeine),[11c] and dopamine receptors (e.g.
D3).[11d] Rhodopsin, the photoreceptor used in animal vision,
also belongs to this category.[11b] In this case, however, the
photoswitch retinal is covalently bound in an inactive form
(11-cis) and undergoes photoisomerization to the active form
(all-trans), followed by hydrolysis and recycling, instead of
reversible binding. As such, it resembles a PTL to a certain
extent. Given this analogy, it is entirely conceivable that well-
characterized ligands for other class A GPCRs could be
replaced with PTLs and PCLs, thus turning them into
photoreceptors.
Trimeric ion channels are also interesting targets, since
they have recently been structurally characterized in atomic
detail and have good pharmacology (Figure 19). They include
purinergic receptors (P2X receptors), acid-sensing ion chan-
nels (ASICs), and epithelial sodium channels (ENaCs). The
ionotropic P2X receptors are nonselective cation channels
that are activated by extracellular adenosine 5’-triphosphate
(ATP). They are widely expressed in the nervous and immune
system, and are involved in numerous neurological functions,
such as pain sensation.[97]
The first X-ray crystal structure of a P2X receptor, the
zebrafish P2X4 receptor, was solved in its closed state at 3.1 
resolution.[13] The structure confirmed the trimeric channel
architecture and provided important insights into the ion-
conducting pore. The position of the ATP binding site was
proposed to be located between each subunit at the outer
extracellular surface of the receptor. However, the P2X4
structure was solved without ATP or an antagonist bound
(e.g. the azobenzene PPADS), thus leaving the exact binding
mode of ligands undefined.
One particular P2X receptor, P2X2, holds a special place
in the development of optochemical genetics. After heterol-
ogous expression, this cationic channel could be optically
stimulated with caged ATP. This system was reported in 2003,
and was one of the first systems to work in neurons. Since
ATP is hydrolyzed rapidly, even in the extracellular space,
photostimulation could be carried out repeatedly and with
relatively good temporal resolution. Incidentally, caged ATP
is also one of the first caged ligands, if not the first.[35]
ASIC channels belong to the degenerin/epithelial sodium
channel (DEG/ENaC) family. They are ligand-gated trimeric
cation channels that are activated by extracellular protons
and favor Na+ over K+ ions by a factor of ten. Isoforms of
ASICs are distributed throughout the mammalian central and
peripheral nervous system. They play important physiological
roles, for example, in the detection of tissue acidosis during
ischemia.[98] Two crystal structures of homotrimeric ASIC
channels have been reported recently.[99]
Unfortunately, this is not yet the case for ENaC, a
heterotrimeric channel that is constitutively open and is
extremely selective for sodium. It plays a key role in sodium
reabsorption and the perception of salt taste, and is the target
of widely used diuretics, such as Amiloride.[100]
Transient-receptor potential channels (TRP channels)
have been identified as major molecular players in sensory
perception.[101] They are tetrameric cation channels that are
polymodal and sensitive to a wide variety of input signals,
including temperature, small molecules, and ligands. One
famous member of this large superfamily is TRPV1, which is
activated upon heating, but also responds to capsaicin, the
active component of chili peppers.[102] Therefore, on a
molecular level, “hot” as in “hotplate” and “red-hot chili
peppers” are really the same thing. In one of the first
applications of optochemical genetics, TRPV1 was hetero-
Figure 17. Clamshell-like LBDs as potential targets for optochemical
genetics. a) The maltose-binding protein, a typical periplasmic binding
protein (pdb 1ANF). b) The extracellular clamshell of mGluR3 with an
agonist (pdb 2E4X). c) The extracellular clamshell of mGluR1 with an
antagonist (pdb 3KS9). d) The clamshell dimer of the ANP receptor, a
receptor-linked enzyme (pdb 1YK0). e) The chemical structures of
ligands for clamshell-containing receptors.
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logously expressed in neurons and stimulated with caged
capsaicin and light (Figure 4b,c).[35]
TRP channels are not only responsible for sensing heat
and coldness but may also play a role in sensing pressure.[101]
As such, they could have physiological roles in mechanor-
eception (touch), balance, pain, the regulation of blood flow,
and hearing.[103] The regulation of pressure sensors with light
would indeed be a very interesting exercise. This has not yet
been done with a TRP channel, but proof of principle has
been given with a comparatively simple bacterial mechanor-
eceptor isolated from Mycobacterium tuberculosis
(Figure 20).[104] This homopentameric channel, called MscL,
was crystallized in its closed form and its structure was
elucidated by X-ray crystallography.[105] If the tension of the
membrane in which it is embedded exceeds a certain value, it
opens to form a very large pore, thus functioning like a valve
that relieves osmotic pressure in the bacterium. The closed
gate of the channel is formed by a ring of five hydrophobic
residues that prevent ions and other solutes from passing
through. Detailed biophysical investigations had shown that
replacement of these hydrophobic residues with charged
amino acids leads to a constitutively open channel, presum-
ably as a result of electrostatic repulsion.[106]
In a first approach toward the photosensitization of MscL,
a caged carboxylic acid was covalently attached to a cysteine
residue to replace the hydrophobic residues at the gate. Upon
irradiation with UV light, the cages were cleaved and the
resulting negative charges triggered the opening of the
channel. In a second step, the caged acids were replaced
with a covalently attached spiropyran/merocyanine (SP/MC)
photoswitch. Switching from the comparatively nonpolar SP
state to the highly polar MC state resulted in the opening of
the valve. This process was reversible over a few cycles.[104]
Although this system was developed as a “nanovalve” for
drug delivery and may never find its way into neurobiology, it
is nevertheless a very nice example of the optical control of
channel activity and it involves both cages and photoswitches.
Interestingly, photoswitchable lipids have also been used to
change the membrane tension with light and reversibly
activate MsCl.[107] Indeed, photoswitchable lipids may provide
yet another general way to influence the function of trans-
membrane proteins and cells with light.
Figure 18. Family A GPCRs as potential targets of optochemical genetics. a) Rhodopsin, a natural photoreceptor with a covalently attached
photoswitch (pdb 1U19). b) The b2 adrenergic receptor bound to the inverse agonist carazolol (pdb 2RH1). c) The A2A adenosine receptor bound
to the agonist UK-432097 (pdb 3QAK). d) The D3 dopamine receptor bound to the antagonist eticlopride (pdb 3PBL). Protein domains used to
facilitate the crystallization have been cut off. e) Chemical structures of the cocrystallized and endogenous ligands for the receptors depicted
above. f) Isomerization of 11-cis-retinal to all-trans-retinal in rhodopsin.
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12. Summary and Outlook
As outlined above, there is certainly no shortage of
protein targets that could be addressed with optochemical
genetics. These include naturally occurring photoreceptors,
such as the channelrhodopsins, which could be fitted with
synthetic switches to tune their spectral properties. However,
many variants of synthetic molecules attached to naturally
blind receptors are also conceivable. For example, all of the
PTLs and PCLs presented herein are either agonists or
blockers, but it should be possible to turn them into
antagonists or find photochromic molecules that function as
channel openers. In addition, photoswitchable cross-linkers
could be developed that could be hooked up to two cysteine
residues.[108] These have been used with great success to
control the helical content of peptides,[108b,109] and they have
already found applications in governing the activity of
proteins.[110] It is entirely possible that this approach could
be extended to transmembrane receptors, thereby providing
yet another way to control neural activity with light.
Other types of photoswitches, such as hemthioindigos or
SPMCs, could be systematically explored and applied in
regard to neurobiologically relevant receptors. However,
much could be done even if one sticks with azobenzenes,
since azobenzenes can be easily tuned toward specific photo-
physical and thermal requirements. For example, the red-
shifted variants that operate far in the visible range of the
spectrum and turn themselves off in the dark need to be
further developed. Perhaps, one could even push the spectral
sensitivity of azobenzenes into the near-infrared, in keeping
with the grand challenge of Sir Francis Crick. Even if it is not
possible to develop single-photon switches that respond to
these wavelengths, one could explore two-photon photo-
switches that would also allow for the precise activation of
PCLs in very small volumes. These could be used, for
example, to photochemically stimulate a single dendritic
spine, which can be simultaneously monitored with two-
photon fluorescence imaging.
Light, however, is not the only “unnatural” input signal
that could be considered. For example, one could reprogram a
ligand-gated ion channel to respond to an orthogonal ligand,
that is, a molecule that does not interact with native receptors.
This strategy has already been achieved with much success
with kinases and GPCRs, and it should be possible to extend
this approach to other types of receptors.[111] One could even
speculate about sensitizing ion channels to signals that can
penetrate deep into tissues, such as radiofrequency electro-
magnetic fields or static magnetic fields.
Yet, as tempting as these speculations are, light is, and will
remain, the most interesting input signal for neuroscience.
The technology needed to quickly modulate its wavelength
and intensity is highly developed and new ways to deliver light
with spatiotemporal control and deep within tissues continue
to emerge. These include digital micromirror arrays[112] and
fiber-optic microendoscopy.[113] At the same time, genetic
targeting through viral transfection is becoming increasingly
Figure 19. Trimeric ion channels as potential targets for optochemical
genetics. a) The ASIC1 channel (pdb 3HGC). b) The P2X4 receptor
(pdb 3H9V). c) Chemicals acting on trimeric ion channels. Amiloride:
a blocker for ASIC and ENaC channels. PPADS: an antagonist of
purinergic receptors. Caged ATP: a CL for P2X2 receptors.
Figure 20. Photosensitization of a bacterial mechanosensitive ion
channel. a) The structure of MsCl in its closed form: side and top view
(pdb 2OAR). b) A caged acid used to trigger MscL opening. c) The SP
and MC forms of a photoswitch used to reversibly gate MscL.
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precise and effective, and the application of synthetic photo-
switches will certainly benefit from new drug-delivery tech-
niques. Thus, we expect that many neurobiological questions
will be tackled with optochemical genetics in the future.
Much could be learned, for example, about the innate
function of receptors and their many isoforms, since the
optical control of genetically defined receptor subtypes could
clarify their individual contributions to various physiological
processes (see Figure 5). So far, this has been carried out with
a variety of Kv channels (see Section 6), but we anticipate that
the optochemical genetic approach can be applied more
broadly. Simple pharmacological approaches frequently fail
because of a lack of selectivity, and genetic knock-out
strategies are often inconclusive because of compensatory
effects. Therefore, a knock-in animal, wherein the receptor of
interest is substituted with a simple cysteine mutation for PTL
attachment and can be conditionally activated and deacti-
vated with light could be very useful.
In addition to basic neuroscience research, where the goal
is to understand existing systems through systematic pertur-
bation, one could apply optochemical genetics to what could
be called “synthetic neurobiology”. Here, the emphasis lies on
rewiring nervous systems and altering their components to
create new forms of neural processing or sensory perception.
For example, the receptors that underlie our sense of temper-
ature or mediate pain sensation could be reprogrammed to
become photoreceptors. The mechanoreceptors responsible
for our sense of hearing and balance could be engineered in a
similar fashion. Perhaps, the day is not far away where taste
receptors and odorant receptors can be stimulated with light!
This may sound a bit outlandish, but such a philosophy
may actually lead to useful human therapies. A premier
therapeutic target would be the retina, which can be easily
reached with light, viruses, and small molecules. In many
forms of blindness, such as retinitis pigmentosa, the natural
photoreceptor cells of the retina, that is, the rods and cones,
have been destroyed, but its remaining layers are largely
intact. Their neurons express numerous receptors that could
be persuaded to become light-sensitive by using PTLs or
PCLs. Indeed, the first attempts to use optochemical genetics
to restore vision are very promising (Figure 21). In a recent
study, LiGluR was expressed in the retinal ganglion cells of
blind mice after transfection with adeno-associated virus
(AAV). Following injection of MAG-0 into the vitreous body,
the retinal ganglion cells, which communicate directly with
the brain trough the optical nerve, responded to stimulation
with light. This information was relayed to the visual cortex
and, as a consequence, the pupillary reflex as well as natural
light-avoidance behavior of the animals was restored.[114] The
first experiences with PCLs have also been promising and
bode well for applications of synthetic photoswitches in
human therapy.
For us, it is simply amazing that our attempts to teach old
receptors new tricks have gone from a proof of principle to
studies of vision restoration within seven years. This pace is
likely to increase, as numerous new targets are on the horizon
and a growing number of neurobiologists, biophysicists, and
chemists are drawn into the field. We are convinced that these
highly collaborative efforts will yield many useful techniques
with which to study neural networks or treat disorders of the
nervous system. But usefulness aside, optochemical genetics
will always remain an incredibly rewarding intellectual
exercise and a nice demonstration that the complexities of
Figure 21. Restoring visual responses with synthetic photoswitches.
a) Cross-section of a mouse eye with the retina shown in orange. b) A
schematic diagram of the retina, showing its layered architecture.
RGC: retinal ganglion cell, AC: amacrine cell, BP: bipolar cell, HC:
horizontal cell, PH: photoreceptor cells (rods and cones). c),d) Elec-
trical activity of RGCs expressing LiGluR before (c) and after addition
of MAG (d).
Figure 22. Harnessing the complexities of life. a) A dog (a natural
creature slightly modified through breeding) with a leash (a crude
device used to control its behavior, with mixed success). b) LiGluR (a
complex receptor slightly modified through genetic engineering) on a
comparatively simple synthetic leash.
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life can be harnessed with comparatively simple synthetic
chemistry (Figure 22).
13. Addendum (10. November 2011)
Orthogonal ligands, mentioned in Section 12, have
recently been developed for pentameric ligand-gated ion
channels.[115]
14. Abbreviations
AMPA 2-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid
AP action potential
Cav voltage-gated calcium channel
CL caged ligand
GABA g-aminobutyric acid
GPCR G-protein-coupled receptor
Kv voltage-gated potassium channel
MscL large-conductance mechanosensitive channel
from M. tuberculosis
Nav voltage-gated sodium channel
NMDA methyl-d-aspartate
pLGIC pentameric ligand-gated ion channel
PTL photoswitchable tethered ligand
PCL photochromic ligand
SPMC spiropyran/merocyanine photoswitch
TEA tetraethylammonium ion
TRPV1 transient receptor potential channel, for example,
subtype V1
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2) Rapid optical control of nociception with an ion-channel 
photoswitch 
2.1) Introduction 
 
Local and general anesthetics have a long history in the suppression of pain and 
perception.[1] Both pharmaceutical strategies play an important role during 
therapeutic interventions like surgery and exhibit distinct mode of actions. 
 
General anesthetics, including propofol (1) and isoflurane (2) produce anesthesia, 
unconsciousness, analgesia and immobility (Fig. 1).[1] Little is known about the 
molecular and cellular targets. Recently GABAA receptors have been identified as 
molecular targets of several general anesthetics. New evidence suggest that several 
brain areas are involved in procedure of establishing the typical symptoms of 
general anesthetics.[1] 
 
Local anesthetics play, besides their role in surgery, a fundamental role in the 
treatment of acute and chronic pain. Famous pharmacological representatives are 
lidocaine (3), its permanently charged derivative QX-314 (4), procaine (5) and 
tetracaine (6) (Fig. 1). They typically silence neuronal activity by blocking voltage-
gated sodium (Nav) channels and thus prevent the initiation of action potentials.[2] 
The prevention of Nav channel conductance follows the principle of use-dependent 
block.[3] Here the channel has to be opened first by a depolarization of the 
membrane before the local anesthetic can block the channel.  
 
The class of neurons that are responsible for sensing acute pain and represent the 
main cellular target of local anesthetics are called nociceptors (Fig. 1).[4] Cell bodies 
of nociceptors are located in dorsal root ganglia throughout the body, whereas in 
the head they innervate the trigeminal ganglion.[4] The branches of nociceptors 
project from the epidermis to the dorsal horn of the spinal cord. From there on 
information is processed into hierarchically higher regions of the brain, like the 
brainstem and the somatosensory cortex.[4] 
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Different nociceptors types can be divided into myelinated Aδ afferents and 
unmyelinated C fibers. Distinct subclasses of the Aδ afferents and C fibers are 
responsible for the detection of noxious temperatures or violent pressure. Type II 
nociceptors, which belong to the Aδ afferents, have a high mechanical threshold 
and are responsible for the detection of temperature induced acute pain. Silent 
nociceptors, a subclass of C fibers, are responsible for the slow temperature 
induced pain.[4] 
 
 
Figure 1 . A ) Chemical structures of general anesthetics, local anesthetics, dyes and TRP channel 
agonists. B) Schematic depiction of sensory neurons (nociceptors), projecting from the spinal cord 
into the skin. C) TRP channels responsible for the detection of cold, heat and chemical irritants 
expressed in nociceptors and keratinocytes (modified from publication[5]). 
 
In recent years several ion channels that detect the physical and chemical stimuli of 
heat, chemical irritants and pressure have been found and 
characterized.[4,6,7,8,9,10,11,12,13,14,15] Detection of heat and cold is associated with the 
transient receptor potential (TRP) ion channel family, including the cation selective 
channels TRPV1, TRPV3, TRPM8, TRPM3.[4,6,7,8,9,10,11,12,13,14,15] TRPV1 and TRPA1 are 
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mainly expressed in nociceptors.[9,16] Activation of TRPV1 and TRPA1 leads to 
membrane depolarization, triggering action potential firing and thus pain sensation. 
TRPV1 opens at temperatures above 37 °C and is also activated by the hot chili 
ingredient capsaicin (7) or by acidic pH.[4,8,9] The tetrameric structure of the channel 
shares similarities with Kv channels. Prolonged capsaicin (7) stimulation of TRPV1 
leads to a dilation of the channel pore, which allows huge dyes like YO-PRO 3 (8) to 
enter the cell.[17] Currently the question whether the process of pore dilation occurs 
under normal physiological tissue conditions or in pain states remains unanswered. 
TRPA1 represents a cation selective ion channel that is activated by chemical 
irritants such as allyl isothiocyanate (AITC) (9) and allicin (10).[6,18,19] Both TRPA1 and 
TRPV1 share the phenomena of pore dilation, which is initiated for TRPA1 after 
prolonged AITC (9) application.[20] In contrast, the cold sensing ion channel TRPM8 
that is activated by menthol (11) does not show any agonist induced pore dilation.[20]   
 
Application of lidocaine (3) to prevent pain usually affects other neurons in proximity 
to the treated tissue region, which is due to the membrane permeability of the drug. 
Thus, patients treated with lidocaine (3) suffer from paralysis due to block of motor 
axons, block of autonomic fibers and numbness from the block of low-threshold 
pressure receptors. The discovery of the TRPV1 pore dilation provided the 
opportunity to deliver drugs through this conduit selectively into nociceptors.[21] The 
coapplication of QX-314 (4) and capsaicin (7) on inflamed animal tissue resulted in a 
strong reduction of the side effects providing a potential new strategy in pain 
treatment.[21]  
 
In the attached paper a PCL called QAQ is described, which contains twice the QX-
314 (4) structure.[22] The photoswitch allows to reversibly light control the 
conductance of voltage-gated sodium (Nav), calcium (Cav) and potassium (Kv) 
channels from the internal site. Under 500 nm light or in the dark, QAQ rests in its 
trans state and blocks voltage-gated ion channels. Illumination with 380 nm light 
converts QAQ into its cis state and releases channel block. QAQ is membrane 
impermeable and acts as a reversible neuronal silencer once introduced into 
neurons. Based on the limited expression of TRPV1 to nociceptors and the agonist 
induced pore dilation of TRPV1,[17] QAQ can be selectively loaded into these neurons 
31
allowing for reversible control of neuronal activity. Thus, QAQ acts as a light 
regulated local anesthetic.[22] 
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local anesthetics effectively suppress pain sensation, but 
most of these compounds act nonselectively, inhibiting 
activity of all neurons. moreover, their actions abate slowly, 
preventing precise spatial and temporal control of nociception. 
We developed a photoisomerizable molecule, quaternary 
ammonium–azobenzene–quaternary ammonium (QAQ), that 
enables rapid and selective optical control of nociception.  
QAQ is membrane-impermeant and has no effect on most cells, 
but it infiltrates pain-sensing neurons through endogenous 
ion channels that are activated by noxious stimuli, primarily 
trPV1. After QAQ accumulates intracellularly, it blocks voltage-
gated ion channels in the trans form but not the cis form. 
QAQ enables reversible optical silencing of mouse nociceptive 
neuron firing without exogenous gene expression and can 
serve as a light-sensitive analgesic in rats in vivo. Because 
intracellular QAQ accumulation is a consequence of nociceptive 
ion-channel activity, QAQ-mediated photosensitization is a 
platform for understanding signaling mechanisms in acute  
and chronic pain.
Optogenetic tools enable photoregulation of action potential firing 
in neurons both in vitro and in vivo1 through the introduction 
of exogenous genes. In contrast, small-molecule photoswitches 
enable optical control of neuronal excitability without genetic 
manipulation2,3. Photoswitch molecules confer light-sensitivity 
on the intrinsic excitability of neurons within minutes4–6. 
However, unlike optogenetic tools that can be promoter-targeted 
for expression in particular types of neurons, photoswitches act 
nonselectively on all neurons that are exposed to the molecule. 
Depending on the scientific or biomedical application, it could 
be a benefit or even a requirement to target photosensitivity to a 
particular type of neuron.
Here we used a non-genetic strategy to target a photoswitch 
molecule to pain-sensing (nociceptive) neurons. Nociceptive 
neurons have been particularly inaccessible to selective electro-
physiological manipulation because both their peripheral sen-
sory endings and central synaptic terminals are quite small, either 
embedded in the skin or interspersed with other neurons in the 
spinal cord. Nociceptors are unique in possessing a high den-
sity of ion channels that respond directly or indirectly to noxious 
stimuli7. For example, the capsaicin receptor TRPV1, which is 
sensitive to noxious heat, protons and mediators of inflamma-
tion, is expressed in nociceptive neurons, but it is very sparsely 
expressed elsewhere in the nervous system8. TRPV1 enters into 
a pore-dilated state upon prolonged agonist activation, allowing 
permeation of relatively large cations9. This property has been 
exploited to deliver into nociceptors a membrane-impermeant 
derivative of the local anesthetic lidocaine, QX-314 (ref. 10). The 
selective entry and silencing of nociceptors by QX-314 gives this 
molecule potential as a pain-selective local anesthetic10. However, 
once QX-314 enters cells, it cannot escape, and silencing persists 
for many hours11. The irreversibility of QX-314 precludes tem-
porally precise regulation of nociceptor activity.
Here we describe QAQ, a photoisomerizable molecule that con-
fers reversible light-sensitivity selectively onto neurons involved 
in pain signaling, enabling rapid optical control of nociception 
without genetic manipulation.
results
QAQ photosensitized voltage-gated ion channels
We developed QAQ, a photoswitch that reversibly suppresses 
neuronal excitability by optically regulating voltage-gated Na+, 
Ca2+ and K+ channels. QAQ has a central photoisomerizable 
azobenzene coupled on both sides to quaternary ammonium 
groups (Fig. 1a). Upon illumination with 380-nm light, the elon-
gated trans-QAQ converts to the bent cis form (Supplementary 
Fig. 1a). Cis-QAQ spontaneously reverts to the trans form slowly 
in the dark (Supplementary Fig. 1b), but this transition occurs 
quickly (within milliseconds) in 500-nm light.
QAQ resembles lidocaine and its derivative QX-314 (Fig. 1b,c), 
local anesthetics that block voltage-gated Na+, K+ and Ca2+ 
 channels from the cytoplasmic side12,13. Lidocaine is a tertiary 
amine that crosses the membrane in an uncharged state and 
blocks ion channels after becoming protonated in the cytoplasm. 
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QX-314 contains a permanently charged quaternary ammonium, 
preventing it from crossing the membrane. However, QX-314 is 
a potent blocker of activity when introduced through a patch 
pipette into the cytoplasm14.
To test whether QAQ can act like a photoregulated ion-channel 
blocker, we made whole-cell recordings from NG108-15 cells, a 
mouse neuroblastoma and rat glioma hybrid cell line that expresses 
neuronal voltage-gated Na+ (Nav) channels
15. When we delivered 
QAQ into the cytoplasm through the patch pipette, it blocked most 
of the Na+ current in the trans configuration, but blockade was 
removed in 380-nm light (Fig. 1d). In contrast, bath application 
of QAQ did not block (Supplementary Fig. 2) or photosensitize 
the Na+ current (Fig.  1e), indicating that QAQ is membrane-
impermeant like QX-314 (ref. 10). Light-sensitive block of the Na+ 
current occurred at all membrane potentials tested (Fig. 1f). We 
quantified block of trans-QAQ versus cis-QAQ by examining Na+ 
current during a train of depolarizing stimuli. In the trans form, 
the amount of QAQ blockade is use-dependent, becoming more 
complete with increasing duration or frequency of depolarization 
(56% ± 10% block after 30 s, n = 7 cells, Fig. 1g). In contrast, cis-
QAQ decreased the current by 9.6% ± 0.1% (n = 7 cells), indistin-
guishable from control experiments with no QAQ (8.3% ± 0.1%, 
n = 5 cells, P = 0.52 Student’s t-test). Photocontrol of Na+ current 
could be elicited repeatedly and rapidly without decrement over 
many minutes (Fig. 1h and Supplementary Fig. 3).
Local anesthetics are used to silence the activity of sensory 
neurons, which have a variety of voltage-gated Na+ channels, 
including tetrodotoxin-sensitive and -resistant types7. Whole-
cell recordings from rat trigeminal ganglion neurons showed that 
both channel types could be photoregulated by intracellular QAQ 
(Supplementary Fig. 4).
QAQ also photoregulated voltage-gated Ca2+ channels. We 
recorded from HEK-293 cells stably expressing voltage-gated 
Ca2+ channel Cav2.2 and from GH3 cells, a rat pituitary tumor 
cell line expressing L-type calcium channels16. In both cell types, 
internal trans-QAQ blocked the Ca2+ current, but blockade was 
removed in 380-nm light (Fig. 1i and Supplementary Fig. 5a). 
Photoregulation of both Ca2+ channels was rapid, occurred 
at all voltages tested and exhibited little decrement over time 
(Supplementary Fig. 5b–f).
Voltage-gated K+ channels were also sensitive to QAQ. We 
recorded from HEK-293 cells expressing the inactivation-removed 
Shaker K+ channel17 and again observed robust photoregulation, 
with current blocked by trans-QAQ and unblocked by converting 
the molecule to the cis form (Fig. 1j). QAQ block at 500 nm was 
voltage-dependent, increasing with depolarization, as observed 
with other quaternary ammonium molecules5 (Supplementary 
Fig. 6a). QAQ photosensitized other voltage-gated K+ channels 
exogenously expressed in HEK-293 cells as well as native K+ 
current in hippocampal neurons (Supplementary  Fig.  6b–j). 
Photoregulation of K+ channels occurred rapidly and without 
decrement over time (Supplementary Fig. 6k,l).
Hence whereas QAQ was normally membrane-impermeant, 
it photosensitized current flowing through voltage-gated Na+, 
Ca2+ and K+ channels when introduced into the cell (Fig. 1k). 
Intracellular QAQ photosensitized many but not all K+ channels; 
inward-rectifier (Kir) and hyperpolarization-activated cyclic 
nucleotide–gated (HCN) channels were unaffected by QAQ 
(Supplementary Fig. 7). Intracellular QAQ did not photoregulate 
current through N-methyl-d-aspartic acid (NMDA) and non-
NMDA receptors (Supplementary Fig. 8).
QAQ enabled photocontrol of neuronal excitability
Because it imparted light-sensitive block on voltage-gated Na+, 
K+ and Ca2+ channels, QAQ should have a strong influence on 
the electrical excitability of neurons. To examine the net effect of 
Figure 1 | Intracellular QAQ photosensitized 
voltage-gated ion channels. (a–c) Chemical 
structures of cis and trans QAQ (a), lidocaine (b) 
and QX-314 (c). kBT, thermal energy of 
relaxation, with kB denoting the Boltzman 
constant and T, the temperature. (d) Na+ 
current in cells with intracellular QAQ (100 µM). 
Depolarization was from −70 mV to −10 mV. 
Photoswitching, as defined by (current  
(I)380 nm − I500 nm)/I380 nm, was 60.5 ± 5.8% 
(n = 4 cells) (e) Na+ current in cells with 
extracellular QAQ (1 mM). Photoswitching was 
1.4 ± 1.3% (n = 7 cells). (f) Current versus 
membrane voltage (Vm) of peak Na+ current.  
(g) Na+ current in cells with intracellular  
QAQ (100 µM) and repetitive depolarizing 
pulses (1 Hz). Control with no QAQ is shown.  
(h) Reversibility of Na+ current photoswitching. 
(i) Cav2.2 current using intracellular QAQ  
(100 µM). Depolarizing pulse was from  
−60 mV to +10 mV. Photoswitching was 60.5 ±  
10.5% (n = 3 cells). (j) Shaker K+ channel 
current using intracellular QAQ (100 µM). 
Depolarizing pulse was from −70 mV to +40 
mV. Photoswitching was 60.3 ± 8.6% (n = 4 cells). (k) Percentage photoswitching of currents through voltage-gated Na+ (Nav), voltage-gated Ca
2+ (Cav) 
and voltage-gated K+ (Kv) channels. ‘Neuronal’, Na
+ channels from NG108-15 cells; ‘sensory’, Na+ channels from rat trigeminal ganglion neurons; TTXR, 
tetrodotoxin-resistant; L-type, voltage-gated channels from GH3 cells; Cav2.2, Kv2.1, Kv3.1 and Kv4.2 were expressed in HEK-293 cells; ‘hippocampal’,  
K+ channels from primary hippocampal cultures (n = 3–13 cells, error bars, s.e.m.). NG108-15 cells were examined in d–h, and HEK-293 cells in i,j.
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internal QAQ on action-potential firing we carried out current 
clamp recordings from dissociated rat hippocampal neurons in 
culture. Current pulses of increasing amplitude elicited a pro-
gressive increase in the number of action potentials when QAQ 
was in the cis configuration (Fig. 2a). However, when QAQ was 
converted to the trans form, neurons fired a single spike at the 
onset of stimulation, but did not fire additional spikes even with 
the largest current pulse tested, consistent with use-dependent 
blockade of Na+ channels (Fig. 2a,b). The amplitude of the first 
spike decreased and its half-width increased when we switched 
from 380 nm to 500 nm light, in agreement with both Na+ and 
K+ channels being blocked (Fig. 2c). Higher internal concen-
tration of QAQ (≥200 µM) eliminated all spikes at 500 nm 
(data not shown).
QAQ affected spiking but had little or no effect on the rest-
ing properties of these neurons. Neither the input resistance nor 
the membrane potential changed over time as QAQ diffused into 
the neuron (Fig. 2d,e). Moreover, light had no effect on these 
 parameters, in agreement with QAQ not affecting Kir and HCN 
channels, two channels that have a role in setting the resting 
 membrane potential of neurons. Firing threshold in these neurons 
was the same with (195 pA ± 31 pA; ± s.e.m.) and without (161 pA ± 
12 pA, P = 0.44 Student t-test) QAQ in the pipette and was not 
affected by changing the wavelength of light (Fig. 2f).
QAQ entered cells through nociceptive ion channels
QAQ is normally membrane impermeant, so it does not photo-
sensitize most cells. However, we asked whether QAQ could be 
delivered into cells without requiring dialysis through a patch 
electrode. This strategy involves using nociceptive pore channels 
as a conduit for QAQ entry. We transfected HEK-293 cells with 
the gene encoding the Shaker K+ channel, which we used as 
an indicator of intracellular QAQ accumulation. We first used 
TRPV1, a channel whose pore dilates after exposure to its agonist 
capsaicin9. Control cells treated with capsaicin showed no QAQ-
mediated photosensitization (Fig. 3a). However, cells expressing 
TRPV1 showed photosensitization of Shaker current, but only 
when we applied QAQ on the cells in conjunction with capsaicin. 
We then tested two other TRP channels, TRPA1 and TRPM8, 
but found no significant loading through either TRPA1 (7.3% ±  
4.0%; s.e.m., n = 11 cells, P = 0.39, Student t-test) or TRPM8 
(−0.3% ± 1.4%; s.e.m., n = 3 cells, P = 0.81, Student t-test) channels 
after these channels were activated with allyl isothiocyanate 
(30 µM) or menthol (30 µM), respectively (data not shown).
Some ionotropic receptors for ATP (P2X receptors) also exhibit 
pore dilation upon prolonged activation18,19. Therefore we tested 
whether P2X7 channels could be used as a conduit for QAQ 
entry. Control HEK-293 cells treated with ATP showed no QAQ-
 mediated photosensitization (Fig. 3b). However, cells expressing 
P2X7 receptors showed photosensitization of Shaker current, but 
only when we applied QAQ on the cells in conjunction with ATP. 
The amount of K+ channel photosensitization was nearly the same 
5 min and 30 min after ATP application, suggesting that QAQ 
equilibrated quickly in the cell.
To test whether QAQ can enter into neurons through dilat-
ing pore channels, we recorded from cultured rat hippocampal 
neurons. QAQ alone had no effect on endogenous voltage-gated 
K+ current (Fig. 3c). However, we could bestow light-sensitivity 
to neurons that exogenously expressed P2X7 receptors, by 
treating them with QAQ and ATP. A cell death assay showed 
that there was no toxicity resulting from this treatment 
(Supplementary Fig. 9).
Figure 2 | Intracellular QAQ as a 
photoswitchable inhibitor of neuronal 
activity. (a) Action potential (AP)  
firing in dissociated rat hippocampal  
neurons with 100 µM QAQ in the patch  
pipette under illumination with 380-nm  
or 500-nm light. Firing was elicited with 
current injections (Iinj.) of increasing 
amplitude (35-pA steps). (b) Number  
of action potentials elicited by incremental 
current injections at indicated wavelengths. 
(c) Action potential shape in 380-nm  
and 500-nm light. (d) Input resistance 
directly after (0 min; P = 0.86) and  
~15 min after establishing whole-cell  
mode, in 380-nm and 500-nm light (P = 0.93). 
(e) Resting membrane potential at 0 min  
(P = 0.47) and ~15 min after establishing whole-cell mode in 380-nm and 500-nm light (P = 0.47). (f) Firing threshold ~15 min after establishing 
whole-cell mode in 380-nm and 500-nm light (P = 0.5). All error bars, s.e.m.; Student t-test; n = 4–6 cells.
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Figure 3 | TRPV1 channels and P2X7 receptors as a conduit for QAQ entry 
into cells. (a) Percentage photoswitching of Shaker K+ channels in cells 
expressing (+) or not expressing (−) TRPV1 channels and treated with or 
without capsaicin (1 µM) in conjunction with QAQ (30 min, 1 mM);  
n = 10 cells for each condition. (b) Same experiment as in a using P2X7 
receptors (P2X7R) instead of TRPV1 channels. ATP (1 mM) was applied  
for 5 min or 30 min to activate the P2X7 receptors during QAQ loading;  
n = 3–5 cells for each condition. (c) Percentage photoswitching of 
native K+ channels in hippocampal neurons. Control neurons or neurons 
expressing P2X7R were treated for 30 min with QAQ (100 µM) plus ATP 
(2.5 mM). Error bars, ± s.e.m. (n = 12 cells).
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TRPV1 channels are crucial for nociception in peripheral sen-
sory neurons7,8. The presence of endogenous TRPV1 channels 
suggests that QAQ might enter nociceptive neurons without 
requiring exogenous gene expression. We examined the effect of 
QAQ on three different parts of nociceptive neurons; their cell 
bodies, located in the dorsal root ganglion (DRG), their synaptic 
terminals, located in the spinal cord, and their sensory nerve end-
ings, located in the periphery.
Photosensitization of neurons in intact drGs
We developed a system to record and analyze many mouse DRG 
neurons at once while simultaneously photoregulating their elec-
trical activity (Fig. 4a and Online Methods). We used a three-
dimensional multielectrode array containing 60 pin-shaped 
electrodes. We controlled the isomeric state of QAQ with a light 
source positioned under the multielectrode array; the array 
was transparent to 380-nm and 500-nm light. We positioned a 
suction electrode on the peripheral nerve of the DRG and used 
an external stimulation unit to elicit action potentials, which 
could be recorded as extracellular signals by electrodes of the 
multielectrode array (Fig. 4b). We focused on action potentials 
resulting from slowly conducting C fibers (<2.5 m s−1), which 
specifically belong to nociceptive neurons. With the stimulat-
ing electrode 10–15 mm from the recording electrodes, spikes 
attributable to these neurons appeared >4 ms after the onset of 
the stimulus.
After treatment with QAQ, individual electrodes recorded 
spikes that could be silenced by switching from 380-nm to 500-nm 
light, consistent with QAQ photosensitization (Fig. 4c). This 
suggests that there must be some basal activity of QAQ- 
permeant channels in DRG neurons. We plotted the activity of 
24 neurons on a raster plot (Fig. 4d). Trains of stimuli at 10 Hz 
elicited trains of action potentials, which could be photo-
regulated by switching from 380-nm to 500-nm light. At both 
wavelengths, the number of spikes diminished within a train of 
stimuli, but the extent of spike-train accommodation was much 
greater in 500-nm light.
Principal component analysis is a common method in multi-
electrode array recordings for sorting spikes belonging to differ-
ent neurons, depending on their stereotypical spike waveforms. 
However, QAQ modulated voltage-gated channels underlying 
action potentials, changing the spike waveform as a consequence 
of photoswitching (Fig. 4e). Therefore, instead of assigning spikes 
to different units, which could be particularly error-prone in this 
circumstance, we devised an analytical method that involves inte-
grating the signal over a ‘poststimulus’ time window (Fig. 4e and 
Online Methods).
After treating the DRG with a high concentration of QAQ 
(1 mM for 30 min), we observed a dramatic decrease in the 
integrated signal upon switching from 380-nm to 500-nm light 
(Fig. 4f). At a lower concentration of QAQ (0.3 mM for 5 min), 
the integrated signal decreased to a lesser extent upon switch-
ing to 500-nm light. The weak photoswitching imparted on the 
DRG neurons by mild QAQ treatment suggests that little QAQ 
accumulated in the cells.
If the TRPV1 channel is the main conduit for QAQ 
entry, blocking or eliminating TRPV1 channels should 
reduce QAQ loading and consequently the amount of 
photosensitization. Consistent with this, we found that 
N-(4-ter t iar ybuty lphenyl)-4(3-cholorphyr idin-2-y l)- 
tetrahydro-pyrazine1(2H)-carboxamide (BCTC), a TRPV1 
antagonist that inhibits acid- and capsaicin-induced activa-
tion, considerably reduced DRG photosensitization (Fig. 4g). 
In Trpv1−/− mice, photosensitization was also strongly reduced 
but not completely abolished. Ruthenium red, a nonselective 
TRP channel pore blocker, entirely prevented photosensitiza-
tion. Taken together, these data suggest that TRPV1 channels 
are the main entry route for QAQ into DRGs.
Figure 4 | Photosensitization of intact 
DRGs recorded with a three-dimensional 
multielectrode array (MEA). (a) Experimental 
setup. (b) Mouse DRG placed onto the MEA 
(scale bar, 200 µm). Extracellular recordings  
are shown superimposed on each electrode.  
(c) Signals recorded from one electrode  
(under 380-nm and 500-nm light) after  
30-min treatment with 1 mM QAQ.  
(d) For simultaneous recording of 24 units, 
shown are a raster plot of spiking under  
10-Hz stimulation (top) and average firing  
rate (bottom; 100 ms time bins). (e) Signals 
from a single electrode during a train of  
50 stimuli (stim; 10 Hz). The first response  
is shown in black; the last in violet or green.  
The signal was integrated over a poststimulus 
time window represented by the colored box.  
(f) Average integrated signal over five  
light cycles, from a DRG treated with 1 mM  
QAQ for 30 min or 0.3 mM QAQ for 5 min.  
(g) Quantification of photosensitization  
with the following treatment conditions,  
normalized to photosensitization with QAQ alone (0.3 mM for 5 min, dotted line): BCTC (1 µM), 22 ± 18%, P = 0.03; Trpv1−/− mice, 34 ± 8% photosensitization, 
P = 0.005; ruthenium red (RR, 10 µM), 7 ± 18% photosensitization, P = 0.006; capsaicin (1 µM), 172 ± 30% photosensitization, P = 0.05; Bradykinin  
(BK; 1 µM), 192 ± 30% photosensitization, P = 0.02; and electrical stimulation (stim.: 5-s trains of 1-ms stimuli at 10 Hz, repeated every 30 s for 5 min),  
138 ± 21% photosensitization, P = 0.02. Error bars ± s.e.m.; Mann-Whitney U test (n = 3–5 DRGs).
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This system can be used as a platform for assessing the activity 
of TRP channels in the intact DRG in response to various 
stimuli. We treated the ganglia with capsaicin during QAQ 
loading, followed by thorough washing with normal saline. 
Capsaicin is a selective agonist of TRPV1, and as expected, 
it increased QAQ loading and therefore photosensitization 
(Fig.  4g). Bradykinin is a neuropeptide that promotes 
pain hypersensitivity and inflammation20. We found that 
Bradykinin also promoted QAQ-mediated DRG photosensitiza-
tion, consistent with a signaling cascade that leads to activation 
of TRP channels21.
Direct electrical stimulation of sensory neuron axons in 
the peripheral nerve also promoted DRG photosensitization 
(Fig. 4g), indicating enhanced QAQ entry during the stimulation 
period. Action potential firing may directly promote QAQ entry 
into TRPV1-containing neurons, but TRPV1 channels are only 
weakly voltage-sensitive22. In addition, action potential firing 
may promote DRG somata to release neuro-inflammatory trans-
mitters, and these may indirectly lead to activation of nociceptive 
channels, a positive feedback mechanism that could contribute to 
prolonged hypersensitivity and chronic pain.
Photosensitization of neurons in spinal cord slices
TRPV1 is abundantly expressed throughout the entire length of 
nociceptive neurons, including the central terminals in the spinal 
cord, but it is thought to be largely absent from non-nociceptive 
sensory neurons7. The central terminals of nociceptive neu-
rons are located in laminae I–II of the dorsal horn of the spi-
nal cord, whereas the terminals of non-nociceptive neurons are 
located in laminae III–IV (ref. 7). If QAQ loading is selective for 
nociceptors, it should photosensitize only the subset of sensory 
neurons that terminate in laminae I–II.
We treated spinal cord slices with QAQ and recorded syn-
aptic responses in dorsal horn neurons triggered by electrical 
stimulation of the dorsal root (Fig. 5a). In lamina II, the average 
excitatory postsynaptic current (EPSC) amplitude was reduced 
by switching from 380-nm to 500-nm light, whereas light had 
no effect for EPSCs recorded in laminae III–IV (Fig.  5b,c). 
These results are consistent with preferential photosensitization 
of nociceptive neurons by QAQ (Fig. 5d).
To distinguish between a pre- versus postsynaptic effect of 
QAQ, we recorded spontaneous EPSCs in lamina II neurons 
and analyzed the cumulative distribution of amplitudes and inter-
event intervals. The amplitude of these EPSCs was unaffected by 
the wavelength of light but the frequency of these EPSCs was 
decreased by 500-nm light (Fig. 5e–g) in six of eight cells. A change 
in EPSC amplitude indicates a postsynaptic alteration in neuro-
transmitter receptor function, whereas a change in frequency usu-
ally indicates a change in presynaptic neurotransmitter release.
QAQ-mediated photosensitization also impacted polysynaptic 
pathways on the spinal cord. Trains of stimuli generated a strong 
inward current that persisted for several seconds after the mono-
synaptic EPSCs should have decayed (Fig. 5h). Switching from 
380-nm to 500-nm light caused a dramatic reduction in the 
amplitude of this current. Switching back to 380-nm light largely 
restored the initial amplitude of the response (Fig. 5i).
In some, but not all lamina II neurons, QAQ photosensitized 
not only the presynaptic inputs but also intrinsic voltage-gated 
channels K+ currents (Supplementary  Fig.  10a). In contrast, 
there was little photosensitization of K+ channels in lamina III–IV 
neurons. Photosensitization of lamina II neurons was elimi-
nated by BCTC (Supplementary Fig. 10b). These results suggest 
that TRPV1 channels enabling QAQ entry are present and 
active in lamina II neurons to a much greater extent than in 
lamina III–IV neurons.
In vivo photoregulation of peripheral nerve endings
If QAQ effectively photosensitizes nociceptive neurons, exposure 
to light should alter pain sensation in vivo. We explored this possi-
bility by testing the pain-avoidance (nocifensive) blinking response 
that is elicited by mechanical stimulation of the cornea in rats using 
the von Frey hair test23 (Online Methods). The cornea is densely 
innervated with nociceptors24 that mediate the blink response23. 
Free nerve endings are only a few micrometers below the surface, 
and the cornea is transparent, facilitating optical control. To enable 
QAQ entry into nociceptor nerve endings, we topically applied 
Figure 5 | Photosensitization of spinal cord 
slices. (a) Schematic of a spinal cord slice with 
a whole-cell patch recording from neurons 
either in lamina II or laminae III–IV and using 
electrical stimulation of the dorsal root (stim.). 
(b,c) Postsynaptic responses recorded in a 
lamina II (b) and a laminae III–IV neuron (c), 
in response to single stimuli to the dorsal root. 
(d) Percentage photoswitching of the integrated 
current exhibited by inputs to laminae II  
(35 ± 9%, n = 8 cells) and III–IV neurons  
(−1.5 ± 9.4%, n = 10 cells, *P = 0.01).  
(e,f) Cumulative probability distributions of 
EPSC amplitude (e) and frequency (f) recorded 
in a lamina II neuron in 380-nm and 500-nm 
light. (g) Average light-elicited EPSC frequency 
in 380-nm, 500-nm and again in 380-nm light 
(37.5 ± 11.3% photoswitching, n = 8 cells).  
(h) Polysynaptic responses recorded from a lamina II neuron in response to a 20 Hz train of stimuli to the dorsal root. (i) Quantification of average 
responses to train stimulation (50 Hz for 500 µs) in 11 neurons in 380-nm, 500-nm and again in 380-nm light. Synaptic responses after the stimulus 
train were integrated and normalized to the initial amplitude in 380-nm light (n = 11 cells). In all experiments described in this figure, slices were 
treated with 1 mM QAQ for 20 min before recording. Error bars, ± s.e.m.; Student t-test.
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QAQ with capsaicin in one eye and capsaicin alone in the contra-
lateral eye. We immobilized the rats by mild sedation with xylazine 
and ketamine at low doses that do not interfere with nocifensive 
blinking25. The von Frey hair test in ambient light showed that 
the normalized blink threshold was about fivefold higher in the 
eye treated with QAQ plus capsaicin compared to the eye treated 
with capsaicin alone (Fig. 6a). Moreover, 380-nm light decreased 
the normalized blink threshold in the eye treated with QAQ 
plus capsaicin (Fig. 6b). The decrease in blink sensitivity caused 
by QAQ was completely removed by exposure to 380-nm light 
(Fig. 6c). Taken together, these results show that QAQ can serve 
as a local anesthetic that can be turned off with light.
discussion
Microbial light-sensitive ion transporters, including halorho-
dopsin26 and archaerhodopsin-3 (ref. 27), have been used as opto-
genetic inhibitors of neuronal activity. Genes encoding these proteins 
can be promoter-targeted to subpopulations of neurons1. However, 
for several reasons, nongenetic optical control of nociception with 
QAQ may be preferable to optogenetic methods.
Unlike optogenetic tools that overpower the natural activity of 
cells, QAQ acts on endogenous ion channels that underlie initia-
tion and propagation of action potentials. Hence QAQ suppresses 
electrical excitability at its source. Because the ion-transport rate 
of transporters is much slower than ion flux through channels, 
optical silencing with halorhodopsin and archaerhodopsin-3 
requires very high expression1. Exogenous expression can be 
achieved by injecting viral vectors into the appropriate part of 
the nervous system1, but expression requires days to weeks and 
is restricted to neurons that are exposed to an adequate titer of 
virus. Optogenetic expression can result in permanent genetic 
alteration of neurons, which may not be necessary or desirable 
for the acute regulation of pain signaling, either for scientific 
or biomedical applications. In contrast, QAQ-mediated photo-
sensitization occurs within minutes and persists only until the 
molecule dissipates, either by being metabolized inside the cell 
or diffusing away from targeted neurons. Because QAQ is a small 
molecule, it diffuses readily through tissue and presumably gains 
access to all neurons that have ion channels that permit its entry 
into the cytoplasm.
QAQ has potential value as both a scientific and a clinical tool 
for controlling nociception. Because it selectively accumulates in 
nociceptors, QAQ could selectively inhibit pain signaling while 
sparing other sensory modalities and therefore could function 
as a targeted analgesic. This is similar to the recently proposed 
therapeutic use of QX-314 (ref. 10). However, QAQ has the added 
feature of being rapidly controllable with light. In vivo photo-
control would require delivery of sufficient QAQ and projec-
tion of sufficient light onto target neuronal tissues. Because it is 
doubly charged, QAQ is unlikely to cross the blood-brain bar-
rier. But our results show that QAQ penetrates into spinal cord 
slices and intact DRGs, so if injected, QAQ should have access 
to other neural structures. Implanted fiber-optic systems such as 
those developed for deep brain photocontrol of neurons express-
ing optogenetic tools28 could be adapted for controlling QAQ 
administered to internal neural structures (for example, spinal 
roots or DRGs). QAQ might also be controlled by an external 
light source after topical administration (for example, for treat-
ing corneal pain).
QAQ-mediated photosensitization could facilitate mapping of 
nociceptive circuit connections mediated by fast conventional 
synapses or by slow neuromodulatory neurotransmitters that may 
contribute to central sensitization and pain hypersensitivity20. 
Our synaptic studies in spinal cord were limited to full-field 
 regulation of presynaptic activity, but higher-resolution photo-
control should be possible by projecting through a microscope 
small spots or patterns of light, for example, to target presynaptic 
axons or terminals.
Finally QAQ provides insight into the activity status of ion 
 channels implicated in pain and inflammation. Previously, the 
activity of nociceptive ion channels has been studied almost 
exclusively in isolated neurons that had been enzymatically and 
mechanically dissociated from DRGs21. This disruptive procedure 
could alter the activity and expression of these channels29. QAQ 
enabled investigation of nociceptive ion-channel activity in 
undisrupted neural structures. Moreover, QAQ photosensitized 
regions of a nociceptor that are largely inaccessible to electrodes. 
Hyperalgesia in both inflammatory and neuropathic pain is 
associated with upregulation of TRP channel gene expression in 
peripheral nociceptors7, but the activation status of these channels 
in chronic pain is unknown. Because QAQ-mediated photosen-
sitivity is a consequence of the cumulative activity of nociceptive 
channels, it serves as an ultrasensitive reporter that provides new 
insights about when and where these channels are active, in both 
physiological and pathological conditions.
methods
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/naturemethods/.
Note: Supplementary information is available on the Nature Methods website.
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Figure 6 | QAQ optically regulated nociception in vivo, in live rats.  
(a) Change in blink threshold in the eye treated with capsaicin (10 µM) plus 
QAQ (20 mM), normalized to the contralateral eye treated with capsaicin 
alone. Experiments were performed in ambient light. Average increase was 
5.1-fold (black dot; n = 22 rats, P = 0.007). (b) Change in blink threshold in 
the eye treated with capsaicin (10 µM) plus QAQ (20 mM) after illumination 
with 380-nm light. Average decrease was to 0.5 the value in the dark 
(black dot; n = 9 rats, P = 0.03). (c) Group data for eye-blink threshold 
experiments. Numbers in parentheses indicate the total number of rats 
together with number of rats that did not respond to the maximum force 
applied (1 g). Error bars, ± s.e.m.; Student t-test; *P < 0.05; **P < 0.01.
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General. All animals were housed in the centralized animal 
facilities as assigned by the University of California Berkeley 
and were provided food and water ad libitum. Animal care 
and experimental protocols were approved by the University 
of California Berkeley Animal Care and Use Committee. 
All chemicals were purchased from Sigma-Aldrich, except 
BCTC (N-(4-tertiarybutylphenyl)-4(3-cholorphyridin-2-yl)- 
tetrahydro-pyrazine1(2H)-carboxamide) and AITC (allyl isothio-
cyanate) that were purchased from Tocris.
QAQ synthesis and spectroscopic characterization. QAQ was 
synthetized as previously described5. UV-vis spectra of QAQ were 
measured using a smartSpec Plus spectrophotometer (Bio-Rad) 
in combination with illumination using the Polychrome V (Till 
Photonics), through an optic fiber positioned perpendicular to 
the detection beam of the spectrophotometer.
Cell culture. HEK-293 cells were cultured under standard con-
ditions (Dulbecco’s modified Eagle medium (DMEM) contain-
ing 10% FBS). We grew GH3 cells in F-12K medium containing 
15% horse serum and 2.5% FBS. NG108-15 cell medium con-
tained 95% DMEM mixed with HAT (0.1 mM hypoxanthine, 
400 nM aminopterin and 0.016 mM thymidine) and 5% FBS. 
Cells were plated on poly(l-lysine) (0.1 mg/ml) treated cover-
lips in a density of 12,000 cells per cm2 for electrophysiological 
measurements. Dissociated hippocampal neuronal preparations 
were performed from neonatal Sprague-Dawley rats according 
to standard procedures4. Hippocampi were dissected, dissoci-
ated and cells were plated on poly(l-lysine)-coated coverslips 
at a density of 100,000/cm2. We grew hippocampal neurons 
in minimum essential medium containing 5% FBS, 20 mM 
glucose, B27 (Invitrogen), glutamine and Mito+ Serum Extender 
(BD Biosciences). Trigeminal ganglion (TG) neurons from neo-
natal rats were prepared as previously described30. TGs were 
dissected and neurons were dissociated (with collagenase and 
trypsin) and plated on poly(l-lysine)-coated coverslips. We 
grew TG neurons in minimum essential medium containing 
5% horse serum, MEM vitamins (Invitrogen), glutamine and 
penicillin-streptomycin. HEK-293 cells were transfected using 
calcium phosphate precipitation and measured after 24–48 h 
(ref. 4). GH3 and NG108-15 cells were recorded 24 h after plating. 
Hippocampal neurons were transfected 7 d after plating and 
measured 10–14 d after plating. TG cells were measured 12–48 h 
after plating.
Dorsal root ganglia (DRG) preparation. Mice, C57/BL6 wild 
type or Trpv1−/− aged 1–6 months of either sex, were deeply 
anesthetized with isoflurane and killed by cervical dislocation. 
The spinal column and surrounding muscle, from the sacral to 
cervical regions, was removed from the mouse and dissected in 
cold (4 °C) artificial cerebral spinal fluid (ACSF) (124 mM NaCl, 
4 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 26 mM NaHCO3, 20 mM 
glucose, 2 mM sodium pyruvate and 0.4 mM ascorbic acid, 
pH 7.3) equilibrated with 95% O2 and 5% CO2. A laminectomy 
was performed from the thorax to the sacrum, and the spinal 
cord was gently removed, exposing the DRGs. The DRGs and 
attached nerves (10–20 mm long) were removed from the lumbar 
region and incubated for at least 30 min at room temperature 
(18–22 °C) in an oxygenation chamber on a nitrocellulose 
membrane (Sartorius Stedim Biotech) moistened with ACSF.
Spinal cord slice preparation. C57/BL6 mice were deeply anes-
thetized with isoflurane and quickly beheaded. The spinal column 
and surrounding muscles were removed and dissected in ice-
cold oxygenated low calcium, low magnesium ACSF (101 mM 
NaCl, 3.8 mM KCl, 18.7 mM MgCl2, 1.3 mM MgSO4, 1.2 mM 
KH2PO4, 10 mM HEPES, 1 mM CaCl2 and 1 mM glucose). After 
laminectomy, the spinal roots were cut, the spinal cord was gently 
removed, and its lumbar part was placed into a small agarose 
block. We prepared 300-µm-thick slices using a Leica VTS 1000 
vibratome. The slices were then transferred in warm (31 °C) 
ASCF equilibrated with 95% O2 and 5% CO2 for at least 1 h before 
starting patch-clamp recordings.
Whole-cell  electrophysiology. Patch clamp recordings of 
 mammalian cells were performed at room temperature. Bath 
solution for K+ current contained 138 mM NaCl, 1.5 mM KCl, 
1.2 mM MgCl2, 2.5 mM CaCl2, 1 µM tetrodotoxin (for hippo-
campal neurons only), 5 mM HEPES and 10 mM glucose. Bath 
solution for Na+ current contained NaCl 145 mM, CdCl2 0.5 mM, 
CaCl2 2 mM, HEPES 5 mM and glucose 5 mM. Bath solution 
for Ca2+ current contained NaCl 138 mM, KCl 5.4 mM, MgCl2 
0.8 mM, BaCl2 20 mM, tetrodotoxin 1 µM (for GH3 cells only), 
HEPES 10 mM and glucose 5 mM. Bath solution for current 
clamp experiments contained NaCl 138 mM, KCl 1.5 mM, MgCl2 
1.2 mM, CaCl2 2.5 mM, HEPES 5 mM and glucose 10 mM. Pipette 
solution for K+ current contained NaCl 10 mM, K+ gluconate 
135 mM, HEPES 10 mM, MgCl2 2 mM, MgATP 2 mM, EGTA 
1 mM. Pipette solution for Na+ current contained NaCl 30 mM, 
CsCl 100 mM, HEPES 10 mM, MgCl2 2 mM, CaCl2 1 mM, MgATP 
2 mM, NaGTP 0.05 mM, EGTA 10 mM and glucose 5 mM. Pipette 
solution for Ca2+ current contained CsCl 120 mM, HEPES 20 mM, 
CaCl2 1 mM, MgATP 2 mM, EGTA 11 mM and glucose 5 mM. 
Pipette solution for current clamp experiments contained NaCl 
38 mM, potassium gluconate 97 mM, HEPES 20 mM, MgATP 
4 mM, NaGTP 0.35 mM and EGTA 0.35 mM. All solutions were 
adjusted to pH 7.4. Electrophysiological measurements were 
performed with an Axopatch 200A (Molecular Devices) or a 
Patch-Clamp PC505B (Warner) amplifier. Patch pipettes resist-
ances were 2–4 MΩ. Sodium channel currents in NG108-15 cells 
and calcium channel currents in GH3 cells were corrected by P/N 
leak subtraction. pClampex 8.2 software (Molecular Devices) in 
combination with a Digidata 1200 interface (Molecular Devices) 
were used to create and apply pulse protocols. Voltage clamp 
recordings were low-pass–filtered at 2 kHz and current clamp 
measurements were low-pass filtered at 5 kHz. Illumination of 
cells was based on a xenon lamp either in combination with nar-
row band-pass filters or with a monochromator Polychrome V, 
as described previously5. For direct internal application through 
the patch pipette, QAQ was dissolved to a final concentration 
of 100 µM. Measurements were started after 5–10 min of equi-
libration time for HEK-293, NG108-15, GH3 cells and TG 
neurons, and after 15–20 min for hippocampal neurons. For 
bath incubation, cells were incubated with QAQ (classically 
1 mM) in the presence or absence of agonist (1–2.5 mM ATP 
or 1 µM capsaicin) at 37 °C in the dark. Loading solution is 
similar to K+ current recording solution but with no calcium. 
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Treated coverslips were rinsed with regular calcium-containing 
recording solution before measurement.
For spinal slice electrophysiology, slices were placed in a recod-
ing chamber bathed with warmed (31 °C) ACSF (NaCl 130.5 mM; 
KCl 2.4 mM, CaCl2 2.4 mM, NaHCO3 19.5 mM, MgSO4 1.3 mM, 
KH2PO4 1.2 mM, HEPES 1.25 mM and glucose 10 mM, pH 7.4) 
equilibrated with 95% O2 and 5% CO2. Electrophysiological mea-
surements were performed under the control of an Olympus BX51 
microscope using an Axoclamp 2B (Molecular devices). Patch 
pipettes (7–11 MΩ) were filled with appropriate pipette solution 
(potassium gluconate 120 mM, KCl 20 mM, CaCl2 0.1 mM, MgCl2 
1.3 mM, EGTA 1 mM, HEPES 10 mM, GTP 0.1 mM, cAMP 
0.2 mM, leupeptin 0.1 mM, Na2ATP 3 mM and d-manitol 77 
mM, pH 7.3). Illumination of preparations was performed using 
two different wavelength diodes (380 nm and 500 nm) control-
led by transistor-transistor logic (TTL) pulses. A glass suction 
electrode connected to Master-8 (A.M.P.I.) stimulator was used 
to stimulate dorsal roots. Non-nociceptive primary afferent fibers 
were specifically recruited using low-threshold stimulations 
(50 µs, less than 100 µA), whereas nociceptive fibers were recruited 
using high-intensity stimulations (500 µs, more than 250 µA).
Multielectrode  array  recordings. A DRG was placed onto a 
three-dimensional multielectrode array (MEA) chip (MEA60 
200 3D GND, Ayanda Biosystems) and secured in place with a 
‘harp’ made from dialysis membrane stretched over thick plati-
num wire and bonded with super glue; the wire was U-shaped 
to allow the nerve to exit without being crushed. The MEA chip 
was mounted on an MEA1060-Up amplifier (Multi Channel 
Systems) and placed on the stage of an IX71 inverted microscope 
(Olympus). The nerve was led into a manipulator-mounted glass 
suction electrode of appropriate size driven by a DS2 stimulus 
isolator (Digitimer) triggered by pClamp v10.0 software through 
a Digidata 1440A data acquisition system (Molecular Devices). 
Except during drug incubations, the MEA chamber was continu-
ously perfused with oxygenated ACSF at ~2 ml/min. Recordings 
were performed at ~30 °C.
Before the drug incubation, the DRG was checked for response 
to stimulation at 1 Hz. If the signal was acceptable, the MEA 
chamber solution was replaced with oxygenated ACSF containing 
QAQ with or without other drugs and incubated for 5 min. When 
using blockers, the DRG was preincubated with the blocker 
for 5 min before the application of QAQ with the blocker. The 
DRG was then washed with ACSF for 10 min before performing 
the experiment.
Recordings were done at a stimulation rate of 10 Hz while illu-
minating the DRG with 380-nm or 500-nm light. Each experiment 
consisted of 5 cycles of 30 s under 380-nm light followed by 30 s 
under 500-nm light. The DRG was stimulated with 1-ms pulses 
at 10 Hz for the last 5 s under each wavelength of light, allowing 
25 s to recover from adaptation in between stimulation episodes. 
Illumination was provided by a U-LH100HGAPO mercury lamp 
(Olympus) through a 4× objective, resulting in intensities of 
17–28 mW/mm2. Filters for 380 nm and 500 nm were switched 
by a Lambda 10-3 system (Sutter Instrument Company) under 
the control of Metamorph v7.5.3.0 software (Molecular Devices). 
Evoked responses were recorded at 20 kHz with MC_Rack  
v4.0 software (Multi Channel Systems). Pictures were taken 
using Metamorph with a CoolSNAP HQ2 camera (Photometric) 
connected to the microscope.
Multielectrode array data analysis. Data were recorded in 40-ms- 
long sweeps synced to stimulation pulses, so that the stimulation 
produced an artifact at the beginning of the sweeps. Evoked spikes 
were detected by a negative threshold manually set beyond the 
noise level. For each detected spike, the first millisecond before 
the peak and the two milliseconds after were extracted into 
text files by MC_DataTool software (Multi Channel Systems), 
for processing with a custom Matlab (MathWorks) program.
Our custom Matlab program calculated the area under each 
spike to the threshold level. A region of interest (ROI) was also set 
manually for each recording to exclude the stimulus artifact. The 
total integrated area of all spikes was calculated for each sweep, 
and averaged over the five cycles in each wavelength (Fig. 4e,f). 
This averaged area per sweep was summated over the 5 s of stimu-
lation to quantify the total evoked response in each wavelength of 
light. For each active channel, the normalized photosensitization 
was calculated as (area380nm − area500nm) / (area380nm + area500nm). 
Channels with excessively small and/or irregular signals were 
conservatively culled. The per-channel photosensitization values, 
generated from at least three separate DRGs per drug condition, 
were pooled by condition and compared for significance using a 
Mann-Whitney U test (5% significance level).
Cornea-evoked reflex blinks. Sprague-Dawley rats (3–6 weeks 
old of either sex) were sedated using intraperitoneal injection 
of xylazine (9 mg/kg) and ketamine (60 mg/kg). We placed rats 
on a warming pad, and we intiated behavioral testing when rat 
spontaneous movements ceased but while pinching the rat’s paw 
with a pair of forceps elicited a brisk withdrawal reflex. We used a 
series of von Frey hairs, nylon fibers of increasing diameter, which 
we pressed against the cornea to impart increasing force with high 
accuracy. We held von Frey hairs perpendicular to the cornea for 
~2 s, or until a blink initiated, using progressive increase in force 
from 8 mg to a maximal value of 1 g. Stimuli were presented three 
times for each stiffness, at intervals of several seconds. Both eyes 
were tested, and a positive response was noted if the rat blinked 
two or three times for a given force. Capsaicin (10 µM) was then 
topically applied on one cornea using a pipette (10 µl volume), and 
the contralateral cornea was treated with a mixture of capsaicin 
(10 µM) and QAQ (20 mM). Von Frey testing was done again 
10–15 min after drug application. Immediately after von Frey test-
ing, light was applied using an LED (Prizmatix, λmax = 385 nm, 
30 mW/cm2) for 1 min and von Frey testing was done again.
Statistical analysis. Unless otherwise noted, all data are presented 
as ± s.e.m. and statistics were analyzed using a Student t-test.
30. McKemy, D.D., Neuhausser, W.M. & Julius, D. Identification of a cold 
receptor reveals a general role for TRP channels in thermosensation. 
Nature 416, 52–58 (2002).
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Supplementary Files 
 
Supplementary File  Title 
Supplementary Figure 1   Photochemical properties of QAQ. 
Supplementary Figure 2   External QAQ does not block voltage-gated Na+ 
channels. 
Supplementary Figure 3   Intracellular QAQ quickly blocks and unblocks Na+ 
channels. 
Supplementary Figure 4   QAQ photosensitizes voltage-gated Na+ channels from 
sensory TG neurons. 
Supplementary Figure 5   QAQ photosensitizes various voltage-gated Ca2+ 
channels. 
Supplementary Figure 6   QAQ photosensitizes various voltage-gated K+ 
channels. 
Supplementary Figure 7   QAQ does not photosensitize Kir or HCN channels. 
Supplementary Figure 8   QAQ does not photosensitize glutamate receptors. 
Supplementary Figure 9   Neuronal survival after ATP and QAQ treatment. 
Supplementary Figure 10   QAQ photosensitizes second order neurons in spinal 
cord slices. 
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Supplementary Figure 1: Photochemical properties of QAQ. 
 
 
(a) UV-Vis spectrum of QAQ in solution (10 mM PBS, pH 7.4) either in the dark, or under 
illumination with 500 nm or 380 nm light. (b) Thermal relaxation of QAQ from cis to trans in 
the dark. Data was fitted using a mono-exponential decay (t1/2 = 449 +/- 5 s).  
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Supplementary Figure 2: External QAQ does not block voltage-gated Na+ channels. 
 
(a) Na+ current recorded from an NG108-15 cell upon depolarization from -70 to -10 mV. 
Perfusion with QAQ 100 µM (red) or 1 mM (blue) did not alter Na+ current (black). (b) 
Normalized current (0.1 ± 2.5 % block ± s.e.m., n = 3 cells, p = 0.97 Student t-test).   
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Supplementary Figure 3: Intracellular QAQ quickly blocks and unblocks Na+ 
channels. 
 
(a) Onset of block after switching light to 500 nm. Current was fitted with a bi-exponential 
decay equation. The fast process (t1/2 = 88 ± 5 ms, n = 3 cells) reflects block of Na+ 
channels, whereas the slow process may reflect slow inactivation of Na+ channels. (b) 
Kinetics of unblock after switching light to 380 nm. Current was fitted with a bi-exponential 
decay equation, with t1/2 = 58 ± 30 ms (n = 3 cells). The slow process may reflect slow 
recovery from inactivation of Na+ channels.  
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Supplementary Figure 4: QAQ photosensitizes voltage-gated Na+ channels from 
sensory TG neurons. 
 
(a) Na+ current recorded from a TG neuron upon depolarization from -70 to -10 mV, using 
100 µM QAQ in the pipette and under both wavelengths of light (49.7 ± 5.2 % 
photoswitching ± s.e.m., n = 6 cells). (b) I/V dependency of block and unblock. (c) 
Reversibility of block and unblock. (d) TTX-resistant Na+ current recorded from a TG 
neuron upon depolarization from -70 to -10 mV, using 100 µM QAQ in the pipette, 0.5 µM 
TTX in the bath, and under both wavelengths of light (46.3 ± 7.9 % photoswitching ± 
s.e.m., n = 4 cells). (e) I/V dependency of block and unblock. (f) Reversibility of block and 
unblock under both wavelength of light. 
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Supplementary Figure 5: QAQ photosensitizes various voltage-gated Ca2+ channels. 
 
 
Whole-cell calcium current recording from GH3 cells, using 100 µM QAQ in the pipette, 
showing (a) raw current traces (77.9 ± 2.9 % photoswitching ± s.e.m., n = 5 cells) and (b) 
reversibility of block and unblock under both wavelength of light. Depolarization to +10 mV. 
Whole cell calcium current recording from HEK-293 cells stably expressing Cav2.2, using 
100 µM QAQ in the pipette, showing (c) I/V dependency and (d) reversibility of block and 
unblock. Depolarization to +10 mV. For both voltage-gated Ca2+ channels currents were 
measured using barium instead of calcium, to limit fast inactivation of the current. (e) 
Onset of block on Cav2.2 after switching light to 500 nm. Current was fitted with a bi-
exponential decay equation. For the fast process t1/2 = 187 ± 57 ms (n = 3 cells). (f) 
Kinetics of unblock on Cav2.2 after switching light to 380 nm. Current was fitted with a bi-
exponential decay equation. For the fast process t1/2 = 270 ± 30 ms (n = 3 cells). 
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Supplementary Figure 6: QAQ photosensitizes various voltage-gated K+ channels. 
 
(a) I/V relationship for Shaker steady-state current under 380 and 500 nm light illumination, 
using 100 µM QAQ in the patch pipette. (b) Reversibility of QAQ block for Shaker current, 
using 100 µM QAQ in the pipette. (c), (e), (g) Whole cell current from HEK-293 cells 
transfected with Kv2.1 (86.0 ± 3.5 % photoswitching ± s.e.m., n = 4 cells), Kv3.1 (46.6 ± 
13.4 % photoswitching s.e.m., n = 4 cells) and Kv4.2 (47.1 ± 9.4 % photoswitching s.e.m., 
n = 4 cells), respectively. (d), (f), (h) Reversibility of QAQ block on Kv2.1, Kv3.1 and Kv4.2, 
respectively. (i) Whole cell potassium current from a hippocampal neuron using 100 µM 
QAQ in the patch pipette (36.0 ± 5.3 % photoswitching ± s.e.m., n = 13 cells). (j) 
Reversibility of QAQ block in a hippocampal neuron. For all recordings: depolarization from 
-70 to +40 mV. (k) Onset of block on Shaker after switching light to 500 nm. Current was 
fitted with a bi-exponential decay equation.  For the fast process t1/2 = 201 ± 20 ms (n = 3 
cells). (l) Kinetics of unblock on Shaker-IR after switching light to 380 nm. Current was 
fitted with a bi-exponential decay equation. For the fast process t1/2 = 164 ± 15 ms (n = 3 
cells). 
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Supplementary Figure 7: QAQ does not photosensitize Kir or HCN channels. 
 
(a) Kir currents were measured from HEK-293 cells transfected with Kir 2.1. Currents were 
elicited by voltage steps from -40 to -100 mV, in 10 mV increments, under illumination with 
380 or 500 nm light. (b) Normalized current measured at -100 mV under both wavelengths 
of light (1.2 ± 1.5 % photoswitching, n = 5 cells, p > 0.05). (c) HCN currents were 
measured from acutely dissociated TG neurons upon hyperpolarization to -100 mV under 
380 and 500 nm light. (d) Normalized current under both wavelengths of light (-5.2 ± 4.7 % 
photoswitching, n = 3 cells, p > 0.05). Error bars ± s.e.m.; Student t-test. 
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Supplementary Figure 8: QAQ does not photosensitize glutamate receptors. 
 
 
(a) Glutamate receptor currents were measured from hippocampal neurons in culture two 
days after plating. Extracellular solution is similar to K+ current recording solution without 
Mg2+. The black bar represents perfusion of extracellular solution containing 100 µM 
glutamate and 10 µM glycine. Currents were measured under illumination with 380 or 500 
nm light. (b) Normalized glutamate current under both wavelengths (0.6 ± 2.6 % 
photoswitching, n = 3 cells, p > 0.05 Student t-test). Error bars ± s.e.m. 
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Supplementary Figure 9: Neuronal survival after ATP and QAQ treatment. 
 
The Live/Dead assay was performed as described by Invitrogen (L-7013). Only dead cells 
were quantified by using DEAD Red. P2X7 and GFP co-transfected hippocampal neurons 
were identified by green fluorescence. Cultured hippocampal neurons were transfected 
with P2X7 (d7) and treated for 30 min with ATP (2.5 mM) +/- QAQ (100 µM), without 
external calcium, at d9-10. A Live/Dead Assay (Molecular Probes) was used to quantify 
cell survival among transfected cells, 30 minutes or 24 h after treatment. Both treatments 
did not cause toxicity compared to control (n = 11-18 fields of view, each field of view 
containing approximately 1-10 transfected cells; error bars ± s.e.m.).  
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Supplementary Figure 10: QAQ photosensitizes second order neurons in spinal 
cord slices. 
 
 
(a) Percent photoswitching for laminae II (26.5 ± 5.0 % photoswitching, n = 22 cells) and 
III-IV neurons (8.2 ± 4.9 % photoswitching, n = 11 cells, p<0.05). (b) Percent 
photoswitching for lamina II neurons with (6.6 ± 3.0 % photosensitization, n = 6 cells) and 
without 10 µM BCTC (26.5 ± 5.0 % photoswitching, n = 22 cells, p < 0.05). Error bars ± 
s.e.m.; Student t-test. 
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3) Exploring the Pharmacology and Action-Spectra of 
Photochromic Open Channel Blockers & Tuning Photochromic Ion 
Channel Blockers 
 
3.1) Introduction 
 
The originally introduced PCL and PTL approaches, unifies the fact that all 
photoswitches are based on a bis-acylated azodianiline core.[1,2,3,4,5,6,7] Here 380 nm 
and 500 nm light are best suited for converting the trans and cis states into each 
other, respectively. In principle, photoswitches with a red-shifted absorption 
spectrum could be controlled independently of traditional PCLs and PTLs, creating 
an orthogonal system, which would broaden possibilities to study neuronal 
networks. A second feature that increases the need for PCLs and PTLs lies in the 
application of photoswitches in deeper tissue regions. UV-A light does not penetrate 
into these regions, preventing the use of traditional PCLs and PTLs.[4] Ideally, the 
absorption maximum of photoswitches should be around 650-700 nm light. 
 
Similar considerations have lead to the development of VChR1,[8] a microbial 
rhodopsin from Volvox carteri, which represents a red-shifted ChR2 analogon. Once 
expressed in neurons, this cation selective channelrhodopsin is activated by 589 nm 
light, resulting in a membrane depolarization.[9] The disadvantage of VChR1 lies in 
the incorrect light induced neuronal spike initiation, at frequencies above 5-10 
Hz.[8,10]  
 
In the first paper attached in this chapter, the light regulated local anesthetic QAQ, 
which photocontrols Nav, Cav and Kv channels, has been derivatized to red-shift its 
action spectrum. Here, at the 2,2’ and 6,6’ positions of the bis-acylated azodianiline 
core, different substituents were attached, an approach that has been described 
before.[11,12] Six derivatives were characterized on Kv channels. 2,2´-dimethoxy-QAQ, 
2,6-dimethyl-QAQ and 2,2´,6,6´-tetramethyl-QAQ allow for light control of Kv and Nav 
channel current and thereby for light control of neuronal activity. Among the 
54
successful candidates, 2,2´-dimethoxy-QAQ exhibits a red-shifted action spectrum, 
which allows to use 420 nm light and darkness to switch between the cis and trans 
state.[8,10]  
 
In the second paper presented in this chapter, several red-shifted Kv channel PCLs 
have been synthesized and characterized.[13] Here, one acyl group of the bis-
acylated azodianiline core was replaced by amino functions, generating push-pull 
systems with red-shifted absorption spectra. Among the synthesized compounds, 
DENAQ and PhENAQ turned out to be most applicable. These compounds can be 
converted into their cis state by 470 nm light and quickly relax back into their trans 
state in the dark.   
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1	  Experiments were designed by T. Fehrentz and D. Trauner. Electrophysiological 
characterization of QAQ-derivatives was carried out by T. Fehrentz. Synthesis of 
2,2´-dimethoxy-QAQ, 2,2´-dimorpholino-QAQ and 2,2´-di-methylpiperazin-QAQ was 
performed by C. A. Kutruff. Synthesis of dimethylamino-QAQ was carried out by T. 
Fehrentz and F. M. E. Huber. Synthesis of 2,6-dimethyl-QAQ and 2,2´,6,6´-
tetramethyl-QAQ  was performed by M. A. Kienzler.	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Exploring the Pharmacology and Action-Spectra  
of Photochromic Open Channel Blockers 
 
 
Timm Fehrentz[a], Christian A. Kuttruff[a], Florian M. E. Huber, Michael A. Kienzler, 
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[a] these authors contributed equally to this work. 
* corresponding author 
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Photochromic ligands (PCLs) act as light-dependent agonists or antagonists of 
receptors that allow for the control of neuronal activity with high temporal and spatial 
precision.[1] An important subclass of PCLs is formed by photochromic ion channel 
blockers, which have been successfully applied on voltage-gated potassium (KV) and 
sodium (NaV) channels.[2] These channels are evolutionarily related and share similar 
overall architectures despite marked differences in ion-permeability and subunit 
stoichiometry.[3] Ions enter or leave the channels through a selectivity filter on the 
extracellular side, which is connected to a water-filled inner cavity. The path from this 
inner cavity to the intracellular milieu is controlled by a voltage-gate, which opens and 
closes in response to changes in the membrane potential. Local anesthetics such as 
lidocaine or procaine bind in the inner cavity below the selectivity filter, preventing the 
permeation of cations along their electrochemical gradients.[4] Since the voltage-gate 
has to open before these molecules can reach the inner cavity, they are often 
referred as “use-dependent” or “open channel blockers”.[4-5]  
 
Recently, we introduced a family of azobenzenes that are essentially photochromic 
versions of lidocaine.[5b] One of our most effective compounds is a simple symmetric 
molecule termed QAQ, which functions as a light dependent blocker of a wide variety 
of KV and NaV channels (Figure 1).[2c] Structurally, QAQ consists of two quaternary 
ammonium ions derived from glycine, which are linked to a 4,4’-azodianiline core via 
two amide bonds. Due to its twofold charge, QAQ is membrane-impermeant and only 
infiltrates pain-sensing neurons that express endogenous import channels.[2c, 6] Other 
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cells can be loaded with QAQ more invasively via a patch pipette. QAQ blocks 
voltage-gated NaV and KV channels in the trans form but not the cis form of its 
azobenzene photoswitch. These channels underlie the initiation and propagation of 
action potentials (APs).[3a, 4a, 7] Thus, QAQ enables reversible optical silencing of 
neuronal activity and acts as a light-sensitive analgesic once applied to neural 
tissues. As such, it is a useful tool for studying signaling mechanisms in acute and 
chronic pain.[2c] 
 
While QAQ proved to be an effective tool for the control of neuronal activity, its 
photophysical properties needed to be optimized. As a diacyl derivative of 
azodianiline, QAQ can be best switched to its cis form with 380 nm light and back to 
its trans form with 500 nm light. The short wavelengths used to deactivate it, 
however, are not ideal for physiological applications, where tissue penetration and 
associated phototoxicity is a primary concern. Woolley has recently introduced a 
class of azobenzene photoswitches that are substituted in the 2,2’ and 6,6’ position 
with electron-donating substituents and show red-shifted spectra with respect to their 
unsubstituted analogues.[8] Trying to maintain the symmetrical nature of QAQ, we 
decided to modulate these substitutions in order to red-shift the action spectrum of 
the photochromic blocker. The question was whether these structural changes at the 
azobenzene core would be tolerated by the confined inner cavity of the channel 
protein, while allowing the use of longer-wavelength light to actuate the switch. 
 
To address this question, we synthesized four QAQ derivatives bearing electron 
donating substituents in the indicated positions: 2,2´-dimethoxy-QAQ (1), 2,2´-
dimethylamino-QAQ (2), 2,2´-dimorpholino-QAQ (3) and 2,2´-N-dimethylpiperazine-
QAQ (4) (Figure 1). To better discriminate steric from electronic influences, we also 
synthesized methyl substituted derivatives 2,2´-dimethyl-QAQ (5) and 2,2´,6,6´-
tetramethyl-QAQ (6). The synthesis of these compounds was achieved using short 
sequences that involved diazonium coupling or oxidative coupling to generate the 
azobenzene core, followed by amide bond formation (see Supporting Information). 
 
With compounds 1-6 in hand, we first characterized their ability to induce light 
dependent block of the inactivation-removed Shaker K+ channel (Shaker-IR),[9] a 
voltage-gated K+ channel (Figure 2). Compounds were loaded via patch pipette into 
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HEK293 cells expressing Shaker-IR. Measurements were performed after a short 
equilibration period of the cytosol and pipette solution.  
Application of compounds 1, 5 and 6 permitted the reversible light control of Shaker-
IR K+ current (Figure 2). Derivatives 1, 5 and 6 resulted in 31.8% ± 5,7% (350 µM, n 
= 3 cells), 64.7% ± 5,5% (100 µM, n = 3 cells) and 67.8% ± 4,8% (100 µM, n = 5 
cells) light induced voltage dependent block of the channel current, respectively 
(Figure 2 and 3). The trans state of all active compounds induced block, whereas the 
cis state reversed the effect. Derivatives 5 and 6 were converted into their cis and 
trans states with 380 nm and 500 nm light, respectively.  
Compound 1 represents a red-shifted azobenzene PCL[8a] with an absorption 
maximum λmax = 416 nm light. Irradiation with 420 nm light was used to convert the 
thermally stable trans form into the cis state. Thermal relaxation in the dark was used 
to revert compound 1 into its trans state. Here, the relative channel current follows 
the equation: y0 + A1 exp (-x/τ1) +A2 exp (-x/τ2), y0 = 0.649 ± 0.02, A1 = 0.190 ± 
0.010, A2 = 0.160 ± 0.014,τ1 = 1.948 ± 0.226 s,τ2 = 39.454 ± 10.8 s (see 
Supporting Information). In contrast, thermal relaxation of compound 1 in DMSO 
shows slower kinetics, whereat data were fitted to the equation: y0 + A exp (-x/τ), y0 
= 0.006 ± 0.002, A = 0.978 ± 0.004, τ= 4.61 ± 0.40 min (see Supporting 
Information). The action spectrum of compound 1 indicates that wavelengths 
between 350 nm - 500 nm allow for trans to cis conversion (see Supporting 
Information).	  Compounds 2, 3 and 4 showed no voltage dependent block and thus no 
photoregulation of the Shaker-IR current. 
 
The finding that QAQ acts on both Nav and Kv channels[2c] prompted us to 
investigate, whether QAQ derivatives also block Nav channels. We tested 
compounds 1, 5 and 6 on NG108-15 cells, a mouse neuroblastoma cell line that 
endogenously expresses Nav channel subtypes Nav1.1-1.4, 1.6 and 1.7.[10] After 
delivery through the patch pipette into cells, all three compounds reversibly blocked 
voltage induced Na+ current in a light dependent manner (Figure 4). As for the case 
with Shaker-IR, block was induced by the trans state of all three QAQ derivatives. 
Compounds 1, 5 and 6 resulted in 38,6% ± 6,5% (1 mM, n = 4 cells), 75.5% ± 1,8% 
(50 µM, n = 3 cells) and 46.3% ± 4,7% (100 µM, n = 4 cells) photoregulation of Na+ 
peak current, respectively. 
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Nav and Kv channels play a crucial role in the initiation and propagation of APs in 
neurons.[4a, 7] Application of compounds 1, 5 and 6 via the patch pipette into cortical 
CA1 neurons of mouse slices allowed, after injection of a depolarizing current pulse, 
modulation of AP firing in a light dependent manner (Figure 4). The trans state of all 
three compounds silenced neuronal excitability, whereas the cis state unblocked Nav 
and Kv channels, restoring AP firing. A single spike remained under trans recording 
conditions, which can be explained by the principle of open-channel block, i.e. the 
delay between channel opening and blocker accumulation within the pore that is 
sufficient to trigger a single AP.[2c] 
 
In summary, we have shown that the useful photochromic channel blocker QAQ can 
be further substituted at its azobenzene core. Its derivatives 1, 5 and 6 allowed for 
the rapid reversible control of NaV and KV channel conductance, whereas larger 
substituents showed no block of channel current. Of the three blockers identified, 
only compound 1 shows a red-shifted action spectrum. Our data indicates, that either 
the inner vestibule, or the open gate leading into the inner vestibule of the Shaker-IR 
and Nav channels do not tolerate QAQ derivatives bearing substituents larger than a 
methoxy group in 2,2'-ortho positions. The higher concentration of compound 1 
needed to elicit photoswitching can be interpreted as lower efficacy of the compound 
towards the channel, which may be a consequence of its increased size. Our study 
has provided three new photochromic blockers of voltage-gated channels, which may 
help to probe the influence of Nav and Kv channels on dendritic signaling in 
neurons.[11] Moreover, they could serve as tools to unravel molecular mechanisms of 
pain.[2c, 12]  
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Figure 1. A) QAQ and derivatives act as light controlled open channel blockers. 
Schematic depiction of light induced trans block and cis unblock of QAQ derivatives 
on voltage-gated ion channels. The trans state of the photoswitch prevents ionic 
current, whereas the cis state restores ionic conductance. B) Chemical and crystal 
structure of the parent molecule QAQ. The distance between the quaternary 
ammonium groups is approximately 18,9 Å. C) QAQ derivatives introduced in this 
study. 
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Figure 2. Application of QAQ derivatives on the internal side of a Kv channel subtype. 
from left to right: compound 1 (350 µM), 5 (100 µM) and 6 (100 µM); purple, green, 
blue and dark lines indicate irradiation of 380 nm light, 500 nm light, 420 nm light and 
darkness, respectively. 
 A) Reversible photosensitizing of Shaker-IR K+ current. Individual amplitudes of 
voltage-clamp recordings, under different irradiation wavelengths, are connected by a 
line. B) Comparison of single Shaker current traces under indicated wavelength, 
elicted by a depolarizing pulse from a holding potential of -70 mV to +40 mV for 250 
ms. C) Current-voltage dependent trans block and cis unblock under indicated 
wavelengths from -50 mV to +70 mV. 
62
 
 
 
 
Figure 3. Quantification of QAQ derivative photoswitching on Shaker-IR. Percent 
photoswitching is defined as I500nm(30sec) – I300(30sec)/I380(30sec). Derivative 1 resulted in 
31.8% ± 5,7% (350 µM, n = 3 cells), derivative 5 in 64.7% ± 5,5% (100 µM, n = 3 
cells), derivative 6 in 67.8% ± 4,8% (100 µM, n = 5 cells), derivative 2 resulted in -
9,3% ± 1% (500 µM, n = 3 cells), derivative 3 in -5,8% ± 5,8% (500 µM, n = 4 cells) 
and derivative 4 in -0,4% ± 9,8% (500 µM, n = 4 cells) photoswitching, respectively. 
Negative photoswitching is due to a recording artefact of current rundown. 
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Figure 4. QAQ derivatives act as reversible internal Nav channel bockers and control 
activity of cortical pyramidal neurons. Recording artefacts have been removed for 
clarity A) from left to right: 1 mM compound 1, 50 µM compound 5, 100 µM 
compound 6 induce light dependent Nav current block of NG108-15 cells. B) 
Quantification of QAQ derivatives induced photoswitching. Amount of 
photosensitization of Nav current is defined as Ipeak_current_380nm(10sec) – 
Ipeak_current_500nm(10sec))/Ipeak_current_380nm(10sec). C-E) Reversible silencing of neuronal AP 
trains, evoked by current injection of approximately 150 pA (400 ms). C) 1 mM of 
derivative 1. D) 50 µM of derivative 5. E) 100 µM of derivative 6. Resting potentials of 
all neurons measured were about -75 - -80 mV. 
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General Experimental Details. Unless stated otherwise, all reactions were performed in 
oven-dried or flame-dried glassware under a positive pressure of nitrogen. Commercial 
reagents and solvents were used as received with the following exceptions. Tetrahydrofuran 
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(THF) was distilled from benzophenone and sodium immediately prior to use. Triethylamine, 
diisopropylamine and diisopropylethylamine were distilled over calcium hydride immediately 
before use. Reactions were magnetically stirred and monitored by NMR spectroscopy or 
analytical thin-layer chromatography (TLC) using E. Merck 0.25 mm silica gel 60 F254 
precoated glass plates. TLC plates were visualized by exposure to ultraviolet light (UV, 254 
nm) and/or exposure to an aqueous solution of ceric ammoniummolybdate (CAM), an 
aqueous solution of potassium permanganate (KMnO4), an acidic solution of vanillin or a 
solution of ninhydrin in ethanol followed by heating with a heat gun. Flash column 
chromatography was performed as described by Still et al. employing silica gel (60 Å, 40-63 
µm, Merck) and a forced flow of eluant at 1.3-1.5 bar pressure.2 Reversed phase column 
chromatography was carried out with Waters Prep C18 (55–105 µm, 125 Å) silica gel. Yields 
refer to chromatographically and spectroscopically (1H and 13C NMR) pure material.  
 
Instrumentation. Proton nuclear magnetic resonance (1H NMR) spectra were recorded on 
Varian VNMRS 300, VNMRS 400, INOVA 400 or VNMRS 600 spectrometers. Proton 
chemical shifts are expressed in parts per million (δ scale) and are calibrated using residual 
undeuterated solvent as an internal reference (CDCl3: δ 7.26, DMSO-d6: δ 2.50, CD3OD: δ 
3.31). Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, 
coupling constant (Hz), integration). Multiplicities are reported as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = apparent, or combinations 
thereof. Carbon nuclear magnetic resonance (13C NMR) spectra were recorded on Varian 
VNMRS 300, VNMRS 400, INOVA 400 or VNMRS 600 spectrometers. Carbon chemical 
shifts are expressed in parts per million (δ scale) and are referenced to the carbon resonances 
of the solvent (CDCl3: δ 77.0, DMSO-d6: δ 39.5, CD3OD: δ 49.0). Infrared (IR) spectra were 
recorded on a Perkin Elmer Spectrum BX II (FTIR System). IR data is reported in frequency 
of absorption (cm-1). Mass spectroscopy (MS) experiments were performed on a Thermo 
Finnigan MAT 95 (EI), a Thermo Finnigan LTQ FT (ESI) or a JEOL JMS-700 (FAB) 
instrument. UV/Visible spectra were recorded on a Varian Cary 50 Scan UV-Visible 
Spectrophotometer using STARNA 29/B/12 quartz cuvettes with 10 mm section thickness. 
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Electrophysiology and cell culture. HEK293 and NG108-15 cells haven been cultured and 
cortical slice preparation was performed as described before.3,4  
Patch clamp recordings and analysis have been performed with a standard 
electrophysiological setup, including an HEKA Patch Clamp EPC10 USB amplifier and patch 
master software. Measurements were recorded in whole cell mode. Pipette (Science Products 
GB200-F-8P with filament) resistance varied between 4-6 MΩ. Irradiation of samples have 
been performed with a TILL Photonics Polychrome 5000 monochromator, through a Nicon 
Fluor 60x/1.00w objective.2 
Extracellular potassium current recording solution contained in mM: 138 NaCl, 1.5 KCl, 1.2 
MgCl2, 2.5 CaCl2, 5 HEPES free acid, 10 glucose and pH was adjusted to 7.4. Extracellular 
sodium current recording solution contained in mM: 145 NaCl, 0.5 CdCl2, 2 CaCl2, 5 HEPES 
free acid, 5 glucose and pH was adjusted to 7.4. Internal potassium current recording solution 
contained in mM: 10 NaCl, 135 K gluconate, 10 HEPES free acid, 2 MgCl2, 2 MgATP, 1 
EGTA and pH was adjusted to 7.4. Internal sodium current recording solution contained in 
mM: 30 NaCl, 100 CsCl, 10 HEPES free acid, 2 MgCl2, 1 CaCl2, 2 MgATP 0.05 GTP, 10 
EGTA, 5 glucose and pH was adjusted (CsOH) to 7.3. Ringer solution contained in mM: 96 
NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2, 5 HEPES free acid and pH was adjusted to 7.4. 
Photoswitches were dissolved in internal solution to give the final working concentrations. 
DMSO concentration in internal solutions was below 0.1%. After patching cells, internal 
solution and cytosol were allowed to equilibrate for about 2–3 min. A typical voltage clamp 
protocol to record Shaker-IR current depolarized, in a looped manner, the membrane from its 
holding potential of -70 mV to +40 mV for 250 ms. The protocol was applied with a 
frequency of 0.5 Hz and the depolarization was initiated 250 ms after protocol started. 
Recordings were accompanied by illumination at a defined wavelength, which was changed 
every 30 cycles. To record current-voltage (IV) curves of Shaker-IR, a protocol hold the cell 
at -70 mV and depolarized the cell in a loop sequence to values between -50 mV and +70 mV, 
in 10 mV intervals. Illumination wavelengths were changed for each IV protocol. 
The voltage clamp protocol to record Nav channel current, hold the cell at -100 mV and 
depolarized the cell, for 250 ms, to -10 mV. The depolarisation was initiated 250 ms after the 
beginning of the protocol, which was applied at a frequency of 0.5 Hz. Recordings were 
accompanied by changing irradiation wavelength every 10 cycles. Recording of APs was 
performed in current clamp mode. Single current pulses with the same strength were injected 
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into cortical pyramidal neurons to elicit robust AP firing in the presence of QAQ derivatives 
in the cis state but not in the trans state. All data presented have been analyzed as averages ± 
s.e.m. 
 
Synthesis of 2,2’-Dimethylamino-QAQ (2), 2,2’-Dimorpholino-QAQ (3) and 2,2’-Di-
methylpiperazine-QAQ (4) 
Compounds 2, 3 and 4 were synthesized from the corresponding bisacetamides S2, S3 and S4, 
whose syntheses were described previously.5 
 
 
 
 
2,2’-Dimethylamino-QAQ (2): 
Diazene S2 (32 mg, 0.8 µmol, 1.0 equiv.) was dissolved in conc. HCl (1.0 mL) and the dark 
red reaction mixture was heated to 60 °C for 30 min. The reaction mixture was cooled to rt 
and the solvent removed under high vacuum. The residue was dissolved in dry DMF (1.0 mL) 
and DIPEA (0.3 mL, 8.0 mmol, 10.0 equiv.) was added dropwise. The solution was cooled to 
0 °C and a solution of S9 (130 mg, 8.0 µmol, 10 equiv.) in dry DMF (1.0 mL) was added 
dropwise. The reaction mixture was allowed to warm to rt, stirred overnight and DMF was 
subsequently removed under high vacuum. The crude product was purified by reversed phase 
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column chromatography (gradient: MeOH/H2O/HCOOH = 0:1:1·10−3 → 2:8:8·10−3) to afford 
dimethylamino-QAQ formate salt 2 (12 mg, 17.8 µmol, 21%) as a dark red solid.  
1H NMR (600 MHz, CD3OD) δ: 8.41 (br s, 2 H), 7.65 (d, J = 8.8 Hz, 2 H), 7.54 (d, 
J = 1.9 Hz, 2 H), 7.12 (dd, J = 8.8, 1.9 Hz, 2 H), 4.19 (s, 4 H), 3.68 (q, J = 7.2 Hz, 12 H), 3.06 
(s, 12 H), 1.40 (t, J = 7.2 Hz, 18 H). 
13C NMR (150 MHz, CD3OD) δ: 163.1, 152.8, 142.5, 141.6, 118.9, 113.6, 110.2, 103.3, 57.6, 
55.8, 45.5, 8.0. 
IR (Diamond-ATR, neat) 𝜈: 3255, 2987, 2948, 2780, 2683, 1685, 1659, 1579, 1477, 1456, 
1404, 1371, 1342, 1307, 1250, 1200, 1173, 1157, 1115, 1051, 1007, 950, 857, 790, 774, 765, 
718 cm−1.  
HRMS (FAB) calcd for C32H54O2N8 [M]+•: 582.4359; found: 582.4368. 
UV-Vis (DPBS, pH = 7.4): λmax = 430 nm. 
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UV/VIS spectra of compounds 1-6 
All UV/VIS spectra of compounds 1-6 were recorded in PBS solution. Compound 1 was 
additional recorded in DMSO. 
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To determine the thermal relaxation of compound 1, the spectrum above was recorded in 
DMSO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75
 
 
 
Thermal relaxation of 2,6-dimethoxy-QAQ 1 in DMSO 
 
 
 
Thermal relaxation of 2,6-dimethoxy-QAQ 1, measured by	  an UV-Visible Spectrophotometer 
in DMSO. Measurement was performed after irradiation with 400 nm. The relative absorption 
A/A0 at 403 nm light, is plotted against time. Orange trace represents the recorded absorption. 
Black trace indicates the course of the fitted exponential function: 
y0 + A exp (-x/τ), y0 = 0.006 ± 0.002, A = 0.978 ± 0.004, τ = 4.61 ± 0.04 min. Statistics on 
coefficient values are presented as ± one standard deviation. 
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Thermal relaxation of 2,6-dimethoxy-QAQ recorded on Shaker-IR channel 
 
 
 
Thermal relaxation of 2,6-dimethoxy-QAQ 1 recorded in voltage clamp mode, in the dark. 
Measurement was performed after irradiation with 420 nm. The relative Shaker-IR current I/I0 
(n = 4 cycles) is plotted against time. Orange trace represents the average of four cycles. 
Black trace indicates the course of the fitted biexponential function: y0 + A1 exp (-x/τ1) + A2 
exp (-x/τ2), y0 = 0.649 ± 0.02, A1 = 0.190 ± 0.010, A2 = 0.160 ± 0.014, τ1 = 1.948 ± 0.226 s, τ2 
= 39.454 ± 10.8 s. Statistics on coefficient values are presented as ± one standard deviation. 
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Action spectrum of 2,6-dimethoxy-QAQ recorded on Shaker-IR 
 
 
 
Action spectrum of 2,6-dimethoxy-QAQ (1) recorded on Shaker-IR channels. The protocol 
applied depolarized the cell from - 70 mV to + 40 mV, for 250 ms at 1 Hz. After the first 250 
ms of the protocol, depolarization was initiated. The voltage clamp measurements were 
accompanied with changing illumination, after 10 protocol cycles. Irradiation was varied 
between 350 nm - 550 nm light. The maximum induced current unblock is detected at 400 nm 
light. Wavelength higher than 500 nm light, did not unblock Shaker-IR channels. Power 
output of the Polychrom 5000 has not been considered.6 
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The merger of artificial photoswitches with natural receptorproteins has proven to be an effective way to control neural
activity with light.14 This approach combines the virtually
limitless repertoire of synthetic chemistry with a detailed under-
standing of the transmembrane proteins that underlie the gen-
eration and modulation of action potentials. As such, it provides
a useful alternative to naturally occurring light-gated ion channels
and light-powered pumps, which are currently driving the field of
optogenetics.5 Most of these are based on a single photoswitch,
retinal, which is often endogenously produced and does not need
to be added externally. While this provides advantages in terms
of practicality, it confines the tuning of these systems to muta-
tions in the protein surrounding the chromophore.6 By contrast,
a combination of synthetic photoswitches and natural receptors
should allow for more flexibility, since both components can
be manipulated through chemistry and genetic engineering,
respectively.
Artificial photoswitches can be combined with endogenous
neural receptors through covalent or noncovalent bonding.7 So-
called photochromic ligands (PCLs) bind noncovalently and
contain a photoswitchable moiety whose configuration can be
changed upon irradiation.710 As such, they change their efficacy
in a light-dependent way and essentially function as photochro-
mic neurotransmitters or neuromodulators. Since they are dis-
tributed like small-molecule drugs, they are able to photosensitize
naïve tissues within minutes, as opposed to days in the case of
optogenetic probes. PCLs can be rapidly switched by using two
different wavelengths of light that greatly favor one isomer or the
other. Alternatively, one could use photoswitches that are ac-
tively switched to one isomer with light but thermally revert to
the more stable form in the dark. This obviates the need to work
with two different wavelengths but requires switches that turn
themselves off at appropriate rates.
Recently, we introduced a family of simple azobenzene deri-
vatives that function as PCLs for tetrameric voltage-gated ion
channels, in particular potassium channels.7,9 These molecules,
represented by AAQ and BzAQ (Figure 1), operate as photo-
chromic open channel blockers, that bind in a light-dependent
manner to the tetraethylammonium (TEA) binding site located
in the inner cavity of potassium channels.7 In their extended trans
form, AAQ and BzAQ fit into this cavity, but in their bent cis form
their apparent affinity drops sharply. To reach their binding site,
these amphiphilic molecules can either partition into the mem-
brane or they can be imported through a patch pipet, whose
content can rapidly exchange with the cytosol. Although many
details of this reversible molecular encapsulation of azobenzenes
by channel proteins remain to be clarified, they have already
proven themselves as effective modulators of neural activity. For
instance, Purkinje neurons and pacemaker neurons in the heart
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ABSTRACT: Photochromic channel blockers provide a conceptually simple and
convenient way to modulate neuronal activity with light. We have recently
described a family of azobenzenes that function as tonic blockers of Kv channels
but require UV-A light to unblock and need to be actively switched by toggling
between two different wavelengths. We now introduce red-shifted compounds
that fully operate in the visible region of the spectrum and quickly turn themselves
off in the dark. Furthermore, we have developed a version that does not block
effectively in the dark-adapted state, can be switched to a blocking state with blue
light, and reverts to the inactive state automatically. Photochromic blockers of this
type could be useful for the photopharmacological control of neuronal activity
under mild conditions.
KEYWORDS: photopharmacology, ion channel blockers, voltage-gated potassium channels, photochromic molecules, azoben-
zenes
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of Hirudo medicinalis could be controlled with photochromic
neuromodulators of this type.9
One of the greatest advantages of azobenzene photoswitches
is the well-understood effect of substitutions and molecular
extensions on their photophysical properties and thermal
stability.11 So-called “regular azobenzenes”, represented by
the parent molecule, as well as the bis-acylated azodianilines
AAQ and BzAQ, are thermodynamically more stable in their
Figure 1. (a) Molecular structures of AAQ and BzAQ, two PCLs for Kv channels; (b) AAQ, BzAQ, and related PCLs are membrane permeable and
function as photochromic open-channel blockers.
Figure 2. (a) Potential photochromic Kv blockers investigated in this study. (b) UV/Vis spectra of the azobenzenes investigated. Spectra were recorded
at room temperature in phosphate buffered saline solution at pH 7.4.
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trans-configuration, which completely predominates in the dark-
adapted state. Their photostationary cis/trans ratios (PSRs) as-
sume their maximum values in the UV-A region of the electro-
magnetic spectrum (315380 nm). At these wavelengths, cis/
trans ratios exceeding 9:1 can be observed.12 Once the light is
turned off, the cis-isomers of regular azobenzenes are thermally
relatively stable. The half-life of AAQ in physiological solution at
room temperature, for instance, is 78 min.
Azobenzenes with strongly electron-donating substituents on
both rings are known to absorb at increased wavelengths and have
an increased rate of thermal back-isomerization from cis to trans.11,13
In addition to these, one could use azobenzenes that feature an
electron-donating substituent on one end and an electron-with-
drawing one on the other. These “pushpull” azobenzenes,
which are also referred to as “pseudo-stilbenes”, are marked
by greatly red-shifted absorption spectra. They are also thermally
instable in their cis form and revert at room temperature to the
thermodynamically more stable trans form on a millisecond to
second time scale. The rate of this reversal is greatly dependent
on the solvent, with polar protic solvents promoting very fast
isomerization.14 As such, pushpull azobenzenes are ideally
suited as photochromic ion channel blockers that can be acti-
vated with visible light and turn themselves off once the light
intensity drops below a certain level. Studies using red-shifted
blockers would generally benefit from the deeper tissue penetra-
tion of light with longer wavelength. Since longer wavelengths
are also associated with less phototoxicity, photochromic com-
pounds of this type would be particularly useful in chemical
approaches toward restoring vision.
’RESULTS AND DISCUSSION
We now present a family of pushpull azobenzenes that have
red-shifted action spectra and decreased thermal stability and
function as photochromic blockers of voltage-gated ion channels
(Figure 2). These molecules feature a strongly electron-donating
dialkylamino or aryl alkylamino group on one side and a mildly
electron-withdrawing acylamino moiety that terminates in a
quaternary ammonium ion on the other side of the azobenzene.
This positively charged “head group” interacts with the TEA
binding site in the inner lumen of the channel, which blocks the
flow of ions. The “tail” of the molecules, that is, the electron-
donating substituent, determines the spectral properties of the
photoswitch as well as the thermal stability of the cis-isomer.
Spectroscopic Characterization of Red-Shifted PCLs.
AAQ, a representative of our original type, which is marked by
a bis-acylated azodianiline core, serves as a point of reference
(Figure 2). Spectroscopically, it can be classified as a “regular azo-
benzene” with a strong ππ* band at 362 nm in water (trans
isomer). Replacement of the lower acylamino group with an
alkylamino group increases the electron density of one side and
shifts the absorption spectrumof the trans-isomer toward the red.
For instance, the absorption spectrum of trans-PhENAQ, which
bears a phenylethylamino group, is shifted to 456 nm in phos-
phate buffered saline solution. BENAQ, which bears a benzy-
lethylamino substituent, has a similar absorption spectrum peak-
ing at 459 nm. The diethylamino derivative DENAQ is shifted
to an larger extent, as its absorption spectrum peaks at 470 nm.
To increase the pushpull effect without significantly altering
the sterics of the azobenzene moiety, we also explored fluori-
nated derivatives, such as DENAQ-F4. This compound shows
a relatively small bathochromic shift with respect to DENAQ
(484 nm). Our most red-shifted compound, AFM2-10, which
peaks at 580 nm, is in essence an azobenzene version of the well-
known fluorescent styrene dye FM2-10. The synthesis of these
compounds follows standard protocols and is summarized in
Scheme 1 (for further details see the Supporting Information).
In general, the absorption spectra of the trans-isomers of azo-
benzenes are correlated with their PSRs at different wavelengths.
Hence, red-shifting of the absorption maximum of their trans
isomer through appropriate substitutions should also red-shift
Scheme 1. Synthesis of BENAQ, PhENAQ, DENAQ, DENAQ-F4, and AFM 2-10a
aReagents and conditions: (a) 4-nitroaniline, isoamylnitrite, HCl,MeOH (87% for 1, 79% for 2, 62% for 3); (b) Na2S, H2O, 1,4-dioxane, 90 C (88% for
4, 42% for 5, 88% for 6); (c) 2-triethylammonium acetic acid chloride, DIPEA, DMF, 0 C to RT (67% for BENAQ, 66% for PhENAQ, 92% for
DENAQ); (d) BF3 Et2O, isoamylnitrite, THF40 to5 C; (e) diethylaniline, NaOAc, 0 C to RT (36% over two steps); (f) piperidine, Et2O, 0 C to
RT (85%); (g) 2-triethylammonium acetic acid chloride, DIPEA, DMF, 0 C to RT (38%); (h) DMF, 80 C (92%).
82
539 dx.doi.org/10.1021/cn200037p |ACS Chem. Neurosci. 2011, 2, 536–543
ACS Chemical Neuroscience RESEARCH ARTICLE
the PSR maximum as a function of the wavelength. This is dif-
ficult to measure with our pushpull azobenzenes because their
thermal relaxation is too fast to enrich the cis isomer in aqueous
solution for detection by standard spectrophotometric methods.15
Similar observations were made by Uyeda et al.16 who investi-
gated structurally related azobenzenes that bore a dimethylamino
substituent on one side and acylamino substituents on the other.
In this case, thermal cis- to trans-isomerization was very fast in
aqueous solution and only detectable by flash laser photolysis.
By contrast, the thermal isomerization was found to be relatively
slow in dimethyl sulfoxide (DMSO), and PSRs up to 78% cis
could be observed in this solvent. Nevertheless, these photo-
switches performed well in aqueous solution when incorporated
in DNA.17 Preliminary experiments with our compounds show
similar PSRs in DMSO (see Supporting Information Figure 1),
but it is difficult to extrapolate this to aqueous buffer solutions.
Electrophysiological Characterization of Red-Shifted PCLs.
The electrophysiological action spectrum of photochromic chan-
nel blockers should mirror their absorption spectra and PSRs in
solution, provided the interaction with the channel protein does
not greatly influence these. Pushpull azobenzenes, such as
DENAQ or PhENAQ, with their red-shifted absorption spectra, are
therefore expected to show a red-shifted action spectrum and fully
operate in the visible region of the electromagnetic spectrum. This
is indeed the case. Figure 3 shows the effects of 100 μMDENAQ
on the conductance of a voltage-gated potassium channel at dif-
ferent wavelengths. Recordings were performed in HEK 293 cells
transiently expressing Kv3.1 in whole-cell voltage clamp mode
after transient treatment with the PCL. Our data show that DE-
NAQ is a much better blocker in the dark adapted-state than at
480 nm (Figure 3a), which is true at all membrane potentials
tested (Figure 3b). Unblock could be achieved at all wavelengths
between 380 and 540 nm, with maximum unblock observed
around 480 nm (Figure 3c and d). At this wavelength, percent
photoswitching, as determined by the difference between the
maximum current under irradiation and in the dark, divided by the
maximum current under irradiation, is 63.2 ( 7.2% (n = 5 cells).
Thus, the action spectrum of DENAQ is shifted by ca. 100 nm
with respect to AAQ and BzAQ. Remarkably, the blocking effect
of trans-DENAQ is restored within seconds once the light is
turned off (t1/2 = 305 ( 57 ms, averaged over n = 4 cells,
Figure 3e). DENAQ is therefore a trans-blocker with a strongly
Figure 3. Effect of DENAQ on Kv3.1 expressed in HEK293 cells.
(a) Cells were treated with 100 μMDENAQ. Kv current was measured
in whole cell mode using a 200 ms depolarization from60 to +40 mV,
in the dark and under 480 nm light. Capacitive currents have been cut off
for clarity. (b) Membrane-voltage dependence of block and unblock.
Steady-state current (at the end of the 200 ms depolarization) is plotted
as a function of membrane potential. (c) Reversibility of photoswitching
and action spectrum of DENAQ on Kv3.1. Potassium current was
measured using the protocol described in (a) looped at 1 Hz. Peak
current is plotted as a function of time. Cycles of dark and illumination
(420500 nm) are indicated. (d) Unblock as a function of wavelength.
Unblock was normalized to 100% for 480 nm light (n = 34 cells).
(e) Apparent thermal relaxation rate of DENAQ measured by electro-
physiology. Kv3.1 peak current is plotted as function of time after light is
switched off. Four light-dark cycles are averaged for this single cell. Data
points were fitted with a biexponential decay equation: y = y0 + A1
exp(x/τ1) + A2 exp(x/τ2) with y0 = 1122 ( 23 pA, A1 = 1148 (
59 pA, τ1 = 392 ( 37 ms, A2 = 422 ( 39 pA, and τ2 = 3.5 ( 0.8 s.
Figure 4. Effects of PhENAQ on Shaker-IR expressed in HEK 293 cells.
Cells were treated with 50 μM PhENAQ. (a) Kv current was measured
using a 200 ms depolarization from 60 to +40 mV, in the dark and
under 480 nm light. (b) Current versus voltage dependence of block and
unblock, under 480 nm light and in the dark, respectively. Steady state
current was plotted as a function of membrane potential. (c) Reversi-
bility of PhENAQ using cycles of 480 nm light and dark. Peak current
was measured using the protocol described in (a) looped at 0.5 Hz.
(d) Apparent thermal relaxation rate of PhENAQ measured by electro-
physiology. Shaker-IR peak current is plotted as a function of time after
the light is switched off. Three light/dark cycles are averaged for this
single cell. Data points were fittedwith amonoexponential decay equation:
y = y0 + A exp(x/τ) with y0 = 838 ( 3 pA, A = 306( 5 pA, and τ =
3.9 ( 0.2 s.
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red-shifted action spectrum and decreased thermal stability with
respect to AAQ and BzAQ.
The compound PhENAQ has similar spectral properties but
shows a key difference in terms of its blocking state. It is a red-
shifted azobenzene that preferentially blocks in its thermodyna-
mically less stable cis-form, that is, at 480 nm (Figure 4a). In this
case, electrophysiological recordings were performed in HEK
293 cells transiently expressing Shaker-IR in whole-cell voltage
clamp mode. Percent photoswitching, as determined by the dif-
ference between the steady-state current in the dark and in
480 nm light, divided by the current in the dark, was found to be
29.4 ( 4.8% (n = 3 cells). cis-Block occurred at all membrane
potentials tested (Figure 4b) and was fully reversible over many
cycles (Figure 4c). Once the light is turned off, PhENAQ quickly
reverts to the less blocking trans state (t1/2 = 2.6( 0.1 s, averaged
for n = 3 cells) (Figure 4d). Thus, PhENAQ has little effect when
added in the dark (or at longer wavelengths) but becomes an
efficient blocker when irradiated with blue light.
In comparison, DENAQ and PhENAQ show some key dif-
ferences, beyond their trans versus cis activity. Structurally, they
are only distinguished by the presence of an ethyl and phenyl
substituent, respectively. However, DENAQ does not appear to
affect Shaker-IR channels, which we routinely use in our inves-
tigations on photochromic Kv blockers, yet it cleanly blocks Kv3.1
channels. By contrast, PhENAQ blocks Shaker-IR and a range
of other Kv channels (not shown). Why it does so preferentially
in its cis-form remains an open question. It could be due to an
attractive interaction of the phenyl ring with an amino acid
residue lining the inner lumen of the channel, which can only take
effect when the azobenzene is cis-configured. Also noticeable is
the difference in the rate of thermal relaxation (t1/2 = 305 (
57 ms vs 2.6( 0.1 s). This could reflect either differences in the
dissociation from the channel protein as the rate-determining
step or different rates of the thermal isomerization in solution.
Detailed structural and kinetic investigations will be needed to
clarify these points.
The remaining azobenzenes shown in Figure 2 were tested on
HEK cells expressing various channels but failed to show func-
tional features that significantly go beyond DENAQ or PhENAQ.
Despite its seemingly small chemical modification, DENAQ-F4
proved too to toxic to be viable as a photochromic blocker.
AFM2-10 had virtually no effect on the conductance of potassium
channels, even at very high concentrations (500 μM). It appears
that subtle changes in the composition the molecules influence
not only the photophysical and thermal but also the pharma-
cological properties of our photochromic blockers.
Optical Regulation of Neuronal Excitability. cis-Blockers,
such as PhENAQ, have the inherent advantage that they have
little effect on ion channels in their thermodynamically more
stable, dark-adapted state, which should make them less toxic to
excitable cells. We therefore decided to focus on PhENAQ and
investigate its effect on neuronal firing patterns. In accordance
with its effect on Shaker-IR in HEK 293 cells, PhENAQ behaves
as a cis-blocker of voltage-gated potassium channels endogen-
ously expressed in hippocampal neurons (percent photoswitch-
ing = 24.5 ( 4.5%, n = 3 cells, Figure 5a). To look at optical
Figure 5. Effect of PhENAQ on neuronal firing. (a) Voltage-clamp recording from a hippocampal neuron treated with 50 μMPhENAQ. Voltage-gated
potassium current was elicited using a 200 ms depolarization from60 to +40 mV, under 480 nm light irradiation or in the dark. (b) Reproducibility of
light-evoked membrane depolarization in neurons. Current clamp recordings were made from a hippocampal neuron treated with 50 μM PhENAQ.
Average trace (black) and standard deviation (gray) of four light cycles are shown. Apparent thermal relaxation rate was fitted with a monoexponential
decay equation (red): y = y0 + A exp(x/τ) with y0 = 46.78 ( 0.01 mV, A = 3.86 ( 0.02 mV, and τ = 237 ( 3 ms. (c) Optical regulation of action
potential firing. (d) Multielectrode array recording from an acute rat cerebellar slice. Top, raster plot of spiking; bottom, average firing rate calculated in
100 ms time bins. (e) Extracellular recording from a single cell using the multielectrode array. Color bars represent illumination with 480 nm (blue) or
periods of darkness (black).
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modulation of membrane potential, we performed current clamp
experiments. When the membrane potential of the cell was close
to the resting potential, PhENAQ rapidly and reliably elicited
membrane depolarization upon 480 nm light irradiation (Δ =
6.0( 0.4mV, n= 4 cells) without inducing cell firing (Figure 5b).
When switched back to the dark, repolarization occurred within a
second (t1/2 = 163 ( 2 ms, n = 4 cells). When current was
injected to bring the cell closer to threshold for firing, light-
induced depolarization triggered action potential firing, which
ceased rapidly when the light was switched off (Figure 5c).
The depolarization required to induce spiking depends not
only on the various ion channels expressed in a given type of cell
but also on the strength and variability of its synaptic input. To
test whether PhENAQ can modulate action potential firing of
cells that are not artificially depolarized, we recorded extracellu-
larly from cerebellar slices using a multielectrode array (MEA)
with three-dimensional electrodes. Cerebellar slices are marked
by high levels of spontaneous neuronal activity, probably origi-
nating from Purkinje neurons.18 As can be seen in Figure 5d,
neuronal firing was increased upon irradiation with 480 nm but
decreased markedly once the light was turned off. Although the
effects are not large, they are reversible and reproducible. They
are probably limited by the low solubility of PhENAQ in buffer
solution, which makes it difficult to deliver uniformly in brain
slices. Figure 5e shows an example of a single cerebellar neuron
whose activity was strongly photomodulated. As a control, we
checked that light itself has no effect on the activity of naïve
cerebellar slices (Supporting Information Figure 2).
’CONCLUSION
Following a general paradigm for tuning azobenzene photo-
switches, we have developed compounds that function as red-
shifted photochromic blockers of potassium channels, which turn
themselves off automatically in the dark. The lessons learned
during this study could be applied to other types of photo-
switches, including photochromic versions of the neurotransmit-
ter glutamate19,20 and covalently tethered blockers, agonists, and
antagonists of neural receptor proteins (so-called photochromic
tethered ligands, or PTLs).12,2124
One of our most advanced compounds, DENAQ, is a blocker
of Kv3.1 channels that is active in its dark-adapted trans state. By
contrast, PhENAQ is a cis-blocker that becomes active upon
irradiation with blue light, which makes it an attractive molecule
for the optical regulation of neuronal excitability. A photochro-
mic cis-blocker of Shaker channels has been previously observed,
but it was neither red-shifted nor thermally instable and it proved
to be too toxic to be of any practical use.7 Although tonic blockers
have performed remarkably well in complex neural systems, cis-
blockers such as PhENAQ could have advantages where a mini-
mum of perturbation upon addition of the compound is desir-
able. Both DENAQ and PhENAQ revert thermally, that is, in the
dark, to their default trans states within hundreds of milliseconds
to seconds.
The use of these compounds in the photopharmacological
control of electrical activity with visible light in neural tissue such
as the retina is currently under investigation. Their effects on
other voltage-gated ion channels, such as Nav and Cav channels,
are also under study in our laboratories. Finally, the incorpora-
tion of red-shifted, thermally destabilized azobenzenes into other
soluble and tethered photochromic ligands is under active
investigation and will be reported in due course.
’METHODS
Synthesis. See the Supporting Information.
Spectroscopic Analysis. UV/Vis spectra were measured at room
temperature using a SmartSpec Plus photometer (Biorad). UV/Vis
spectra of thermally unstable compounds were measured on a Nano-
Drop 2000c (Thermo Scientific) instrument at concentrations of ap-
proximately 1 mM in DMSO solvent. Photoisomerization was achieved
by directly illuminating a 1 μL sample on the pedestal with 473 nm light
from a 200 μm, 0.22 NA fiber optic cable placed perpendicular to the
optical path such that the sample was at the focal point of the fiber tip.
150 mWwas delivered to the sample from a 200mWDPSS blue 473 nm
laser (MBL-III-473, Opto Engine).
Cell Culture. HEK 293 cells were grown in Dulbecco's modified
Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS).
Cells were plated on 12mmdiameter poly-L-lysine coated glass coverslips
at a density of 20 000 cells/cm2. Transfection was performed using the
calcium phosphate method, as already described.9 We transfected cells
either with Shaker-IR (Inactivation Removed)25 or rat Kv3.1 cDNA,
using a bicistronic GFP-expression vector (pIRES). Cells were recorded
1248 h after transfection. Primary cultures of neonatal rat hippocampal
neurons were performed using standard procedures, as previously
described.9 Recordings were performed 23 weeks after plating.
Cerebellar Slice Preparation. Sagittal cerebellar slices were
prepared from 1317 day-old SpragueDawley rats. Briefly, the animal
was decapitated under isoflurane anesthesia and the brain was quickly
removed. Sagittal slices (340 μm thick) were cut with a microtome
(Leica VT1000S; Leica Microsystems, Wetzlar, Germany) in an ice-cold
artificial cerebrospinal fluid (ACSF) and then placed in an incubating
chamber for 30 min at 34 C. Thereafter, slices were kept at room
temperature. Bicarbonate-buffered ACSF was used as the slicing,
storage, and recording solution; composition in mM: NaCl 126, KCl
2.5, NaHCO3 26, NaH2PO4 1.25, CaCl2 2.5,MgSO4 1.3, and glucose 10,
saturated with O2/CO2 (95/5%).
Animal care and experimental protocols were approved by the
University of California Berkeley Animal Care and Use Committee.
Electrophysiology. Cells were incubated with 10 μM to 1 mM
(as indicated) photoswitch for 15 min in the cell incubator (37 C,
7% CO2, dark). The photoswitch was diluted in extracellular solution
(contains in mM: NaCl 138, KCl 1.5, MgCl2 1.2, CaCl2 2.5, HEPES
free acid 5, and glucose 10, pH 7.4). Final DMSO content was always
e1% vol/vol. Cells were then washed twice with 500 μL of extracellular
solution and directly used for electrophysiological recordings. Whole-cell
recordings were performed using an PC-505B amplifier (Warner Instru-
ments, CT) linked to a personal computer equipped with pClamp8
(Molecular Devices). Patch pipettes had resistances between 3 and
4 MΩ and were filled with intracellular solution (contains in mM: NaCl
10, K+ gluconate 135, HEPES free acid 10, MgCl2 2,MgATP 2, EGTA 1,
pH 7.4). For neuronal recordings only, synaptic transmission was
blocked using 25 μMDNQX and 20 μM biccuculine, and voltage-gated
sodium channels were blocked using 1 μM tetrodotoxin in the extra-
cellular solution (in voltage-clamp mode only). To measure voltage-
gated K+ current from HEK cells or neurons, the holding membrane
potential was set to 60 mV and stepped to +40 mV (unless otherwise
indicated) for 200 ms at 0.5 or 1 Hz. In current clamp mode, injection of
currentwas used to depolarize the cell and induce actionpotential firing. For
illumination, we used a monochromator (Polychrome V, Till photonics)
controlled using Clampex and connected to the back of the microscope
using a UV/Vis quartz fiber. Light output measured using a hand-held
power meter (Newport 840-C) and through a 20 objective was
47 mW/mm2. Data were filtered at 2 kHz and acquired at a sampling
frequency of 10 kHz.
Multielectrode Array (MEA) Recordings. Experiments were
performed at room temperature in ACSF saturated with O2/CO2. Slices
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were incubated with 50 μM PhENAQ (DMSO concentration 0.5% vol/
vol) for 15 min at room temperature and then washed 5 min prior to
recording. Slices were then placed on a tridimensional microarray made
of 60 pyramid-shape microelectrodes (MEA60 200 3D GND, Ayanda
Biosystems SA, Lausanne, Switzerland). Recordings were acquired with
an MEA-1060 amplifier board (gain 1200, sampling frequency 20 kHz,
Butterworth second order highpass filter 300Hz,Multi Channel Systems,
Reutlingen, Germany) positioned on the stage of an inverted micro-
scope (Olympus IX71). Principal component analysis of spike wave-
forms was used for sorting spikes generated by individual cells (Offline
Sorter; Plexon, Denton, TX). Light was delivered using the 100 W
halogen lamp of the microscope and a 480/40 bandpass filter, and was
focused on the slice using a 4 objective (Olympus UPLanFL N, NA
0.13). Light was computer-controlled using a filter-wheel controller
(Lambda 10-3, Sutter Instruments) and an ultrafast shutter (Uniblitz
VCM-D1, Vincent Associates). Light intensity measured at the back of
the 4 objective and through the MEA was 1728 mW/mm2. Slices
were continuously superfused during recording with fresh ACSF.
Statistics and Data Analysis. Data were analyzed using Clampfit
10 (Molecular Devices, Sunnyvale, CA), MC Rack (Multi Channel
Systems, Reutlingen, Germany), Offline Sorter (Plexon, Denton, TX),
and Origin (OriginLab, Northampton, MA) software. Statistical analysis
was performed usingOrigin. All values reported aremean( SEM except
when stated.
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Supplementary Information 
 
Supplementary Figure 1: Photoisomerization of DENAQ and PhENAQ in DMSO solution. 
UV/VIS spectra of a) DENAQ and b) PhENAQ in the dark adapted, presumably all trans 
state (black) and at the photostationary states produced under constant 473 nm laser 
illumination (blue).  
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Supplementary Figure 2: Multi-electrode array recording from acute rat cerebellar slices. 
Condensed firing rate (average firing rate calculated in 100 ms time bins, 10 cycles of 480 
nm / dark averaged) for a) a slice treated with 50 µM PhENAQ (same slice as in Figure 
5d) and b) a control slice.  
 
  
General Experimental Details. Unless otherwise noted, all reagents were purchased 
from commercial suppliers and used without further purification. Unless otherwise noted, 
all reaction mixtures were magnetically stirred in oven-dried glassware under a nitrogen 
atmosphere. External bath temperatures were used to record all reaction mixture 
temperatures. Analytical thin layer chromatography (TLC) was carried out on Merck silica 
gel 60 F254 TLC plates. TLC visualization was accomplished using 254 nm UV light, 
0.1% HCl in MeOH or a charring solution of cerric ammonium molybdenate. All aqueous 
solutions were saturated unless otherwise noted. Normal phase flash chromatography 
was performed on Dynamic Adsorbents Silica Gel (40–63 µm particle size) using a forced 
flow of eluant at 1.3–1.5 bar pressure. Reverse-phase chromatography was carried out 
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with Waters Preparative C18 Silica Gel WAT010001 125 Å. Yields refer to 
chromatographically and spectroscopically (1H NMR and 13C NMR) homogenous material. 
1H, 13C, and 19F NMR spectra were recorded on Varian ARX 200, AC 300, WH 400, or 
AMX 600 instruments. Chemical shifts (δ) are reported in ppm with the solvent resonance 
employed as the internal standard (CDCl3 at δ = 7.26 and 77.0 ppm; DMSO-d6 at 
δ = 2.50 and 39.5 ppm; Acetone-d6 at δ = 2.05 and 206.3/29.8 ppm; Methanol-d4 at 
δ = 3.31 and 49.0 ppm; THF-d8 at δ = 3.58/1.73 and 67.4/25.2 ppm; D2O at 
δ = 4.80/4.81 ppm). Chemical shifts of 19F NMR spectra were calibrated to δ = 0 ppm 
using CFCl3 as internal standard. The following abbreviations are used to explain the 
multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. 
Coupling constants (JH and JF) are reported in Hz. Infrared spectra were recorded in the 
of 4000–400 cm–1 on a Perkin Elmer BY FT-IR spectrometer using a Smiths Detection 
Dura Sample IR II Diamond ATR sensor for detection. Samples were prepared as neat 
film. UV/Visible spectra were recorded on a Varian Cary 50 Bio UV-Visible 
Spectrophotometer using Starna 29/B/12 quartz cuvettes with 10 mm section thickness. 
High resolution mass spectroscopy (HRMS) data was recorded using a Varian MAT 711 
instrument by electrospray ionization (ESI) or using a Varian MAT CH 7A by electron 
impact (EI) techniques. 
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Experimental Procedures. 
 
 
Standard Procedure 1: Azo coupling of a p-nitroaniline (A) with an aniline (B) to form the 
corresponding azobenzene derivatives (C). 
 
1.0 Eq. of p-nitroaniline (A) was dissolved in methanol and cooled in an ice bath to 0 °C, 
at which point 12M HCl was added. The resulting solution was stirred for five minutes, 
and then 1.0 eq. of isoamyl nitrite was added over a period of five minutes. The reaction 
was stirred for one hour at 0 °C. Meanwhile, 1.0 eq. of aniline B was dissolved in water or 
methanol, depending on solubility, and 12M HCl and cooled to 0 °C. To this solution, the 
diazonium salt was added over a period of ten minutes. The solution turned deep red and 
was stirred for another 1.5 hours at 0 °C. Once all starting material was consumed as 
gauged by TLC, the reaction mixture was poured on an ice-cooled saturated solution of 
NaHCO3. The crude product was extracted three times with ethyl acetate and, if 
red/orange color remained in the aqueous layer, twice with dichloromethane. The 
combined organic layers were washed with brine, dried over MgSO4, and concentrated in 
vacuo. 
 
 
Standard Procedure 2: Reduction of an aromatic nitro group to the corresponding amine 
in the presence of an azobenzene group using sodium sulfide. 
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1.0 Eq. of p-nitroazobenzene C was dissolved in a 10:1 mixture of 1,4-dioxane and water.  
To this solution 1.0 eq. of sodium sulfide was added, and the reaction mixture was 
heated to 90 °C for one hour. The reaction was monitored by TLC, and after every hour 
that starting material C was observed, another eq. of sodium sulfide was added. When all 
starting material was consumed, the solution was poured on a saturated solution of 
NaHCO3. The crude product was extracted three times with dichloromethane and the 
combined organic layers were washed with brine, dried over MgSO4, and concentrated in 
vacuo. 
 
 
Standard Procedure 3: Amide bond formation between an azoaniline (D) and betaine (E) 
to form the corresponding azobenzene quaternary ammonium derivatives (G).  
 
According to Fortin et al.1 5.0 eq. of betaine E were dissolved in acetonitrile. To this 
solution, 3 drops of DMF and 5.05 eq. of oxalyl chloride were added and the solution was 
stirred for 45 minutes at room temperature. The solvent then was removed in vacuo until 
all residual HCl had faded. The acid chloride F thus generated was partially dissolved in a 
1:1 mixture of acetonitrile and DMF. This suspension was then was added dropwise to a 
flask containing 1.0 eq. of azoaniline D and 5.0 eq. of DIPEA in DMF at 0 °C over a period 
of ten minutes. The reaction was warmed to room temperature, stirred overnight, and 
then concentrated in vacuo. 
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Nitroazobenzene S1.  Following standard procedure 1, 1.38 g (10 mmol) of 
p-nitroaniline dissolved in 20 mL of MeOH and 5 mL of 12M HCl first reacted with 1.4 mL 
(10 mmol) of isoamylnitrite to form a diazonium salt, which then further reacted with 
2.07 mL (10 mmol) of N-benzyl-N-ethylaniline dissolved in 20 mL of MeOH and 5 mL of 
12M HCl. Column chromatography on silica gel (hexanes/EtOAc, 20:1 then 9:1) gave 
1.45 g (87%) of nitroazobenzene S1 as a deep red, glassy solid. Rf(EtOAc/hexanes, 
3:10) = 0.7; 1H NMR (CDCl3, 600 MHz): δ = 8.31 (d, 
3J = 9.0 Hz, 2H), 7.92–7.85 (m 4H), 
7.35 (t, 3J = 7.5 Hz, 2H), 7.30–7.25 (m, 2H), 7.23 (d, 3J = 7.6 Hz, 2H), 6.78 (d, 3J = 9.1 Hz, 
2H), 4.67 (s, 2H), 3.61 (q, 3J = 7.1 Hz, 2H), 1.31 ppm (t, 3J = 7.1 Hz, 3H); 13C NMR (CDCl3, 
150 MHz): δ = 156.8, 152.0, 147.4, 143.8, 137.5, 131.5, 128.8, 124.9, 124.0, 123.3, 122.6, 
111.7, 53.8, 45.8, 12.3 ppm; IR: 3427, 3049, 2971, 2924, 2254, 1734, 1598, 1512, 1451, 
1423, 1392, 1357, 1339, 1281, 1246, 1197, 1177, 1156, 1140, 1104 cm–1; HRMS (ESI), 
m/z calcd. for C21H21N4O2 [MH]
+: 361.1659, found [MH]+: 361.1649. 
 
 
Aminoazobenzene 4.  Following standard procedure 2, 350 mg (0.97 mmol) of 
nitrobenzene S1 in 20 mL of 1,4-dioxane and 1 mL of water was reduced by three 
separate additions of 76 mg (0.97 mmol) of sodium sulfide. Purification of the crude 
product by column chromatography on silica gel (hexanes/EtOAc, 9:1→1:1) gave 280 mg 
(88%) of aminoazobenzene 4 as a deep red, glassy solid. Rf(hexanes/EtOAc, 10:3) = 0.3; 
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1H NMR (CDCl3, 400 MHz): δ = 7.80–7.69 (m, 4H), 7.36–7.20 (m, 5H), 6.80–6.65 (m, 4H), 
4.60 (s, 2H), 3.90 (s, 2H), 3.54 (q, 3J = 7.1 Hz, 2H), 1.32–1.21 ppm (m, 3H); 13C NMR 
(CDCl3, 100 MHz): δ = 146.1, 144.2, 142.1, 139.9, 134.4, 122.4, 120.4, 120.3, 120.0, 
100.9, 110.7, 107.7, 49.9, 41.6, 8.4 ppm; IR: 3452, 3378, 2965, 2923, 2853, 1618, 1595, 
1511, 1450, 1394, 1355, 1293, 1275, 1242, 1198, 1178, 1151, 1125, 1073 cm–1; HRMS 
(ESI), m/z calcd. for C21H23N4 [MH]
+: 331.1917, found [MH]+: 331.1907. 
 
 
BENAQ.  Following standard procedure 3, 96.4 mg (0.61 mmol) of betaine E dissolved 
in 5 mL of acetonitrile were reacted with 0.32 mL (2M solution in CH2Cl2, 0.64 mmol) of 
oxalyl chloride to form acid chloride F, which was further reacted with 100 mg 
(0.30 mmol) of aminoazobenzene 4 dissolved in 3 mL of DMF and 0.11 mL (3.0 mmol) of 
DIPEA. The crude product was purified by column chromatography on reversed-phase 
silica gel (0.1% formic acid in water/methanol, 1:0→2:3) to yield 105 mg (67%) BENAQ 
formate salt as a red-orange, glassy solid. 1H NMR (CD3OD, 600 MHz): δ = 8.40 (s, 1H), 
7.84–7.69 (m, 6H), 7.30–7.23 (m, 2H), 7.23–7.14 (m, 3H), 6.79–6.68 (m, 2H), 4.58 (s, 2H), 
4.22 (s, 2H), 3.60 (q, 3J = 6.9 Hz, 6H), 3.53 (q, 3J = 7.0 Hz, 2H), 1.33 (t, 3J = 6.9Hz, 9H), 
1.19 ppm (t, 3J = 7.0 Hz, 3H); 13C NMR (CD3OD, 151 MHz): δ = 167.9, 163.2, 152.5, 151.4, 
144.8, 140.1, 139.8, 129.8, 128.1, 127.7, 126.2, 124.0, 121.7, 112.9, 57.8, 55.9, 54.8, 
46.8, 12.8, 8.1 ppm; IR: 3189, 3028, 2958, 2928, 2854, 2684, 1691, 1585, 1557, 1502, 
1479, 1464, 1447, 1374, 1343, 1320, 1304, 1255, 1223, 1158, 1095, 1074, 1042 cm–1; 
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HRMS (ESI), m/z calcd. for C29H38N5O
+ [M]+: 506.2681, found: 472.3070; UV/Vis (DPBS, 
pH = 7.4): λmax = 459 nm. 
 
 
Nitroazobenzene S2.  Following standard procedure 1, 385 mg (2.8 mmol) of 
p-nitroaniline in 50 mL of MeOH and 5 mL of 12M HCl first reacted with 0.375 mL 
(2.8 mmol) of isoamylnitrite to form a diazonium salt, which then further reacted with 
0.27 mL (2.8 mmol) of freshly prepared N-ethyl-N-phenylaniline2 in 50 mL of MeOH and 
5 mL of 12M HCl. Column chromatography on silica gel (CH2Cl2/hexanes, 1:1) gave 
763 mg (79%) of nitroazobenzene S2 as a red solid. Rf(hexanes/EtOAc, 5:2) = 0.9; 
1H NMR (acetone-d6, 400 MHz): δ = 8.37 (d, 
3J = 9.2 Hz, 2H), 7.98 (d, 3J = 9.2 Hz, 2H), 
7.85 (d, 3J = 9.2 Hz, 2H), 7.50 (t, 3J = 7.2 Hz, 3H), 7.33 (t, 3J = 8.0 Hz, 3H), 6.85 (d, 
3J = 9.2 Hz, 2H), 3.92 (q, 3J = 7.2 Hz, 2H), 1.27 ppm (t, 3J = 7.2 Hz, 3H); 13C NMR 
(acetone-d6, 100 MHz): δ = 156.6, 152.2, 147.7, 145.6, 144.5, 130.1, 127.4, 126.4, 125.6, 
124.7, 122.6, 114.0, 46.8, 11.9 ppm; IR: 3454, 3016, 2969, 2361, 2338, 1738n, 1602, 
1584, 1513, 1490, 1477, 1448, 1425, 1372, 1230, 1217, 1155, 1143, 1132, 1091 cm–1; 
HRMS (ESI), m/z calcd. for C20H18N4O2 [MH]
+: 346.38, found [MH]+: 347.1504. 
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Aminoazobenzene 5.  Following standard procedure 2, 763 mg (2.2 mmol) of 
nitrobenzene S2 in 30 mL of 1,4-dioxane was reduced by two separate additions of 
1.05 g (13.2 mmol) and 516 mg (6.6 mmol) of sodium sulfide. Purification of the crude 
product by column chromatography on silica gel (hexanes/EtOAc, 9:1→4:1) gave 291 mg 
(42%) of aminoazobenzene 5 as a red solid. Rf(hexanes/EtOAc, 5:1) = 0.3; 
1H NMR 
(CD3OD, 400 MHz): δ = 7.65 (dd, 
3J = 8.6 Hz, 2H), 7.61 (dd, 3J = 8.6 Hz, 2H), 7.38 (t, 
3J = 9.2 Hz, 2H), 7.17 (m, 3H), 6.85 (dd, 3J = 8.6 Hz, 2H), 6.73 (dd, 3J = 8.6 Hz, 2H), 3.84 
(q, 3J = 7.2 Hz, 2H), 1.21 ppm (m, 3H); 13C NMR (CD3OD, 100 MHz): δ = 150.8, 149.6, 
146.6, 145.2, 144.6, 129.4, 125.4, 124.3, 123.9, 123.2, 115.5, 114.0, 46.3, 11.6 ppm; 
IR: 3464, 3379, 3213, 3037, 2974, 2536, 2361, 2339, 1618, 1599, 1586, 1504, 1493, 
1372, 1375, 1347, 1269, 1245, 1151, 1132, 1090 cm–1; HRMS (ESI), m/z calcd. for 
C20H21N4 [MH]
+: 317.1761, found [MH]+: 317.1760. 
 
 
PhENAQ.  Following standard procedure 3, 73 mg (0.46 mmol) of betaine E in 5 mL of 
MeCN reacted with 0.24 mL (2M solution in DCM, 0.48 mmol) of oxalyl chloride to form 
acid chloride F, which was further reacted with 143 mg (0.45 mmol) of aminoazo-
benzene 5 in 10 mL of DMF and 0.1 mL (10.0 mmol) of DIPEA over the course of two 
days. The crude product was purified by column chromatography on reversed-phase 
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silica gel (0.1% formic acid in water/MeOH, 1:0→1:1) to yield 149 mg (66%) 
PhENAQ  formate salt as a red solid. Rf(0.1% formic acid in water/MeOH, 1:1) = 0.1; 
1H 
NMR (CD3OD, 200 MHz): δ = 8.53 (s, 1H), 7.79 (d, 
3J = 8.8 Hz, 2H), 7.72 (m, 4H), 7.40 (t, 
3J = 7.6 Hz, 2H), 7.21 (m, 3H), 6.79 (d, 3J = 9.2 Hz, 2H), 4.19 (s, 2H), 3.83 (q, 3J = 7.2 Hz, 
2H), 3.63 (q, 3J = 7.2 Hz 6H), 1.35 (t, 3J = 7.2 Hz, 9H), 1.22 ppm (t, 3J = 7.2 Hz, 3H); 
13C NMR (CD3OD, 100 MHz): δ = 168.3, 161.7, 150.9, 149.8, 146.1, 144.5, 138.8, 129.6, 
129.4, 126.5, 125.4, 125.3, 124.2, 123.9, 122.6, 120.1, 114.4, 56.2, 54.4, 46.4, 11.5, 
6.6 ppm; IR: 3500–3200, 3030, 2980, 2660, 1678, 1585, 1556, 1506, 1461, 1385, 1345, 
1320, 1276, 1135, 1089, cm–1; HRMS (ESI), m/z calcd. for C28H36N5O [M]+: 458.2914, 
found [M]+: 358.2912; UV/Vis (H2O): λmax = 463 nm. 
 
 
Nitroazobenzene S3. Following standard procedure 1, 1.38 g (10 mmol) of 
p-nitroaniline dissolved in 20 mL of MeOH and 5 mL of 12M HCl first reacted with 1.4 mL 
(10 mmol) of isoamylnitrite to form a diazonium salt, which then further reacted with 
1.66 g (10 mmol) of diethylaniline in 20 mL of MeOH and 5 mL of 12M HCl. Column 
chromatography on silica gel (hexanes/EtOAc, 10:3 then 2:1) gave 1.85 g (62%) of 
nitroazobenzene S3 as a red-brown solid. Rf(hexanes/EtOAc, 10:3) = 0.7; 
1H NMR 
(600 MHz, CDCl3): δ = 8.32–8.29 (m, 2H), 7.92–7.86 (m, 4H), 6.75–6.71 (m, 2H), 3.48 (q, 
3J = 7.1 Hz, 4H), 1.25 ppm (t, 3J = 7.1 Hz, 6H); 13C NMR (150 MHz, CDCl3): δ = 157.0, 
151.3, 147.2, 143.3, 126.4, 124.7, 122.5, 111.0, 44.9, 12.7 ppm; IR: 3427, 2965, 2926, 
1937, 1600, 1587, 1518, 1504, 1444, 1425, 1408, 1391, 1341, 1324, 1274, 1258, 1194, 
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1139, 1103, 1076 cm–1; HRMS (ESI), m/z calcd. for C16H19N4O2 [MH]+: 299.1503, found 
[MH]+: 299.1492. 
 
 
Aminoazobenzene 6.  Following standard procedure 2, 1.8 g (6.0 mmol) of 
nitrobenzene S3 in 90 mL of 1,4-dioxane and 9 mL of water was reduced by three 
separate additions of 0.47 g (6.0 mmol) of sodium sulfide. Purification of the crude 
product by column chromatography on silica gel (hexanes/EtOAc, 7:3) gave 1.41 g (88%) 
of aminoazobenzene 6 as a deep red, glassy solid. Rf(EtOAc/hexanes, 3:10) = 0.3; 
1H NMR (400 MHz, DMSO-d6): δ = 7.62–7.57 (m, 2H), 7.53–7.47 (m, 2H), 6.73–6.68 (m, 
2H), 6.62–6.57 (m, 2H), 5.68 (m, 2H), 3.38 (q, 3J = 7.0 Hz, 4H), 1.10 ppm (t, 3J = 7.0 Hz, 
6H); 13C NMR (100 MHz, DMSO-d6): δ = 162.7, 151.4, 149.1, 143.7, 142.8, 124.2, 113.9, 
111.4, 44.4, 13.0 ppm; IR: 3440, 3323, 2972, 2252, 1896, 1669, 1623, 1590, 1557, 1512, 
1450, 1403, 1386, 1374, 1350, 1307, 1271, 1250, 1196, 1166, 1148, 1095 cm–1; HRMS 
(ESI), m/z calcd. for C16H21N4 [MH]
+: 269.1761, found [MH]+: 269.1751. 
 
 
DENAQ.  Following standard procedure 3, 478 mg (3.0 mmol) of betaine E dissolved in 
10 mL of acetonitrile was reacted with 1.5 mL (2M solution in DCM, 3.0 mmol) of oxalyl 
chloride to form the acid chloride F, which was further reacted with 161 mg (0.6 mmol) of 
aniline 6 dissolved in 20 mL of DMF and 0.51 mL (3.0 mmol) of DIPEA. The crude product 
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was purified by column chromatography on reversed-phase silica gel (0.1% formic acid in 
water/acetonitrile, 1:0→17:3) to yield 250 mg (92%) of DENAQ formate salt as a deep 
red, glassy solid. 1H NMR (CD3OD, 400 MHz): δ = 8.48 (s, 1H), 7.79–7.67 (m, 6H), 6.74–
6.62 (m, 2H), 4.23–4.12 (m, 2H), 3.64–3.48 (m, 6H), 3.43–3.31 (m, 4H), 1.37–1.24 (m, 9H), 
1.18–1.05 ppm (m, 6H); 13C NMR (CD3OD, 100 MHz): δ = 167.2, 161.7, 150.3, 149.9, 
142.7, 138.6, 125.0, 122.4, 120.2, 110.8, 56.3, 54.4, 44.2, 11.7, 6.7 ppm; IR: 2972, 1688, 
1630, 1597, 1547, 1514, 1448, 1394, 1351, 1249, 1194, 1154, 1138, 1076 cm–1; HRMS 
(ESI), m/z calcd. for C24H36N5O [MH]
+: 410.2914, found [MH]+: 410.2899; UV/Vis (H2O): 
λmax = 470 nm. 
 
 
 
Diazonium tetrafluoroborate S4.  Under argon atmosphere a solution of 100 mg 
(0.25 mmol) of 4-{N-[(9-fluorenylmethoxy)carbonyl]amino}tetrafluoroaniline (synthesized 
following the procedures of Chehade et al.3) in 1 mL of dry THF was added dropwise to 
47.2 µL (0.37 mmol) of boron trifluoride etherate at −40 °C. The resulting solution was 
stirred for 5 minutes and 41.8 µL isoamyl nitrite (0.31 mmol, 1.25 eq) was subsequently 
added dropwise. The reaction mixture was warmed to −5 °C over 3 hours, causing a 
color change to orange. The crude diazonium salt was precipitated by addition of 15 mL 
of cold pentane. The supernatant was transfused and when necessary centrifuged at 
4 °C. The orange and solid diazonium tetrafluoroborate S4 was dried in vacuo at −5 °C 
for one hour and employed for further reaction without additional purification. 1H NMR 
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(DMSO-d6, 200 MHz): δ = 9.96 (s, br, 1H), 7.90–7.80 (m, 2H), 7.72–7.63 (m, 2H), 7.44–7.27 
(m, 4H), 4.58–4.56 (m, 3J = 6.8 Hz, 2H), 4.35–4.25 ppm (m, 1H). 
 
 
 
 
Tetrafluoroazobenzene 8.  601 mg (1.20 mmol) of freshly prepared diazonium 
tetrafluoroborate S4 was dissolved in 6 mL of dry THF under argon atmosphere. To this 
solution, 0.23 mL (1.44 mmol) of N,N-diethylanilin and 98 mg (1.44 mmol) of sodium 
acetate were added at 0 °C. The dark red reaction mixture was allowed to warm to room 
temperature and stirred overnight. Then the mixture was poured into 100 mL of EtOAc 
and washed with saturated bicarbonate solution, water, and brine. The organic phase 
was dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography (hexanes/EtOAc = 20:1→8:1) yielded 246 mg (36%) of carbamate 8 as a 
red-orange solid. Rf(hexanes/EtOAc = 7:3) = 0.42. 
1H NMR (THF-d8, 400 MHz): δ = 8.90 (s, 
br, 1H), 7.83–7.75 (m, 4H), 7.64 (d, 3J = 7.4 Hz, 2H), 7.38–7.33 (m, 2H), 7.28 (td, 
3J = 7.4 Hz, 2H), 6.81–6.76 (m, 2H), 4.52 (d, 3J = 6.6 Hz, 2H), 4.27 (t, 3J = 6.6 Hz, 1H), 3.51 
(q, 3J = 7.1 Hz, 4H), 1.21 ppm (t, 3J = 7.1 Hz, 6H). 13C NMR (THF-d8, 100 MHz): δ = 155.0, 
153.4, 146.2–146.0 (m), 145.9, 145.8, 143.8–143.5 (m), 143.2, 141.3–143.0 (m), 132.9–
132.7 (m), 129.2, 126.8, 127.7, 126.6, 121.5, 117.7, 112.7, 49.0, 46.3, 13.7 ppm. 19F NMR 
(THF-d8, 376 MHz): δ = −147.93 (dd, 
3J = 20.6 Hz, 4J = 9.3 Hz, 2F), −153.09 ppm (dd, 
3J = 20.6 Hz, 4J = 9.3 Hz, 2F). IR: 3255, 2976, 1703, 1602, 1527, 1498, 1473, 1406, 1383, 
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1353, 1305, 1273, 1231, 1195, 1144, 1104, 1077, 1023 cm–1. HRMS (ESI), m/z calcd. for 
C31H27F4N4O2 [MH]
+: 563.2065, found [MH]+: 563.2061. UV/Vis (EtOH): λmax = 446 nm.  
 
 
 
Tetrafluoroazobenzene S5.  243 mg of freshly prepared FMOC-protected azo-
benzene 8 (0.43 mmol) was suspended in 9 mL of degassed diethyl ether under argon 
atmosphere and cooled to 0 °C. After addition of 0.9 mL (774 mmol) of piperidine, the 
mixture was warmed to room temperature, stirred for 3 hours, subsequently diluted with 
100mL of diethyl ether , and washed with HCl (1M), water, and brine. The organic layer 
was dried over Na2SO4 and concentrated in vacuo. Purification by column 
chromatography (CH2Cl2/hexanes= 1:4→2:3) yielded 125 mg (85%) of tetrafluoroaniline 
S5 as red crystals. Rf(hexanes/EtOAc = 7:3) = 0.64. 
1H NMR (Acetone-d6, 400 MHz, 
27 °C): δ = 7.77–7.70 (m, 2H), 6.84–6.78 (m, 2H), 5.72 (s, br, 2H), 3.52 (q, 3J = 7.1 Hz, 4H), 
1.21 ppm (t, 3J = 7.1 Hz, 6H). 13C NMR (Acetone-d6, 100 MHz, 27 °C) δ = 150.6, 143.9, 
143.0–142.9 (m), 140.6–140.4 (m), 137.8–137.5 (m), 135.3135.1 (m), 124.9, 110.9, 44.3, 
12.0 ppm. 19F NMR (Acetone-d6, 376 MHz, 27 °C): δ = −155.12– −155.30 (m, 2F), 
−165.55– −165.74 ppm (m, 2F). IR: 3500, 3397, 2972, 2926, 1654, 1596, 1559, 1515, 
1501, 1455, 1399, 1351, 1296, 1273, 1238, 1196, 1138, 1095, 1080, 1058, 1012, 
1000 cm–1. HRMS (ESI), m/z calcd. for C16H17F4N4 [MH]+: 341.1384, found [MH]+: 
341.1381. UV/Vis (EtOH): λmax = 430, 458 nm. 
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DENAQ-F4.  Following Standard Procedure 3, 125 mg (0.37 mmol) of tetrafluoro-
aniline S5 and 0.32 mL (1.83 mmol) of DIPEA were dissolved in 7 mL of dry DMF. To this 
solution, 390 mg (1.83 mmol) of betaine acid chloride F dissolved in 10 mL of dry DMF 
was added. The resulting mixture was allowed to warm to room temperature, stirred 
overnight, and DMF was subsequently removed in vacuo. Reversed phase column 
chromatography (0.1% formic acid in water/methanol, 9:1→1:1) yielded 74.1 mg (38%) of 
DENAQ-F4 formate salt as a deep red hygroscopic solid. Rf(0.1% formic acid in 
water/methanol = 1:1) = 0.20. 1H NMR (CD3OD, 400 MHz): δ = 8.51 (s, 1H) 7.84–7.72 (m, 
2H), 6.84–6.70 (m, 2H), 4.36 (s, 2H), 3.64 (q, 3J = 7.2 Hz, 6H), 3.49 (q, 3J = 7.1 Hz, 4H), 
1.38 (t, 3J = 7.2 Hz, 9H), 1.20 ppm (t, 3J = 7.1 Hz, 6H). 13C NMR (CD3OD, 100 MHz) 
δ = 167.6 (br), 162.6, 152.0, 144.2–143.9 (m), 143.7, 141.8–141.4 (m), 139.3–139.1 (m), 
132.1–131.9 (m), 126.0, 110.8, 55.6, 54.5, 44.4, 11.5, 6.6 ppm. 19F NMR (CD3OD, 
376 MHz): δ = −148.72 (dd, 3J = 19.2 Hz, 4J = 8.5 Hz, 2F), −155.15 ppm (dd, 3J = 19.2 Hz, 
4J = 8.5 Hz, 2F).  IR: 3406, 3186, 2978, 1673, 1597, 1555, 1519, 1494, 1380, 1352, 1307, 
1274, 1246, 1200, 1150, 1116, 1076, 1008 cm–1. HRMS (ESI), m/z calcd. for 
C24H32F4N5O [M]
+: 482.2537, found [M]+: 482.2533. UV/Vis (DPBS, pH = 7.4): 
λmax = 487 nm. 
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AFM 2-10.  In a 10 mL Schlenk flask equipped with a reflux condenser, 100 mg 
(0.39 mmol) of 4-(4-diethylaminophenylazo)pyridine and 358 mg (1.18 mmol) of 
(3-bromopropyl)triethylammonium bromide (see Jeon et al.4) were dissolved in 8 mL of 
dry DMF under argon atmosphere. The reaction mixture was stirred at 80 °C for 30 hours, 
cooled to room temperature, and subsequently dried in vacuo. Purification by reversed 
phase column chromatography (0.1% formic acid in water/methanol, 1:0→50:1) had to 
be performed two times, yielding 180 mg (92%) AFM 2-10 as deep purple hygroscopic 
solid bisformate salt. 1H and 13C NMR samples were taken from the corresponding 
trifluoroacetate salt, which was obtained by further purification using reversed phase 
HPLC. Rf(0.1% formic acid in water/methanol, 1:10) = 0.05. 
1H NMR (D2O, 400 MHz): δ = 
8.48 (d, 3J = 7.4 Hz, 2H), 7.77 (m, br, 4H), 7.31 (s, br, 2H), 4.40 (t, 3J = 7.6 Hz, 2H), 3.90 (q, 
3J = 7.2 Hz, 4H), 3.21–3.16 (m, 8H), 2.29 (m,2H), 1.29 (t, 3J = 7.2 Hz, 6H), 1.13 ppm (t, 
3J = 7.2, 9H). 13C NMR (D2O, 100 MHz): δ = 162.7 (q), 160.2, 154.1, 144.4, 141.9, 126 (br), 
126.5 (br), 116.2 (q), 112.7, 56.1, 52.9, 52.6, 49.4, 23.0, 12.8, 6.5 ppm. IR: 3390, 2977, 
1650, 1634, 1593, 1543, 1513, 1502, 1476, 1418, 1395, 1370, 1343, 1318, 1300, 1266, 
1189, 1164, 1115, 1071, 1025, 1006 cm–1. HRMS (ESI), m/z calcd. for C24H39N5 [M]2+: 
198.6597, found [M]2+: 198.6596. UV/Vis (DPBS, pH = 7.4): λmax = 580 nm. 
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 4) L-type calcium channels as potential targets for PCLs 
 
Calcium ions represent a key second messenger in the intracellular communication 
of cells, which is crucial for adaptations to environmental changes.[1] In neurons for 
instance, the difference between internal and external Ca2+ concentration, which is 
about 10000 fold, allows for a precise temporal control of intracellular processes.[1] 
Voltage-gated calcium (Cav) channels are opened by a depolarization of the 
membrane, which leads to internal Ca2+ elevation in a defined space and triggers 
further downstream signaling.[2,3] These processes are involved in neuronal 
regulation of gene expression and neurotransmitter release at presynapses, which is 
important for dendritic differentiation and neuronal communication, respectively.[3] 
 
4.1) Calcium as a second messenger 
 
In a neuronal context, the class of L-type calcium channels (LTCCs), which are 
voltage-gated, have been extensively studied in terms of their influence on gene 
regulation.[3] Different LTCCs related second messenger pathways trigger the 
phosphorylation of the cAMP response element-binding protein (CREB) at Serine 
133.[3] The phosphorylated state of CREB represents the active form of a 
transcription factor, which is for instance crucial in the gene expression of 
neutrophins. An example of this class is BDNF, which has an important influence on 
dendritic growth and synaptic development.[3] 
A rather slow second messenger pathway, initiated by LTCCs, includes the 
Ras/MAP kinase pathway.[4] Here, calmodulin (CaM) is associated with the internal 
side of a LTCC and coordinates Ca2+ upon channel opening, thereby triggering the 
RAS/MAP kinase cascade, which leads to the phosphorylation of CREB. This 
pathway reaches its maximal activity after 30-60 min.[4] 
Another second messenger pathway starts with the Ca2+ influx through LTCCs and 
the binding of Ca2+ to closely located CaM.[5] Activated Ca2+/CaM units directly 
translocate to the cell nucleus, where they control CaMKIV dependent CREB 
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phosphorylation. This process happens within 1-3 minutes and represents a rather 
fast pathway.[5]  
A third LTCCs initiated CREB phosphorylation pathway, which shows maximal 
activity in a timescale of minutes, involves CaMKII.[6] Ca2+ entering via LTCCs binds 
to apoCaM, which then coordinates to CaMKII. The second messengers that follow 
this process and finally phosphorylate CREB are still under investigation.  
 
 
 
Figure 2. Two schematic depictions of a LTCC including the α-subunit co-assembled with β, α2δ and 
γ auxiliary subunits. A) A spatial representation of a LTCC arrangement (modified from publication[7]). 
B) A detailed presentation of the α -subunit homologue domains I-IV and their transmembrane 
domains 1-6 (modified from publication[8]). 
 
4.2) Molecular composition of Cav channels. 
 
The core of Cav channels includes a central α-subunit with a mass of about 200 kDa, 
which forms an ion-conducting pore (Fig. 2). Several α-subunit families exist and are 
divided in Cav1 (LTCC/L-type), Cav2 (P/Q-, N-, R-type), Cav3 (T-type) channels.[8,9] So 
far 10 α -subunits have been identified.[10] The α -subunit co-assembles with the 
auxiliary subunits β, α2δ and γ (Fig. 2). These auxiliary subunits modulate biophysical 
properties of the channel and have an influence on the surface expression.[7,8,9] 
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The α-subunit contains four homologue domains, I-IV, whereat each domain has six 
transmembrane domains, 1-6 (Fig. 2).[7,8,9]  
The β -subunit is located in the cytosol and contains two main protein-protein 
interaction domains, a SH3 domain and a GK domain (Fig. 2).[7,8,9] Four different β-
subunits, β 1-β4, have been identified. Additionally, alternative splicing events 
increase the number of β-subunits. The main interaction site of the α- and β-subunit 
lies for the α -subunit on the connecting loop between domains I/II and for the β -
subunit on the GK domain.[8] 
 
The α2δ-subunit consists of two polypeptides, α2 and δ , which are connected by a 
disulfide bond. Four different isoforms have been identified, α 2δ-1 - α2δ-4.[7,8,9] 
Although the polypeptides are separated, they were originally found as one 
transcript, which is separated by proteolytic cleavage.[7,8,9] The α 2δ-subunits have 
only a minor influence on the biophysical properties of the Cav channels. These 
subunits seem to be upregulated in certain parts of the brain, during development of 
physiological dependence on drugs of abuse.[11] 
 
The γ -subunit is a glycoprotein with four transmembrane segments. So far, eight 
genes encoding γ 1-γ8 have been characterized, whereat the N- and C-terminus are 
both located in the cytosol.[7,8,9] 
 
4.3) Subtypes and physiological role of LTCC α-subunits 
 
The human genome encodes four LTCC α-subunit genes, known as Cav1.1-1.4.[8,9,10] 
Cav1.1 is mainly expressed in skeletal muscle. The channel has influence on 
intracellular calcium release by activating the ryandine receptor in the sacroplasmic 
reticulum.[10] Cav1.2 is expressed in diverse tissue like ventricular cardiac muscle, 
pancreatic cells and neurons. An important role of Cav1.2 channel lies in the 
initiation of cardiac muscle contraction, by the influx of calcium during channel 
opening.[10] Cav1.2 channels expressed in neurons play an important role in 
intracellular downstream signaling. 
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Cav1.3 and Cav1.2 channels have similar expression patterns and subcellular 
localizations in different tissue. In neurons, Cav1.2 and Cav1.3 channels are present 
in the dendritic region.[10,13] Activity of Cav1.3 compared to Cav1.2 channels initiate a 
stronger phosphorylation of CREB, via second messenger pathways.[13] In heart 
tissue, Cav1.3 is not expressed in ventricular muscle but in atrial tissue. Here the 
channel influences the pacemaking of heart contraction.[10] Cav1.3 compared to 
Cav1.2 channels, start to open at a membrane potential which is approximately 20 
mV more hyperpolarized.[10,12] 
 
Cav1.4 represents a member of LTCCs with unusual characteristics. The expression 
of the channel is almost limited to the synaptic terminals of rod photoreceptors and 
bipolar cells within the retina.[10,14] Cav1.4 compared to other LTCCs does not show 
calcium dependent inactivation, which is due to an autoinhibitory domain within the 
C terminus.[14] This characteristic of Cav1.4 can be interpreted as a functional need of 
rod photoreceptors and bipolar cells to adapt to certain variations of input signals, 
which is important in the vision process.[14] 
 
4.4) Pharmacology of LTCCs 
 
As LTCCs play for instance a central role in controlling the activity of the mammalian 
heart, by linking cardiac membrane depolarization to contraction, they have been 
intensively studied as pharmacological targets. From an historical point of view, the 
influence of calcium on the contraction of heart muscle was first described by Sir 
Sidney Ringer, in the year 1882. He discovered that in calcium free medium 
contractility of the heart muscle is quickly lost.[15] Later Albrecht Fleckenstein 
demonstrated that contractility was prevented by applying random drugs including 
nifedipine (12), verapamil (13) and diltiazem (14) on the muscle in calcium containing 
medium (Fig. 3).[15] He concluded that these drugs have an antagonistic effect on 
calcium.[15] In the year 1975 4-Aryl-1,4,dihydropyridine-3,5-dicarboxylic diesters of 
the nifedipine type (Adalat®) (12) have been introduced for treatment of coronary 
diseases in Germany.[16] Soon after the discovery of 1,4-dihydropyridines (DHPs) 
effects on cardiovascular properties, certain LTCCs were identified as main protein 
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targets of DHPs.[15,16] Here they act as blockers, preventing influx of calcium through 
LTCCs. 
 
 
 
Figure 3 . A ) Representation of different DHP LTCC agonists, antagonist and the energetically 
preferred DHP boat conformation (aryl axial). B) Structures of the activator FPL-64176 (16), the 
antagonists (S)-verapamil (13) and diltiazem (14). 
 
Most DHPs act as antagonists, whereas few examples, such as BAY K 8644 (15), 
act as agonists.[16,17] The classes of phenylalkylamines (PAAs) and benz(othi)azepines 
(BTZs) were additional indentified as LTCC blockers, whereat verapamil (13) and 
diltiazem (14) represent members of PAAs and BTZs with clinical application, 
respectively (Fig. 3).[15] Many DHPs, PAAs and BTZs do not, or only to a small extent, 
affect T-, Q-, R-, N- and P-type Cav channels, which makes them useful 
pharmacological tools. All three LTCC antagonists bind to overlapping binding sites 
within the α -subunits.[15] FPL-64174 (16) represents a LTCC activator, which 
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increases macroscopic inward current and has frequently been used to answer 
scientific questions.[6,18]  
 
 
 
Figure 4 . A) A current-voltage (I-V) curve of Cav1.3α1 under normal conditions () and under 
nimodipine influence (o).  B) Single current traces reveal the amount of block induced by nimodipine 
at indicated voltage. C) DHPs block late phase of the current initiated by a depolarizing pulse. D) 
Dose-response curve of nimodipine block  (A)-D) modified from publication[12]) . 
 
4.5) DHPs on Cav1.3 and Cav1.2 channels 
 
Subtypes of LTCCs own different binding affinities towards DHPs. Cav1.3 and 
Cav1.4 channels are significantly less sensitive to DHPs than Cav1.2 channels.[10,12] 
Nimodipine, like other DHPs, blocks mainly the late phase of the Ca2+ current, 
elicited by depolarization of the membrane. Based on a dose-response curve, the 
half maximal inhibitory concentration (IC50) of nimodipine (17) on Cav1.3 channel was 
calculated to be IC50 = 2.7 μM  ± 0.3 μ M (Fig. 4).[10,12] Typical DHP antagonist 
concentrations that inhibit Cav1.2 and Cav1.3 currents lie in the range of IC50 = 1 nM -
10 μM. 
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4.6) Theoretical models of Cav channel gating 
 
Simplified biophysical description of Cav channel gating resulted in two main kinetic 
models. One is based on a gating scheme of the Shaker Kv channel, introduced by 
Zagotta and Aldrich. Here multiple closed states of a channel are connected by 
voltage-dependent transitions followed by a final voltage-independent opening 
state.[19] Another model presented by Marks and Jones describes multiple open 
states in parallel with closed states, which account for binding effects of some DHP 
agonists.[19] In a simplified, but intuitive model, only three channel-states are 
considered, whereat from each state both other states can be kinetically entered. 
Here a closed, occupied at rest, an open and an inactivated channel-state are 
connected in a triangle. After depolarization, occupation of the open state is 
kinetically faster compared to the inactive state.[19] In equilibrium however, the 
inactivated state is higher populated.[19] In absence of a DHP, the channel 
interconverts between the states. DHPs prefer to bind to the inactivated state of the 
channel.[19] The probability of the channel to rest in its inactivated state increases 
with less negative cell membrane potential. Based on this, DHPs act as voltage-
dependent blockers.[15] 
 
4.7) Molecular interaction site of DHPs and LTCCs 
 
Several investigations have been performed to localize the binding site of DHPs on 
LTCCs and the amino acids involved in the direct ligand-receptor interaction. A 
rather rough estimation of the DHP binding position as well as the access route of 
DHPs toward their binding site has been determined by an approach of molecular 
tape measurements.[20,21] 
(S)-BK-n (19), a series of DHPs with long alkyl chains of different length at their 
starboard side and a positively charged quaternary ammonium group at the end 
allowed to estimate how distant the DHP binding site is from the external and the 
cytosolic side of the receptor (Fig. 3). (S)-BK-n (19) with an n>2 were shown to have 
access to the binding site from the external side via the “sidewalk“, but not from the 
internal side. Based on the ligand with the highest efficacy on LTCCs, (S)-BK-10 
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(19), the length from extracellular side to the DHP binding side was estimated to be 
11-14 Å.[20,21] 
The exact position of the DHP binding side and the molecular surrounding of ligand, 
have been revealed by antibody mapping, photoaffinity labeling, chimeric Cavα1 
subunits and site-directed mutagenesis.[15] The binding site is located below the 
selectivity filter of LTCCs and interacting amino acids are located in transmembrane 
segments IIIS5, IIIS6, IVS6 as well as in the pore helix IIIP.[15] DHP antagonists have 
been shown to stabilize the impermeable state of LTCCs with only one calcium ion 
bound to the selectivity filter, which is associated with a direct interaction of an 
antagonist with calcium ion occupancy.[22] 
Until today, the mode of action of DHP agonists is unclear and highlights the need 
for a LTCC crystal structure in coordination with DHPs. 
 
4.8) Chemical structure of DHPs 
 
Unsubstituted DHP rings have an almost planar conformation. Introduction of an 
Aryl group into 4 position shifts the energetically preferred structure into a flattened 
boat form 18 (Fig. 3) with the Aryl ring in pseudoaxial position.[16] This conformation 
has been confirmed by several crystal structures and calculations.[16] 
Pharmacological effective DHPs have an H-bond donor on their stern and H-bond 
acceptor at their bowsprit, portside and starboard side (Fig. 3).[22] Modeling of DHP 
binding site interactions proposed the portside substituents to induce block of 
LTCCs.[22]  
 
4.9) Design of photoswitchable LTCC ligands 
 
The influence of LTCCs on gene regulation motivated to design photoswitchable 
agonists and antagonists.[3] Light gated LTCCs should in principle improve the 
understanding of the temporal and spatial relation of LTCC activity and CREB 
phosphorylation. 
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Different PCLs were designed that potentially could bestow light sensitivity on 
LTCCs currents. The successfully applied molecular tape measurements and the 
number of DHPs with bulky substituents on the starboard and portside positions 
(Fig. 5),[23,24] indicate that these positions are well suited for the attachment of an 
azobenzene.  
 
 
 
                      
Figure 5 .  Chemical structures of Efonidipine (21),[25] DHP derivative 22,[24] 23,[23] and 24.[16] These 
DHPs exhibit bulky substituents at their portside and starboard sides, indicating potential tolerance 
towards azobenzenes.  
 
Nifedipine (1) and other DHPs are sensitive towards 200-450 nm light.[26,27] Irradiation 
oxidizes the 1,4-Dihydropyridine structure yielding pyridines, which have no 
antagonistic effect on LTCCs. This sensitivity was even transformed into an 
approach called “light-flash physiology“, which allows to delete nifedipine (12) 
induced LTCCs block with high temporal and spatial precision.[28] One study on the 
light sensitivity of DHPs revealed Felodipine (20), a LTCC antagonists, to be stable 
for some hours under irradiation with 300-800 nm light.[29] Based on this finding, 
Felodipine (20) was chosen as the DHP core of LTCC PCLs. Furthermore, 
compound 20 was shown to exhibit an IC50 = 14.9 nM on Cav channels.[30] 
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Figure 6. Chemical structures of potential antagonistic and agonistic LTCC PCLs. 
 
Several neutral derivatives of Felodipine (20) coupled to an azobenzene were 
designed and named Feazo-x. It was hypothesized that the transition between the 
cis and trans state of the azobenzene and the associated change in polarity of about 
2-3 debye,[31] could result in different efficacies of Feazo-x towards its binding site. 
The spacer length between the portside ester and the azobenzene and the 
substitution pattern of the azo group within the azobenzene was varied to give 
Feazo-2 (25), Feazo-3 (26), Feazo-4 (27), Feazo-4l (28) (Fig. 6). 
 
Another strategy to generate an antagonistic PCL for LTCCs aimed to hitchhike the 
tape measurement approach of (S)-BK-n (19).[20,21,32] It was reasoned that a positive 
charge positioned at the azobenzene end of a Feazo-x derivative would selectively 
allow the elongated trans state to reach the DHP binding site, resembling the length 
of (S)-BK-10 (19). Thereby, channel blocking would be installed. The shortened cis 
state would locate the DHP in proximity to the membrane surface and release block. 
By switching between the two states reversible light control of LTCCs should be 
possible. Together this considerations lead to the design of Feazo-3,4-(+) (29). 
N
H
COOMeEtOOC
Cl
Cl
Felodipine (20)
N N
HN
O
O
O
N
H
MeOOC
Cl
Cl
O
O N N
N
H
MeOOC
Cl
Cl
O
O
N N
N
H
MeOOC
Cl
Cl
O
O
N N
N
H
MeOOC
Cl
Cl
O
O N N
N
H
MeOOC
Cl
Cl
O
O
N N
N
Feazo-4 (27)
Feazo-2 (25) Feazo-3 (26)
Feazo-4l (28)
FPL-azo (30)Feazo-3,4-(+) (29)
127
	  
 
To generate a PCL activator for LTCCs, FPL-64176 (16) was chosen as a lead 
structure (Fig. 3).[18,33,34] Here the diphenylmethane part was replaced by an 
azobenzene. Compared to the parent molecule a carbonyl bridge between the 
pyrrole and the azobenzene was installed in the 3’ instead of the 2’ position, yielding 
FPL-azo (30).  
 
4.10) DHP synthesis 
4.10.1) Synthesis of Feazo-x 
 
The synthesis of Feazo-x 25-28 commenced with coupling of substituted 
benzylalcohols 31-34 with nitrosobenzene to give diazene 35-38, via Mills reaction.[35] 
In the following step, diketone 39-42 was furnished by nucleophilic attack of 
compound 35-39 on in situ formed ketene. Finally, compound 39-42 was converted 
into the desired 1,4-dihydropyridine called Feazo-x 25-28, via Hantzsch reaction.  
 
 
 
Scheme 1. Synthesis of Feazo-x derivatives 25-28 
 
4.10.2) Synthesis of Feazo-3,4 (48) 
 
4-Aminobenzylamine 43 was reacted with Boc2O to give tert-butyl 4-
aminobenzylcarbamate	  44. Oxidation of the latter using Oxon® yielded carbamate 45. 
3-Aminobenzylalcohol was coupled to compound 45 via Mills reaction,[35] resulting in 
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diazene 46. This was reacted with an in situ formed ketene to give diketone 47. 
Finally, a Hantzsch reaction of 47 with aminocrotonate and 2,3-dichlorbenzaldehyd 
yielded Feazo-3,4 (48).  
 
Acidic treatment of compound 48 with a saturated solution of HCl in EtOAc effected 
the removal of the Boc-protecting group to yield free amine. Since the latter could not 
be purified, it was directly methylated using methyl iodide. However, this reaction 
afforded a inseparable mixture of different products and even the attempted 
purification by reverse phase column chromatography or HPLC failed to give clean 
Feazo-3,4-(+). Therefore, Feazo-3,4 (48) was pharmacologically characterized on 
LTCCs. 
 
 
 
 
Scheme 2. Synthesis of Feazo-3,4 (48) 
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4.10.3) Synthesis of FPL-azo (30) 
 
The synthesis of FPL-azo (30) started with coupling of anthranilic acid (49) with 
nitrosobenzene to yield diazene 50 via Mills reaction.[35] This was next treated with 
oxalyl chloride to generate benzoyl chloride 51. Friedel crafts acylation of pyrrole 52 
with benzoyl chloride 51 resulted in the formation of FPL-azo (30).[33]  
 
  
 
Scheme 3. Synthesis of FPL-azo (30) 
 
4.11) Characterization of Feazo-x on LTCCs 
 
The first question was whether Feazo-x derivatives would induce block of LTCC 
current in the dark. Therefore, derivatives were characterized on Cav1.3α1 channels, 
co-expressed with the auxilary subunits Cavβ3 and Cavα2δ in HEK293T cells. The 
electrophysiological protocol is described in Ref. 12.[12] During experiments LTCCs 
typically lose current strength, which is called rundown.[28] This process is often 
difficult to distinguish from antagonist induced current reduction. Thus, control 
measurements were performed to quantify the amount of rundown. The 
quantification of Felodipine (20) block on the Cav1.3α1 channel, established the 
fundament to determine the block of Feazo-x derivatives (Fig. 7). 
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Figure 7 . A) Determination of Felodipine (20) and Feazo-x block on Cav1.3α1, co-expressed with 
auxilary subunits Cavβ3 and Cavα2δ in HEK293T cells. Current traces, of each single compound, were 
superimposed to visualize the temporal course of current reduction. Black, orange and blue traces 
represent the wash-in period, second recording period and third recording period, respectively. The 
first and last current trace of all three periods are shown. Based on temporal lack of the Cavβ3 clone, 
Feazo-2 (25) and Feazo-3,4 (48) were recorded without co-transfection of Cavβ3. B) Sequence of 36 
protocol-cycles, used to study LTCCs in the dark.  
 
HEK293T cells expressing Cav1.3α1 were depolarized from a holding potential of -70 
mV to -10/0 mV for 80 ms, with a frequency of 0.25 Hz (Fig. 7). The complete 
measurement contained 36 protocol-cycles. During the initial 16 cycles a blocker 
was perfused on cells, whereas in control experiments only external solution was 
applied. Within the following 20 protocol-cycles, block accumulation was continued 
to be recorded.  
The physiological function of the Cav1.3α1 channel, to conduct Ca2+ ions, goes along 
with Ca2+ dependent inactivation of the channel current. This inhibitory process 
hampers to study antagonist induced channel blocking. To prevent and reduce this 
unrequested effect, Ca2+ was replaced by Ba2+ in the external recording solution.[12] 
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Figure 8. A) Quantification of Feazo-x induced blocking on Cav1.3α1 channel current. Cavβ3 was not 
present for Feazo-2 (25) and Feazo-3,4 (48) recordings. Error bars, ± s.e.m.; Student t-test; *P < 0.05, 
**P < 0.01. B) Current trace of representative Feazo-3,4 (48) photoswitching on Cav1.3α1 channel. 
Data indicate that photoswitching has no influence on current size. The trace was recorded after the 
36 protocol-cycles in the dark. 
 
To quantify the block, the current size of the first and last elicited depolarization 
were compared, using the given equation protocol-cycle(36)/protocol-cylce(1). For 
control experiments, the statistics on the latter equation revealed a rundown to 
51.7% ± 15.6% of the initial Ba2+ current (n = 11 cells) (Fig. 8). Application of the 
antagonist Felodipine resulted in a strong reduction of the LTCC current. Only 7% ± 
2.4% (n = 9 cells, 10 μM) of current remained after 36 protocol-cycles, indicating, 
that the system applied to study the blocking of the DHP-derivatives is reliable. The 
compound Feazo-4l (28) showed no statistically significant block compared to 
Felodipine (20) and control experiments (Fig. 8). Application of the compound 
decreased the current strength to 31.8% ± 12.0% (n = 7 cells, 30 μM). Feazo-4 (27) 
did not induce clear block, which was even less than for control experiments. The 
measurement resulted in a current strength of 70.2% ± 35.1% (n = 4 cells). 
Application of Feazo-2 (25) and Feazo-3,4 (48) resulted in 76.6% ± 12.0% (n = 3 
cells, 30 μM) and 87.2% ± 50.0% (n = 3 cells, 20 μM) current strength, respectively. 
All Feazo-derivatives were applied at maximal solubility in external solution. Once 
the sequence of protocols to determine Feazo-x block was completed in the dark, 
additional protocol-cycles were performed. Here, every 10 protocol-cycles 
irradiation was alternated between 350 nm and 430 nm light. The wavelengths were 
132
	  
chosen based on UV/VIS spectra of the compounds (see Appendix UV/VIS spectra). 
These recordings revealed no photocontrol of LTCC current, see representative 
current trace in Fig. 8. 
 
 
Figure 9. A) Comparison of I-V before (green) and after (orange) FPL-azo (30) application on Cav1.3α1 
channel in the dark (n = 3 cells, error bars, ± s.e.m.). B) Sequence of protocols used to determine 
FPL-azo (30) effect on Cav1.3α1. C) Current elicit at 0 mV of I-Vs recorded after FPL-azo (30) 
application (wash-in). The first I-V was recorded in the dark and afterwards under changing irradiation 
wavelengths. Error bars, ± s.e.m.. 
 
FPL-azo (30) was characterized on Cav1.3α1 channels, co-expressed with the 
auxilary subunit Cavα2δ. A single I-V curve was recorded before and after the wash-
in of FPL-azo (30), which was applied at a concentration of 10 μM. The protocol 
applied to record the I-V relationship depolarized cells from a holding potential of -
70 mV up to + 70 mV in 10 mV intervals (Fig. 9). The depolarization lasted 80 ms 
with a frequency of 0.25 Hz. The protocol to wash-in FPL-azo (30) was taken from 
Feazo-x experiments including 16 cycles of depolarization. The I-Vs recorded (n = 3 
cells) in the dark showed a small increase in current strength, raising the possibility 
of a modest agonistic effect of FPL-azo (30) (Fig. 9). After the processes of wash-in 
and I-V recording in the dark were completed, I-V protocols with alternating 
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irradiation of 350 nm and 430 nm light were applied (Fig. 9). Analysis of the current 
at 0 mV of all I-Vs recorded, after the wash-in period, revealed no light induced 
influence on the current strength (Fig. 9). 
 
4.12) Discussion 
  
The data presented here indicate, that Feazo-2 (25), Feazo-3 (26), Feazo-4 (27), 
Feazo-4l (28) did not induce block on the Cav1.3α1 channel. The reasons for this 
finding may be associated with the size of the azobenzene as a substituent. To 
answer this question a series of Feazo-x derivatives, with benzene instead of 
azobenzene, could be synthesized and characterized on the Cav1.3α1 channel. Here, 
one would expect to generate DHP antagonists with less sterical hindrance. 
However, DHP derivatives presented in Fig. 5 suggested that a certain tolerance 
towards bulky substituents at the starboard and portside position is given. 
Furthermore, Felodipine derivatives with huge substituents, e.g. compound 22 were 
reported (Fig. 5),[24] which still exhibit a high affinity towards Cav channels. Light 
control of Feazo-x states did not result in modulation of Cav1.3α1 current size. To 
improve chances to generate an active DHP photoswitch, other structures than 
Felodipine could be considered. To form Feazo-3,4-(+) (29) or similar derivatives, 
other synthetic strategies could be considered. 
FPL-azo (30) showed a slight increase of Cav1.3α1 current strength. An effect that 
hampers the determination of the agonistic effect lies in the presence of current 
rundown, which acts opposed to the increasing effect. However, changing 
wavelength between 350 nm and 430 nm light did not alter the current strength. 
To increase chances to create a photoswitchable PCL for LTCCs, combinations of 
phenylalkylamines and benz(othi)azepines with azobenzenes could be designed and 
tested. 
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4.13) General experimental details 
 
General experimental details were carried out as reported beforehand in reference.1 
In brief, unless stated otherwise, all reactions were carried out in oven-dried 
glassware under a nitrogen or argon atmosphere. Solvents for flash column 
chromatography extraction and some reactions were distilled under reduced 
pressure. Tetrahydrofuran (THF) was distilled from benzophenone and sodium prior 
to use. Flash column chromatography was performed as described by Still et al. 2 
using Merck silica gel (SiO2; 60 Å, 40-63 µm) or for reversed phase column 
chromatography waters C18 (C18; 55-105 µm, 125 Å). 1.3-1.5 bar have been 
applied to force flow of eluant. Reactions were monitored by analytical thin-layer 
chromatography (TLC) using E. Merck 0.25 mm silica gel 60 F254 precoated glass 
plates. Chemicals on TLC plates were detected by exposure to ultraviolet light.  
 
4.14) Instrumentation 
 
Instrumentation was carried out as reported beforehand in reference1. In brief, all 
presented proton (1H) and carbon (13C) NMR spectra were recorded with Varian 
VNMRS 300, VNMRS 400, INOVA 400 or VNMRS 600 spectrometers. 1H spectra 
were measured at 300 MHz, 400 MHz or 600 MHz. 13C NMR spectra have been 
detected by 50 MHz, 75 MHz, 150 MHz. For 1H spectra shifts were presented as 
parts per million (δ), signals arising from residual non-deuterated solvent were used 
as the internal standard and the solvent shifts reported were used as references.3 
Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, 
coupling constant (Hz), integration). Multiplicities are reported as follows: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, mc = centrosymmetric multiplet, br 
= broad, or combinations thereof. 13C spectra shifts are presented as parts per 
million (δ), signals arising from residual non-deuterated solvent were used as the 
internal standard and the solvent shifts reported were used as references.3 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 T. Fehrentz, C. A. Kutruff, Florian M. E. Huber, Michael A. Kienzler, Peter Mayer, Dirk   
  Trauner, under revision. 
2 W.C. Still, M. Kahn, A. Mitra, J. Org. Chem. 1978, 43, 2923–2925. 
3 G. R. Fulmer, A. J. M. Miller, N. H. Sherden, H. E. Gottlieb, A. Nudelman, B. M. Stoltz, J. E. 
  Bercaw, K. I.  Goldberg, Organometallics 2010, 29, 2176−2179. 
  P. Stawski, M. Sumser, D. Trauner,  Angew. Chem. Int. Ed. 2012, 51, 5748-5751. 
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Mass spectrometry was performed with a Thermo Finnigan MAT 95 (EI), a Thermo 
Finnigan LTQ FT (ESI) apparatus. Melting points (mp) were detected using a 
Standford Research Systems MPA apparatus. IR spectra were obtained using a 
Perkin-Elmar BXII-FTIR spectrometer equipped with an ATR unit. UV/Vis spectra 
were recorded with a Varian Cary50 Scan Systems MPA120 instrument and 
STARNA 29/B/12 quartz cuvettes (10 mm light path). Absorption spectra, which 
were recorded under an additional perpendicular illumination to the UV/VIS light 
beam, were pre-irradiated for 5 minutes. 
 
4.15) Electrophysiology and cell culture 
 
HEK293T cells (tsA-201 cells, large T-antigen transformed HEK293 cells) have been 
grown in DMEM (Biochrom, Dulbeco’s MEM, Cat. No. FG0445, F0445) 95% and 5% 
(FBS, Biochrom) with a final concentration of 2mM L-Gln. Cells wer splitted once 
confluency was reached. Between 20000 to 25000 cells were plated on a single 
coverslip, coated with poly L-lysine. HEK293T cells were transfected with 1μg 
Cav1.3α1, Cavβ3 and Cavα2δ in a molar ratio of 1:1:1.4 To simplify the detection of 
transfected cells, eGFP was co-transfected. Transient transfection was carried out 
using the calcium phosphat method. Before recordings were performed, transfected 
cells were incubated at 37 °C for 12 hours, followed by period at 32 °C for 48 hours. 
 
Patch clamp recordings and analysis have been performed with a standard 
electrophysiological setup, including an inverse microscope, a HEKA Patch Clamp 
EPC10 USB amplifier and patch master software. Measurements have been 
recorded in whole cell mode. Pipette (Science Products GB200-F-8P with filament) 
resistence varied between 4-8 MΩ. Irradiation of samples has been performed 
through a Nicon Fluor 60x/1.00w objective, with a TILL Photonics Polychrome 5000 
monochromator as light source.5 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4  W. Xu, D. Lipscombe, J. Neurosci. 2001, 21, 5944-5951. 
5  A. Mourot, T. Fehrentz, Y. Le Feuvre, C. M. Smith, C. Herold, D. Dalkara, F. Nagy, D.     
   Trauner, R. H. Kramer, Nat. Methods 2012, 9, 396-402.	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External barium current recording solution contained in mM: 82 NaCl, 30 BaCl2, 5.4 
CsCl, 1 MgCl2, 5 HEPES free acid, 10 glucose and pH was ajusted to 7.4. Internal 
barium current recording solution contained in mM: 112 CsCl, 3 MgCl2, 5 HEPES 
free acid, 3 MgCl2, 3 MgATP, 10 EGTA and pH was ajusted to 7.4 using CsOH. 
Photoswitches were solved in external bath solution to give the final working 
concentrations. DMSO concentration was below 0.1%.  
 
The voltage clamp protocol used to record antagonist/Feazo-x block of Cav1.3α1 
channel current, depolarized the membrane from its holding potential of -70 mV to -
10/0 mV for 80 ms, with a frequency of 0.25 Hz (Fig. 7). This protocol was looped 
and within the first 16 cycles of the recording, external solution containing an 
antagonist was perfused on cells. In total 36 cycles were performed in the dark (Fig. 
7). Afterwards, irradiation was altered between 350 nm and 430 nm light every ten 
protocol cycles. 
 
To study the FPL-azo (30) effect on Cav1.3α1 channels, a current-voltage (I-V) 
protocol was followed by a wash-in sequence of the agonist, before an additional I-
V was recorded in the dark. Further I-Vs were recorded under alternating 350 nm or 
430 nm light irradiation (Fig. 9). To record I-V curves of Cav1.3α1 channels, cells were 
hold at -70 mV and depolarized in a loop sequence to values between -70 mV and 
+70 mV, in 10 mV intervals at 0.25 Hz. For the wash-in of FPL-azo (30), the protocol 
for the detection of Feazo-x block was coppied (Fig. 9). 
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4.16) Synthetic procedures 
Procedure 1 
 
 
 
4-aminobenzylamin (43) (1.00 g, 8.19 mmol, 1.00 eq) was dissolved in THF (10 mL) 
and the mixture was cooled to 0 °C. Di-tert-butyldicarbonat (1.965 g, 9.00 mmol, 1.1 
eq) in THF (2 mL) was slowly added to the reaction mixture. The reaction mixture 
was stirred at 0 °C for 40 minutes and an additional hour at rt. The reaction was 
stopped after TLC monitoring showed no starting material. The reaction mixture was 
concentrated and the crude material was purified by flash column chromatography 
(silica, EtOAc: hexanes = 1:3) to yield the title compound 44. 
 
Procedure 2 
 
 
 
A solution of aniline 44 (1.00 g, 4.50 mmol, 1.00 eq) in dichlormethan (250 mL) was 
treated with an aqueous solution of Oxone® (8.62 g, 22.5 mmol, 5.0 eq). The mixture 
was stirred at rt for four hours, while the colour of the solution turned green. The 
organic phase was separated and the aqueous phase was extracted four times with 
DCM (100 mL). The combined organic phases were washed with aqueous HCl (150 
mL, 1M), aqueous saturated NaHCO3 solution (150 mL) and a 10% aqueous NaCl 
solution (150 mL). The organic phase was dried over Na2SO4 and the solvent was 
concentrated under reduced pressure. Due to volatility of the title compound 45 no 
further purification was carried out and the nitrosoarene 45 was directly added to 
next reaction. 
NH2
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Boc2O, THF, 0 °C#
→#rt, 2 h
95%
H
N
O
O
NH2
H
N
O
O
NO
Oxone®,#DCM, 
H2O, rt, 4 h
44 45 not purified
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Procedure 3 
 
  
 
Nitrosoarene 53 (1.0 eq) was dissolved in glacial acid (3.8 mL/mmolnitrosoarene). To this 
solution aniline 31-34, 49 (0.83 eq) was added and the reaction mixture was stirred 
at rt. The colour of the reaction mixture turned red. The reaction was stopped after 
TLC monitoring did not show any more presence of aniline 31-34, 49. The solution 
was pured on an aqueous saturated NaHCO3 solution (46 mL/mmolnitrosoarene, CO2 
release). The product was extracted four times with EtOAc (23 mL/mmolnitrosoarene). 
The combined organic phases were dried over Na2SO4 and the solvent was removed 
under reduced pressure. The crude product was purified by flash column 
chromatography (silica, EtOAc: hexanes = 1:4) to yield title compounds 35-38, 46, 
51. 
 
Procedure 4 
 
  
 
NH2
X
NO
Y
X
N N
Y
AcOH, rt, 12 h
OH=X
n=1,2
=Y
35 (70%), 36 (76%), 37 (51%), 
38 (73%), 46 (42%), 51 (45%)
        yield over two steps
31-34, 49
COOH
,
H , NHBoc
53
O
O
O
O
O O
X2 =OH=X1
X2
N N
Y
X1
N N
Y
toluene, 150 °C, 30 min
n=1,2
n=1,2
39 (52%), 40 (87%), 
41 (72%), 42 (87%), 47 (63%)
=Y H , NHBoc
35-38, 46
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To a solution of toluene (1.06 mL/mmolalcohol) and alcohol 35-38, 46 (1.0 eq) was 
added 2,2,6-trimethyl-4H-1,3-dioxin-4-one (1.0 eq). Under vigorously stiring the 
mixture was heated to 160 °C under strong gas release. The reaction was stopped 
after TLC monitoring did not show any more starting material. The reaction mixture 
was concentrated and the crude product was purified by flash column 
chromatography (silica, EtOAc: hexanes = 1:4-1:7) to yield the title compound 39-
42, 47. 
 
Procedure 5 
 
 	    
 
A solution of aminocrotonate (1.0 eq), 2,3 dichlorobenzaldehyd (1.0 eq) and diketone 
39-42, 47 (1.0 eq) dissolved in ethanol (1 mL/mmol39-42, 47) was refluxed. The reaction 
was stopped after TLC monitoring did not show any more presence of the diketone. 
The reaction mixture was concentrated and the crude product was purified by flash 
column chromatography (silica, EtOAc: hexanes = 1:2-1:6) to yield the title 
compound 25-28, 48. 
 
Procedure 6 
 
	     
 
N
H
EtOOC
Cl
Cl
O
O
X
O
O
X
O
X =
n=1,2
X
N N
Y
Y
n=1,2
2,3 dichlorobenzaldehyde, 
aminocrotonate, EtOH, reflux, 4 h
39-42, 47 25 (32%), 26 (26%), 27 
(32%), 28 (3%), 48 (42)%
= H NHBoc,
N
H
O
O
O
Cl methyl acetoacetate, NH3, rt, 17h
54 52
14%
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A solution of methyl actoacetate (5.2 mL, 48 mmol, 1.0 eq), ammonia (25 mL), and 
H2O (25 mL) was treated with chloracetone 54 (4.0 mL, 50 mmol, 1.0 eq). The 
reaction mixture was stirred at rt for 17 hours and the colour turned into red. The 
product was extracted five times with EtOAc (25 mL). The combined organic phases 
were washed with 10% aqueous NaOH (10 mL) and 5% aqueous HCL solution (10 
mL). Organic solvent was removed under reduced pressure and the resulting solid 
was purified by flash column chromatography (silica, EtOAc: Hexanes = 1:5) to yield 
Methyl N-(tert-Butoxycarbonyl)-2,5-dimethylpyrrole-3-carboxylate (52). 
 
Procedure 7 
 
	    
 
In a schlenk flask 3-(phenyldiazenyl)benzoic acid (50) (50.0 mg, 0.22 mmol, 1.00 eq) 
and oxalylchlorid (22.2 mL, 0.26 mmol, 1.20 eq) were dissolved in THF (3 mL) under 
a nitrogen atmosphere. The reaction was initiated by adding three drops of DMF. 
The solvent was evaporated, after TLC monitoring did not show any more starting 
material. Product 51 was not further purified and directly added to the next reaction. 
 
Procedure 8 
 
  
 
Methyl N-(tert-Butoxycarbonyl)-2,5-dimethylpyrrol-3-carboxylat (52) (38.0 mg, 0.25 
mmol, 1.12 eq) and AlCl3 (104 mg, 0.78 mmol, 3.56 eq) were dissolved in THF (2 mL) 
under Argon atmosphere. The mixture was cooled to -40 °C and kept at the 
N N COOH N N COCl
50 51
(COCl)2, DMF, 
THF, 2 h
not purified
N N COCl
N N O
HN
O
O
N
H
O
O
51
52
FPL-azo 25
AlCl3, THF, -40 °C, 30 min, then
-40 °C → 0 °C, then 0 °C → −40 
°C, then
 then -40 °C → rt, 20 h
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temperature for 20 minutes. The reaction was allowed to warm up to rt and recooled 
to -40 °C. Reactant 51 was added and the reaction mixture was kept at -40 °C for 
45 minutes.6 The reaction mixture was allowed to warm up to rt and stirred for 20 
hours. The reaction mixture was poored on water followed by addition of saturated 
NaHCO3 solution (20 mL, gas release). Under reduced pressure THF was removed 
and the product was extracted five times with EtOAc (10 mL). The combined organic 
phases were dried over Na2SO4 and the solvent was removed under reduced 
pressure. The resulting brown oil was purified by silica column chromatography 
(silica, EtOAc:hexanes = 3:4) to yield FPL-azo (25). 
 
 
Feazo-2 (25), 3-methyl 5 -(2-(phenyldiazenyl)benzyl) 4 -(2,3-dichlorophenyl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
 
 
 
The synthesis was carried out according to general Procedure 4. Utilizing 2-
(phenyldiazenyl)benzyl 3-oxobutanoate (39) (200 mg, 0.50 mmol, 1.00 eq), 2,3-
dichlorobenzaldehyde (118 mg, 0.67 mmol, 1.34 eq) and methyl 3-aminobut-2-
enoate (78.0 mg, 0.50 mmol, 1.00 eq) yielded the desired product Feazo-2 (25) (117 
mg, 0.21 mmol) as an orange solid and as a 1:4.8 mixture of (E)/(Z) isomers. 
 
Yield = 32%. 
Rf = 0.19 (hexanes: EtOAc = 6:1). 
Melting point = oil. 
 
NMR spectroscopic data for major isomer: 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6	  	  A. J. Baxter, J. Dixon, F. Ince, C. N. Manners, S. J. Teague, J. Med. Chem. 1993, 36, 
   2739-2744.	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1H NMR (CDCl3, 600 MHz): δ = 7.84 (mc, 2H), 7.69 (mc, 1H), 7.47 (mc, 3H), 7.38 (mc, 
2H), 7.23 - 7.13 (m, 3H), 6.9 (mc, 1H), 5.78 (d, J = 13.0 Hz, 1H), 5.63 (s, 1H), 5.57 (d, 
J  = 12.6 Hz, 1H), 5.46 (s, 1H), 3.54 (s, 3H), 2.31 (s, 3H), 2.27 (s, 3H) ppm.  
13C NMR  (CDCl3, 150 MHz): δ = 167.9, 167.2, 152.8, 149.8, 147.8, 145.0, 144.0, 
135.8, 133.0, 131.2*, 131.2*, 129.8, 129.3, 129.1, 128.8, 128.7, 128.3, 127.0, 123.3, 
115.6, 103.7, 103.4, 61.9, 51.0, 38.9, 19.9, 19.6 ppm. 
* represents different signals 
 
ESI-MS for H26C29Cl2N3O4  [(M + H)+]:                      calcd.     550.1300 
                                                                                 found     550.1294. 
 
IR (ATR): 𝜈/cm−1 = 3335, 2947, 2361, 1735, 1681, 1617, 1488. 1446, 1431, 1418, 
1378, 1301, 1274, 1206, 1138, 1113, 1090, 1042, 1017, 864, 799, 773, 750, 734, 
686. 
 
UV-Vis (DMSO): λmax = 333.9 nm. 
 
 
Feazo-3 (26), 3-methyl 5 -(3-(phenyldiazenyl)benzyl) 4 -(2,3-dichlorophenyl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
 
 
                                          
The synthesis was carried out according to general Procedure 5. Utilizing 3-
(phenyldiazenyl)benzyl 3-oxobutanoate (40) (148 mg, 0.50 mmol, 1.00 eq), 2,3-
dichlorobenzaldehyde (87.5 mg, 0.50 mmol, 1.00 eq) and aminocrotonate (57.5 mg, 
0.50 mmol, 1.00 eq) yielded the desired product 3-methyl Feazo-3 (26) (73.0 mg, 
0.13 mmol) as an oil and as a 1:2 mixture of (E)/(Z) isomers. 
 
Yield = 26%. 
Rf = 0.21 (hexanes: EtOAc = 2:1). 
Melting point = oil. 
O
O
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NMR spectroscopic data for major isomer: 
1H NMR (CDCl3, 600 MHz): δ = 7.94–7.88 (m, 2H), 7.84–7.71 (m, 2H), 7.55–7.35 (m, 
5H), 7.28–7.23 (m, 3H), 5.76 (s, 1H), 5.49 (s, 1H), 5.21 (d, J  = 13 Hz, 1H), 5.12 (d, J  
= 13 Hz, 1H), 3.57 (s, 2H), 2.32 (s, 3H), 2.28 (s, 3H) ppm.  
13C NMR  (CDCl3, 150 MHz): δ = 167.9, 167.1, 152.7*, 152.7*, 148.0, 145.3, 144.1, 
137.8, 137.7, 131.2*, 131.2*, 130.7, 129.9, 129.2, 128.8, 128.4, 127.1, 123.0, 122.8, 
122.3, 103.8, 103.2, 65.8, 51.1, 38.8, 19.9, 19.6 ppm. 
* represents different signals 
 
ESI-MS for H26C29Cl2N3O4  [(M + H)+]:                    calcd.    550.1300  
                                                                               found    500.1292. 
 
IR (ATR): 𝜈/cm−1 = 3338, 3060, 2947, 1681, 1648, 1616, 1516, 1487, 1446, 1431, 
1418, 1380, 1301, 1274, 1206, 1138, 1114, 1096, 1043, 1017, 923, 888, 865, 843, 
796, 775, 732, 692. 
 
UV-Vis (DMSO): λmax = 326.0 nm. 
 
 
Feazo-4 (27), 3-methyl 5 -(4-(phenyldiazenyl)benzyl) 4 -(2,3-dichlorophenyl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
 
         
 
The synthesis was carried out according to general Procedure 5. Utilizing 4-
(phenyldiazenyl)benzyl 3-oxobutanoate (41) (296 mg, 1.00 mmol, 1.00 eq), 2,3-
dichlorobenzaldehyde (175 mg, 1.00 mmol, 1.00 eq) and methyl 3-aminobut-2-
enoate (115 mg, 1.00 mmol, 1.00 eq) yielded the desired product Feazo-4 (27) (177 
mg, 0.32 mmol) as an orange solid and as a 1:5.5 mixture of (E)/(Z) isomers. 
O
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Yield = 32%. 
Rf = 0.2 (hexanes: EtOAc = 2:1). 
Melting point = 68.4 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR (CDCl3, 600 MHz): δ = 7.92–7.90 (m, 2H), 7.84–7.80 (m, 2H), 7.53–7.45 (m, 
3H), 7.30–7.26 (m, 5H), 7.05–7.01 (m, 1H), 5.87 (s, 1H), 5.50 (s, 1H), 5.18 (d, J  = 
15.41 Hz, 1H), 5.10 (d, J  = 13.03 Hz, 1H), 3.60 (s, 3H), 2.30 (s, 1H), 2.28 (s, 1H) 
ppm.  
13C NMR (CDCl3, 150 MHz): δ = 167.9, 167.1, 152.7, 152.2, 148.2, 145.4, 144.1, 
139.6, 133.0, 131.1, 129.8, 129.2, 128.8, 128.4, 127.2, 123.0, 120.7, 120.6, 103.8, 
103.2, 65.1, 51.0, 38.8, 19.8, 19.5 ppm. 
 
ESI-MS for H26C29Cl2N3O4  [(M + H)+]:                     calcd.      550.1300 
                                                                                found      550.1292. 
 
IR (ATR): 𝜈/cm−1 = 3338, 2948, 2250, 1682, 1649, 1617, 1486, 1432, 1418, 1380, 
1301, 1276, 1208, 1138, 1114, 1094, 1044, 1015, 907, 726, 687. 
 
UV-Vis (DMSO): λmax = 333.9 nm. 
 
 
Feazo-4l (28), (3-methyl 5-(4-(phenyldiazenyl)phenethyl) 4-(2,3-dichlorophenyl)-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
 
 
 
The synthesis was carried out according to general Procedure 5. Utilizing 4-
(phenyldiazenyl)phenethyl 3-oxobutanoate (42) (2.00 g, 6.45 mmol, 1.00 eq), 2,3-
dichlorobenzaldehyde (822 mg, 4.70 mmol,  0.72 eq) and methyl 3-aminobut-2-
O
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enoate (541 mg, 4.7 mmol, 0.72 eq) yielded the desired Feazo-4l (28) (96.0 mg, 0.17 
mmol) as an orange solid. 
 
Yield = 2.6%. 
Rf = 0.23 (hexanes: EtOAc = 3:1). 
Melting point = 81.4 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR (CDCl3, 600 MHz): δ = 7.92–7.87 (m, 2H), 7.82–7.78 (m, 2H), 7.54–7.44 (m, 
4H), 7.26–7.22 (m, 3H), 7.06–7.02 (m, 2H), 5.64 (s, 1H), 5.44 (s, 1H), 4.31 (t, J = 7  
Hz, 2H), 3.61 (s, 3H), 3.01–2.89 (m, 2H), 2.3 (s, 3H), 2.26 (s, 3H) ppm.  
13C NMR  (CDCl3, 150 MHz): δ = 167.9, 167.2, 152.8, 151.4, 148.1, 144.8, 144.2, 
141.7, 133.0, 131.0, 129.7, 129.2, 128.5, 127.2, 123.1, 122.9, 121.1, 120.5, 103.9, 
103.7, 64.1, 51.0, 38.9, 35.2, 19.8, 19.6 ppm. 
 
ESI-MS for H28C30Cl2N3O4  [(M + H)+]:                       calcd.     564.1457 
                                                                                  found     564.1461.  
 
IR (ATR): 𝜈/cm−1 = 3342, 2956, 1681, 1618, 1487, 1446, 1432, 1418, 1380, 1302, 
1276, 1210, 1139, 1099, 1043, 1017, 925, 837, 797, 768, 734, 687. 
 
UV-Vis (DMSO): λmax = 337.0 nm. 
 
 
FPL-azo (30), Methyl 2,5 -dimethyl-4-(3-(phenyldiazenyl)benzoyl)-1H-pyrrole-3-
carboxylate 
 
 
 
The synthesis was carried out according to general Procedure 8. Utilizing Methyl N-
(tert-Butoxycarbonyl)-2,5-dimethylpyrrol-3-carboxylat (52), AlCl3 and  3-
N N
O
NH
OO
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(phenyldiazenyl)benzoyl chloride (51) yielded the desired product FPL-azo (30)  as 
an orange solid and as a 1:4.4 mixture of (E)/(Z) isomers 
 
Yield = unknown 
Rf = 0.24 (hexanes: EtOAc = 4:3). 
Melting point = 75 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR (DMSO, 400 MHz): δ = 8.76 (s, 1H), 8.33 (m, 1H), 8.03 (m, 2H), 7.92 (m, 1H), 
7.88 (m, 1H), 7.52 (m, 4H) ppm. 
13C NMR  (DMSO, 100.5 MHz): δ = 193.6, 165.2, 152.7, 152.6, 141.5, 134.5, 131.4, 
131.1, 129.3, 129.1, 125.3, 124.0, 123.1, 120.7, 120.6, 112.1, 50.6, 12.8, 12.0 ppm. 
 
ESI-MS for H19C21N3O3 [(M - H)+]:                                calcd.     360.1348 
                                                                                     found      360.1351. 
 
 
IR (ATR): 𝜈/cm−1 = 3278, 1676, 1635, 1533, 1436, 1381, 1338, 1299, 1234, 1203, 
1170, 1153, 1088, 1020, 908, 809, 766, 690. 
 
UV-Vis (DMSO): λmax = 320.0 nm. 
 
 
(2-(phenyldiazenyl)phenyl)methanol (35) 
  
	    
 
The synthesis was carried out according to general Procedure 3. Utilizing 
nitrosobenzene (700 mg, 6.53 mmol, 1.20 eq) and (2-aminophenyl)methanol (670 
mg, 5.44 mmol, 1.00 eq) yielded the desired product (2-
(phenyldiazenyl)phenyl)methanol (35) (806 mg, 3.80 mmol) as an orange solid and as 
a 1:23 mixture of (E)/(Z) isomers. 
 
Yield = 70%. 
N N
OH
35
148
	  
Rf = 0.2 (hexanes: EtOAc = 4:1). 
Melting point = 74.7–75.1 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR (CDCl3, 300 MHz): δ = 7.90 (m, 2H), 7.82 (m, 1H), 7.52 (m, 6H), 5.05 (s, 2H), 
3.16 (br, 1H) ppm. 
13C NMR  (CDCl3, 75.5 MHz): δ = 152.7, 150.5, 138.6, 131.6, 131.5, 129.4, 129.4, 
128.6, 123.1, 118.5, 63.4 ppm. 
 
ESI-MS for H13C13N2O [(M + H)+]:                       calcd.     213.1022   
                                                                            found     213.1024. 
 
IR (ATR): 𝜈/cm−1 = 3250, 1571,1471, 1451, 1356, 1130, 1239, 1219, 1185, 1145, 
1101, 1069, 1042, 986, 948, 936, 924, 833, 768, 706, 685. 
 
 
(3-(phenyldiazenyl)phenyl)methanol (36) 
 
	    
 
The synthesis was carried out according to general Procedure 2. Utilizing 
nitrosobenzene (700 mg, 6.53 mmol, 1.20 eq) and (3-aminophenyl)methanol (670 
mg, 5.44 mmol, 1.00 eq) yielded the desired product (3-
(phenyldiazenyl)phenyl)methanol (36) (880 mg, 4.10 mmol) as an orange solid, 
whereat only the Z isomers was detected in the 1H NMR measurement. 
 
Yield = 76%. 
Rf = 0.13 (hexanes: EtOAc = 4:1). 
Melting point = 38.2–38.6 °C. 
 
NMR spectroscopic data for major isomer: 
N N
OH
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1H NMR (CDCl3, 600 MHz): δ = 7.95–7.90 (m, 3H), 7.86 (mc, 1H), 7.56–7.45 (m, 5H), 
4.81 (s, 2H), 1.89 (s, 1H) ppm. 
13C NMR  (CDCl3, 150 MHz): δ = 153.0, 152.8, 142.2, 131.2, 129.5, 129.4, 129.2, 
123.0, 122.8, 120.7, 65.1 ppm. 
 
ESI-MS for H13C13N2O [(M + H)+]:                        calcd.    213.1022   
                                                                             found     213.1023. 
IR (ATR): 𝜈/cm−1 = 3287, 3051, 2926, 2870, 2362, 2341, 1954, 1684, 1587, 1491, 
1471, 1446, 1406, 1307, 1243, 1194, 1162, 1144, 1119, 1087, 1071, 1039, 1012, 
991, 948, 918, 896, 872, 807, 793, 768, 669. 
 
 
(4-(phenyldiazenyl)phenyl)methanol (37) 
  
 
	    
 
 
The synthesis was carried out according to general Procedure 3. Utilizing 
nitrosobenzene (700 mg, 6.53 mmol, 1.20 eq) and (4-aminophenyl)methanol (670 
mg, 5.44 mmol, 1.00 eq) yielded the desired product (4-
(phenyldiazenyl)phenyl)methanol (37) (588 mg, 2.80 mmol) as an orange solid, 
whereat only the Z isomers was detected in the 1H NMR measurement. 
 
Yield = 51%. 
Rf = 0.21 (hexanes: EtOAc = 4:1). 
Melting point = 143 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR  (CDCl3, 600 MHz): δ = 7.95–7.91 (m, 4H), 7.54–7.46 (m, 5H), 4.79 (s, 2H), 
1.84 (s, 1H) ppm. 
13C-NMR (CDCl3, 150 MHz): δ = 152.8, 152.3, 144.0, 131.1, 129.2, 127.6, 123.2, 
123.0, 65.0 ppm. 
HO
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ESI-MS for H13C13N2O [(M + H)+]:                        calcd.     213.1028 
                                                                             found     213.1022. 
IR (ATR): 𝜈/cm−1 = 3200, 1440, 1346, 1302, 1148, 1018, 848, 829, 762, 682. 
 
 
2-(4-(phenyldiazenyl)phenyl)ethanol (38) 
  
	    
 
The synthesis was carried out according to general Procedure 3. Utilizing 
nitrosobenzene (1.874 g, 17.49 mmol, 1.20 eq) and (4-aminophenyl)ethanol (2.000 g, 
14.58 mmol, 1.00 eq) yielded the desired product (4-(phenyldiazenyl)phenyl)ethanol 
(38) (2.870 mg, 12.69 mmol) as an orange solid and as a 1:13 mixture of (E)/(Z) 
isomers. 
 
Yield = 73%. 
Rf = 0.16 (hexanes: EtOAc = 4:1). 
Melting point = 85.6–85.8 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR  (CDCl3, 300 MHz): δ = 7.93–7.86 (m, 4H), 7.55–7.45 (m, 3H), 7.4–7.35 (m, 
2H), 3.92 (q, J = 5.84 Hz, 2H), 2.95 (tri, J  = 6.26 Hz, 2H), 1.54 (tri, J  = 5.58 Hz, 1H). 
13C NMR  (CDCl3, 75 MHz): δ = 152.8, 151.6, 142.1, 131.0, 129.9, 129.2, 123.2, 
122.9, 63.6, 39.2 ppm. 
 
EI-MS for H14C14N2O [M+]:                                   calcd.    226.1106   
                                                                             found     226.1100. 
 
IR (ATR): 𝜈/cm−1 = 3314, 2862, 1601, 1500, 1466, 1441, 1412, 1364, 1302, 1219, 
1151, 1106, 1056, 1037, 1010, 921, 840, 822, 795, 763, 727, 683. 
 
N N
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2-(phenyldiazenyl)benzyl 3-oxobutanoate (39) 
 
	    
 
The synthesis was carried out according to general Procedure 4. Utilizing (2-
(phenyldiazenyl)phenyl)methanol (35) (700 mg, 3.30 mmol, 1.00 eq) and 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (472 mg, 3.32 mmol, 1.00 eq) yielded the desired 
product 2-(phenyldiazenyl)benzyl 3-oxobutanoate (39) (507 mg, 1.70 mmol) as an 
orange solid and as a 1:4.2 mixture of (E)/(Z) isomers. 
 
Yield = 52%. 
Rf = 0.2 (hexanes: EtOAc = 7:1). 
Melting point = 65.7–66.2 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR (CDCl3, 400 MHz): δ = 7.93–7.91 (m, 2H), 7.75–7.73 (m, 1H), 7.59–7.57 (m, 
1H), 7.55–7.42 (m, 5H), 5.79 (s, 2H), 3.49 (s, 2H), 2.21(s, 3H) ppm.  
13C NMR  (CDCl3, 150 MHz): δ = 200.4, 167.0, 152.8, 150.0, 134.5, 131.5, 131.3, 
129.7, 129.4, 129.3, 120.9, 115.9, 63.4, 50.2, 30.3 ppm. 
 
ESI-MS for H17C17N2O3  [(M + H)+]:                      calcd.     297.1239 
                                                                            found      297.1234. 
 
IR (ATR): 𝜈/cm−1 = 1742, 1718, 1404, 1360, 1312, 1296, 1264, 1221, 1169, 1150, 
1037, 981, 957, 922, 772, 747, 705, 684. 
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3-(phenyldiazenyl)benzyl 3-oxobutanoate (40) 
 
	    
 
The synthesis was carried out according to general Procedure 4. Utilizing (3-
(phenyldiazenyl)phenyl)methanol (36) (100 mg, 0.47 mmol, 1.00 eq) and 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (67.5 mg, 0.47 mmol, 1.00 eq) yielded the desired 
product 3-(phenyldiazenyl)benzyl 3-oxobutanoate (40) (121 mg, 0.41 mmol) as an 
orange solid and as a 1:15.5 mixture of (E)/(Z) isomers. 
 
Yield = 87%. 
Rf = 0.18 (hexanes: EtOAc = 4:1). 
Melting point = oil. 
 
NMR spectroscopic data for major isomer: 
1H NMR  (CDCl3, 400 MHz): δ = 7.95–7.87 (m, 4H), 7,56–7,46 (m, 5H), 5.28 (s, 2H), 
3.54 (s, 2H), 2.27 (s, 3H) ppm.  
13C NMR  (CDCl3, 100 MHz): δ = 200.4, 167.0, 152.9, 152.6, 136.5, 131.4, 130.7, 
129.5, 129.2, 123.3, 123.0, 122.0, 66.8, 50.1, 30.3 ppm. 
 
ESI-MS for H17C17N2O3  [(M + H)+]:                    calcd.    297.1239 
                                                                           found    297.1240. 
 
IR (ATR): 𝜈/cm−1 = 3063, 2960, 2363, 1742, 1715, 1651, 1586, 1448, 1408, 1360, 
1312, 1227, 1146, 1086, 1071, 1030, 1000, 972, 924, 892, 796, 765, 692. 
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4-(phenyldiazenyl)benzyl 3-oxobutanoate (41) 
 
 
	    
 
The synthesis was carried out according to general Procedure 4. Utilizing (4-
(phenyldiazenyl)phenyl)methanol (37) (400 mg, 1.90 mmol, 1.00 eq) and 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (0.27 g, 1.90 mmol, 1.00 eq) yielded the desired 
product 4-(phenyldiazenyl)benzyl 3-oxobutanoate (41) (397 mg, 1.34 mmol) as an 
orange solid and as a 1:8 mixture of (E)/(Z) isomers. 
 
Yield = 72%. 
Rf = 0.2 (hexanes: EtOAc = 7:1). 
Melting point = 70.8–71.5 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR  (CD2Cl2, 400 MHz): δ = 7.95–7.92 (m, 4H), 7.57–7.48 (m, 5H), 5.25 (s, 2H), 
3.55 (s, 2H), 2.25 (s, 3H) ppm.  
13C NMR  (CD2Cl2, 100 MHz): δ = 200.3, 167.0, 152.7, 152.5, 138.6, 131.3, 129.2, 
128.9, 123.0, 122.9, 66.4, 50.0, 30.1 ppm. 
 
ESI-MS for H17C17N2O3  [(M + H)+]:                      calcd.    297.1239 
                                                                            found     297.1232. 
 
IR (ATR): 𝜈/cm−1 = 2926, 2360, 1738, 1701, 1484, 1411, 1362, 1311, 1265, 1145, 
1030, 1000, 962, 828, 768, 724, 689. 
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4-(phenyldiazenyl)phenethyl 3-oxobutanoate (42) 
 
	    
 
The synthesis was carried out according to general Procedure 4. Utilizing (4-
(phenyldiazenyl)phenyl)ethanol (38) (2.000 g, 8.84 mmol, 1.84 eq) and 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (68.00 mg, 4.74 mmol, 1.00 eq) yielded the desired 
product 4-(phenyldiazenyl)phenethyl 3-oxobutanoate (42) (2.397 g, 7.73 mmol) as an 
orange solid and as a 1:12 mixture of (E)/(Z) isomers. 
 
Yield = 87%. 
Rf  = 0.26 (hexanes: EtOAc = 4:1). 
Melting point = 85.9–86.4 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR (CDCl3, 400 MHz): δ = 7.92–7.86 (m, 4H), 7.55–7.45 (m, 3H), 7.39–7.35 (m, 
2H), 4.42 (t, J  = 7 Hz, 2H), 3.45 (s, 2H), 3.05 (t, J  = 6.93 Hz, 2H), 2.2 (s, 3H) ppm.  
13C NMR  (CDCl3, 100 MHz): δ = 200.5, 167.1, 152.8, 151.7, 140.9, 131.1, 129.8, 
129.2, 123.2, 122.9, 65.5, 50.2, 35.0, 30.3 ppm. 
 
EI-MS for H18C18N2O3  [M+]:                                 calcd.    310.1317 
                                                                            found     310.1316. 
 
IR (ATR): 𝜈/cm−1 = 2960, 2937, 2866, 1732, 1712, 1648, 1630, 1602, 1499, 1464, 
1474, 1446, 1416, 1362, 1316, 1284, 1270, 1238, 1177, 1157, 1109, 1070, 1040, 
1006, 971, 928, 847, 835, 771, 726, 688. 
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Tert-butyl 4-aminobenzylcarbamate (44) 
  
	    
 
The synthesis was carried out according to general Procedure 1. Utilizing 4-
aminobenzylamine (1.000 g, 8.19 mmol, 1.0 eq) and di-tert-butyl dicarbonate (1.965 
g, 9.0 mmol, 1.1 eq) yielded the desired product tert-butyl 4-aminobenzylcarbamate 
(44) (1.73 g, 7.78 mmol) as a white solid. 
 
Yield = 95%. 
Rf = 0.23 (hexanes: EtOAc = 3:1). 
Melting point = 80.8 °C. 
 
NMR spectroscopic data: 
1H NMR  (CDCl3, 400 MHz): δ = 7.05 (d, J = 8.09 Hz, 2H), 6.62 (d, J = 8.82 Hz, 2H), 
4.80 (brs, 1H), 4.17 (d, J = 5.42 Hz, 2H), 3.61 (brs, 1H), 1.45 (s, 9H) ppm. 
13C NMR  (CDCl3, 100 MHz): δ = 155.9, 145.8, 128.9, 128.8, 115.2, 79.3, 44.4, 28.5 
ppm. 
 
EI-MS for H18C12N2O2 [M+]:                                    calcd.    222.1368  
                                                                               found    222.1355. 
 
IR (ATR): 𝜈/cm−1 = 3901, 3854, 3745, 3711, 3676, 3367, 2360, 2341, 1684, 1653, 
1576, 1559, 1540, 1507, 1457, 1394, 1363, 1246, 1162, 1048, 1027, 930, 865, 821 
668. 
 
 
Tert-butyl 4-((3-(hydroxymethyl)phenyl)diazenyl)benzylcarbamate (46) 
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The synthesis was carried out according to general Procedure 3. Utilizing tert-butyl 
4-nitrosobenzylcarbamate (45) (unknown, estimated to be 1 g, see Procedure 1) and 
3 aminophenyl)methanol (1 g, 8.12 mmol) yielded the desired tert-butyl 4-((3-
(hydroxymethyl)phenyl)diazenyl)benzylcarbamate (46) (1.16 g, 3.4 mmol) as an 
orange solid and as a 1:15 mixture of (E)/(Z) isomers. 
 
Yield = about 42%. 
Rf = 0.2 (hexanes: EtOAc = 2:1). 
Melting point = 114.7–115 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR  (CDCl3, 600 MHz): δ = 7.79 (s, 1H), 7.86 (d, J = 9.11 Hz, 2H), 7.82 (d, J = 
7.51 Hz, 1H), 7.51-7.46 (m, 2H), 7.40 (d, J = 8.06 Hz, 2H), 4.99 (brs, 1H), 4.78 (s, 2H), 
4.37 (d, J = 5.23 Hz, 2H), 2.26 (brs, 1H), 1.47 (s, 9H) ppm. 
13C NMR  (CDCl3, 150 MHz): δ = 156.1, 152.9, 152.0, 142.3, 129.4, 129.4, 128.1, 
127.6, 123.3, 122.7, 120.7, 79.9, 65, 44.5, 28.5 ppm. 
 
ESI-MS for H24C19N3O3 [M+H+]:                                    calcd.    342.1817 
                                                                                      found     342.1811. 
 
IR (ATR): 𝜈/cm−1 = 3351, 2358, 1678, 1503, 1364, 1245, 1167, 1050, 1020, 847, 800, 
692.  
 
 
3-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)diazenyl)benzyl 3-
oxobutanoate (47) 
 
	    
 
The synthesis was carried out according to general Procedure 4. tert-butyl 4-((3-
(hydroxymethyl)phenyl)diazenyl)benzylcarbamate (46) (1.00 g, 2.93 mmol, 1.00 eq) 
O
O
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N
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and 2,2,6-trimethyl-4H-1,3-dioxin-4-one (342 mg, 2.41 mmol, 1.20 eq) yielded the 
desired product 3-((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)diazenyl)benzyl 3-
oxobutanoate (47) (651 mg, 1.53 mmol) as an orange solid and as a 1:5 mixture of 
(E)/(Z) isomers. 
 
Yield = 63%. 
Rf  = 0.23 (hexanes: EtOAc = 3:1). 
Melting point = 101.2 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR  (CDCl3, 400 MHz): δ = 7.91–7.87 (m, 1H), 7.54–7.51 (t, J = 7.50 Hz, 1H), 
7.47 (d, J = 7.43 Hz, 1H), 7.43 (d, J = 8.34 Hz, 2H), 5.28 (s, 2H), 4.40 (d, J = 5.41 Hz, 
2H), 3.54 (s, 2H), 2.27 (s, 3H), 1.48 (s, 9H) ppm.  
13C NMR  (CDCl3, 100 MHz): δ = 200.4, 167.0, 152.9, 152.0, 136.6, 130.7, 129.6, 
128.2, 127.8, 127.1, 123.4, 123.3, 122.4, 121.1, 66.8, 50.2, 44.5, 30.4, 28.6 ppm. 
 
ESI-MS for H28C23N3O5  [M+H+]:                          calcd.    426.4855    
                                                                            found     426.2021. 
 
IR (ATR): 𝜈/cm−1 = 3364, 2975, 1738, 1720, 1678, 1500, 1465, 1412, 1365, 1312, 
1244, 1149, 1049, 1028, 1013, 965, 920, 871, 850, 798, 781, 727, 690.  
 
 
 
Feazo-3,4 (48), 3-methyl 5-(3-(phenyldiazenyl)benzyl) 4-(2,3-dichlorophenyl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
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The synthesis was carried out according to general Procedure 5. Utilizing 3-((4-
(((tert-butoxycarbonyl)amino)methyl)phenyl)diazenyl)benzyl 3-oxobutanoate (47) (700 
mg, 1.64 mmol, 1.00 eq), 2,3-dichlorobenzaldehyde (288 mg,  1.64 mmol, 1.00 eq) 
and methyl 3-aminobut-2-enoate (189 mg, 1.64 mmol, 1.00 eq) yielded the desired 
Feazo-3,4 (48) (152 mg, 0.22 mmol) as an orange solid and as a 1:7 mixture of (E)/(Z) 
isomers. 
 
Yield = 14%. 
Rf = 0.11 (hexanes: EtOAc = 2:1). 
Melting point = 89.1 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR (CDCl3, 600 MHz): δ = 7.88 (d, J  = 8.78 Hz, 2H), 7.80 (d, J  = 7.68 Hz, 1H), 
7.72 (s, 1H), 7.44–7.39 (m, 3H), 7.26–7.24 (m, 2H), 7.18–7.16 (m, 1H), 6.99 (t, J  = 
7.74 Hz, 1H), 5.80 (s, 1H), 5.49 (s, 1H), 5.21 (d, J  = 12.43 Hz, 1H), 5.11 (d, J  = 13.06 
Hz, 1H), 4.40 (d, J  = 5.63 Hz, 2H), 3.57 (s, 3H), 2.31 (s, 3H), 2.28 (s, 3H), 1.48 (s, 9H) 
ppm.  
13C NMR  (CDCl3, 150 MHz): δ = 167.9, 167.1, 156.1, 152.7, 152.0, 148.0, 145.3, 
144.1, 142.2, 137.8, 133.0, 131.3, 130.7, 129.9, 129.2, 128.4, 128.1, 127.1, 123.3, 
122.8, 122.3, 103.8, 103.3, 79.9, 65.3, 51.0, 44.5, 38.8, 28.6, 19.9, 19.6 ppm.  
 
ESI-MS for H37C35Cl2N4O6  [(M + H)+]:                    calcd.    679.2090 
                                                                               found    679.2083.  
 
IR (ATR): 𝜈/cm−1 = 3337, 2979, 1683, 1618, 1491, 1446, 1432, 1419, 1380, 1366, 
1301, 1274, 1208, 1163, 1138, 1115, 1098, 1044, 1017, 935, 864, 798, 749, 690, 
666.  
 
UV-Vis (DMSO): λmax = 337.0 nm. 
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3-(phenyldiazenyl)benzoic acid (51) 
 
 
 
The synthesis was carried out according to general Procedure 3. Utilizing 
nitrosobenzene (700 mg, 6.53 mmol, 1.20 eq) and Anthranilic acid (746 mg, 5.44 
mmol, 1.00 eq) yielded the desired product (51) (0.55 g, 2.43 mmol) as an orange 
solid, whereat only the Z isomer was detected in the 1H NMR measurement. 
 
 
Yield = 45%. 
Rf = 0.2 (DCM, 1% acetic acid). 
Melting point = 171.8 °C. 
 
NMR spectroscopic data for major isomer: 
1H NMR  (DMSO, 300 MHz): δ = 13.31 (br, 1H), 8.38 (m, 1H), 8.13 (m, 2H), 7.93 (m, 
2H), 7.74 (m, 1H), 7.6 (m, 3H) ppm. 
13C NMR (DMSO, 75.45 MHz): δ = 166.6, 151.8*, 151.8*, 132.1, 131.9, 131.8, 129.9, 
129.5, 127.3, 122.7, 122.3 ppm. 
* represents different signals 
 
ESI-MS for H9C13N2O2 [(M - H)+]:                                 calcd.    225.0664 
                                                                                     found    225.0671. 
 
IR (ATR): 𝜈/cm−1 = 3051, 2359, 1684, 1586, 1470, 1448, 1431, 1394, 1236, 1208, 
1175, 1156, 1080, 1018, 998, 923, 852, 819, 765, 686. 
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Methyl N-(tert-Butoxycarbonyl)-2,5-dimethylpyrrole-3-carboxylate (52) 
  
	    
 
The synthesis was carried out according to general Procedure 6. Utilizing methyl 
acetoacetate (5.2 mL, 48 mmol, 1.0 eq)  ammonia (50 mL) and chloracetone (4.0 mL, 
50 mmol, 1.0 eq)  yielded the desired product Methyl N-(tert-Butoxycarbonyl)-2,5-
dimethylpyrrole-3-carboxylate (52) (1.1 g, 7.1 mmol) as a yellow solid.  
 
Yield = 14%. 
Rf = 0.2 (hexanes: EtOAc = 5:1). 
Melting point = 106.4 °C. 
 
NMR spectroscopic data: 
1H NMR (CDCl3, 400 MHz): δ = 8.16 (br, 1H), 6.18 (d, J  = 1.8 Hz, 1H), 3.78 (s, 3H), 
2.47 (s, 3H), 2.19 (s, 3H) ppm. 
13C NMR  (CDCl3, 100,55 MHz): δ = 166.4, 134.6, 125.8, 111.4, 107.5, 50.8, 13.2, 
12.7 ppm. 
 
EI-MS for H11C8N1O2 [(M)+]:                               calcd.     153.0790 
                                                                           found     153.0781.     
   
IR (ATR): 𝜈/cm−1 = 3300, 3192, 2949, 1666, 1599, 1518, 1452, 1387, 1327, 1265, 
1222, 1188, 1130, 1089, 1005, 958, 806, 779, 744, 718. 
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4.17) Appendix: NMR spectra  
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1H NMR: 
 
 
 
 
13C NMR: 
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1H NMR: 
 
 
 
 
13CNMR: 
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1H NMR: 
 
 
 
 
13CNMR: 
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1H NMR: 
 
 
 
 
13CNMR: 
 
		

































	







	
	




































	


	
	

	
	




	



























	













	



	




























	



	



	

O
O
N
H
MeOOC
N N
Cl
Cl
28
O
O
N
H
MeOOC
N N
Cl
Cl
28
166
	  
1H NMR: 
 
 
 
 
13CNMR:
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1H NMR: 
 
 
 
 
13CNMR: 
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1H NMR: 
 
 
 
 
13CNMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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1H NMR: 
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4.18) Appendix: UV/VIS spectra  
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1  The fact that the UV/VIS spectrum recorded under 430 nm light shows stronger absorbance than 
the UV/VIS spectrum recorded in the dark, might be due to a not completely established equilibrium 
between the cis and trans compound in the dark, before recording. 
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